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Innate lymphoid cells (ILCs) are a recently discovered lineage of professional cytokine-
producing cells that strikingly mirror T cells in transcriptional circuitry and effector functions, 
but derive from distinct progenitors and do not express recombined antigen-specific receptors. 
These cells include natural killer (NK) cells, which parallel cytotoxic CD8+ T cells, and three 
additional classes of ILCs enriched at mucosal surfaces that generate signature cytokines 
reminiscent of polarized CD4+ helper T cells subsets, called ILC1, ILC2, and ILC3.  As ILCs 
have been implicated in the pathogenesis of colitis, cancer, allergy, and autoimmunity in both 
human and mouse, understanding the functional capacity of these cells as well as the 
mechanisms by which they develop may thus be useful in developing new therapeutics.  
Each class of ILCs can be further subdivided into several subsets, which are 
discriminated based on tissue of residency, expression of cell-surface markers, and differential 
expression of signature cytokines. However, the extent to which ILC subsets and classes have 
unique and overlapping effector functions remained unclear. Furthermore, the functional 
distinctions between ILCs and their adaptive T cell counterparts were unknown. Finally, the 
xii	
developmental requirements for common gamma (γc) chain cytokines among ILC subsets and 
classes remained incompletely understood.  
 Using whole genome microarray, we have comprehensively analyzed the transcriptional 
profiles of mouse and human ILCs. For mouse ILCs, we compared ILC subsets and classes and 
generated subset-defining and class-defining transcriptional profiles. For human, we directly 
transcriptionally profiled tonsillar intraepithelial ILC1 (iILC1) and ILC3, and also compared 
these cells to their respective adaptive counterparts, Th1 and Th17, from the same 
microenvironment. Collectively, these data provide the first comprehensive transcriptional 
analyses of both mouse and human ILCs. 
 We identified a spontaneous loss-of-function mutation in the common gamma (γc) chain-
signaling protein tyrosine kinase Jak3, causing a profound developmental block in ILC 
development. We investigated the requirements for γc cytokines in mouse ILC development 
through systematic analysis of Il7ra–/–, Il15–/–, and Il7ra–/–Il15–/– mice. We also tested the role of 
the immunosuppressive JAK inhibitor tofacitinib on human tonsillar ILC function. These data 
generate a more nuanced understanding of the role of γc cytokines in ILC development and 
function. 
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CHAPTER 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter were adapted from  
 
Robinette ML, Colonna M. Innate lymphoid cells and the MHC. HLA. 87(1): 5-11 (2016). 
© 2015 John Wiley & Sons A/S. 
 
Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J 
Allergy Clin Immunol 138(5): 1243-51 (2016). 
© 2016 American Academy of Allergy, Asthma & Immunology  
 
All work recreated here is that of the author of this dissertation.   
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1.1 Innate and Adaptive Immunity in Lymphocytes 
The immune system functions to sustain organismal homeostasis during normal 
development and to return an organism as close to homeostasis as possible after environmental 
stressors, such as infection. To facilitate this task, it must correctly identify and appropriately 
respond to deviations from homeostasis (1). This is as accomplished on a cellular level by two 
broad, interacting systems, called innate and adaptive immunity. Cells within the hematopoietic 
system are traditionally considered “innate” or “adaptive” primarily based on the types of 
receptors they express, but also based on their kinetics and their capacity for memory responses 
(2, 3).  
Adaptive immune cells consist of T and B-lymphocytes. Each nascent T and B cell 
expresses a single antigen-specific receptor on its cell-surface called the T cell receptor (TCR) or 
B cell receptor (BCR), respectively. There is an immense repertoire of TCRs and BCRs due to 
the ability of these cells to selectively recombine their DNA at the loci encoding the components 
of these receptors (3). TCRs recognize digested peptide antigens bound to Major 
Histocompatibility Complex (MHC) and presented on the cell-surface of other cells, with CD4+ 
helper T cells binding MHC Class II (MHC II) and CD8+ cytotoxic T cells recognizing MHC 
Class I (MHC I). BCRs recognize conformational epitopes that do not require digestion or 
presentation (3). To prevent inappropriate responses to self-antigens, both TCR and BCRs are 
tested for autoreactivity during T cell development in the thymus and B cell development in the 
bone marrow, with the elimination of autoreactive cells. Some CD4+ T cells on the border of 
autoreactivity become regulatory T cells (Treg), which will functionally control missed 
autoreactive cells that continue into the periphery (4). 
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Upon a naïve T or B cell’s recognition of their antigen by TCR or BCR plus activation by 
a second signal in a secondary lymphoid organ (SLO), cells undergo clonal expansion in a 
process that occurs over a period of several days (5, 6). Clonal expansion is a key feature to 
adaptive immune function, as expanded clones provide sufficient numbers of cells with the same 
antigen specificity to combat the threat to homeostasis (6). Depending on the cytokines produced 
during the inflammatory context, activated CD4+ T cells can further polarize to effector modules 
called Th1, Th2, and Th17; in some cases, cells can also become Treg (3). In normal immunity, 
these modules coordinate appropriate responses to the deviation from homeostasis, with Th1 
controlling intracellular pathogens and viruses, Th2 responding to barrier dysfunction and 
helminthes, and Th17 reacting to extracellular bacteria and fungi (3).   
After the threat has been conquered or controlled, there is a contraction of these clonally 
proliferated effector cells; yet, some cells persist as memory cells. Upon secondary encounter of 
the same antigen by the organism, memory cells facilitate a faster and more robust secondary 
clonal recall response (3). For B cells, recurrent antigen encounter acts further to improve the 
quality of their effector antibody response over time. This occurs in the germinal center reaction, 
where additional mutations are introduced into variable regions of genes encoding the BCR, but 
not the TCR; B cells expressing BCRs with higher affinity for antigen are again clonally 
expanded (7). Thus, adaptive immunity is collectively characterized by a large repertoire of 
recombined antigen receptors, relatively slow kinetics, and clonal memory responses that 
typically improve over time. 
 Within the hematopoietic system, innate immune cells consist of all cells except T and B 
cells, which include all myeloid cells and lymphoid Natural Killer (NK) cells. In contrast to the 
adaptive immune cells, innate immune cells express a limited array of receptors that do not 
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recombine and are restricted to the germ-line conformation. These receptors typically recognize 
broadly conserved, though often exquisitely specific, molecular patterns shared by certain classes 
of pathogens, leading to their name of pathogen recognition receptors (PRRs)(1, 2). PRRs 
localize throughout cellular architecture, found on the cell-surface, in the cytoplasm, within 
endosomal compartments, tethered to mitochondrial membranes, and even secreted into the 
extracellular space (8). While all cells, including non-hematopoietic cells and adaptive immune 
cells, have the capacity to express PRRs and many do so constitutively, hematopoietic innate 
immune cells are particularly reliant on these molecules for their activation and effector 
functions. Innate immunity also relies on immunologically active secreted factors from non-
hematopoietic cells, such as complement and other acute phase reactants produced in large 
quantity by hepatocytes (8).  
Upon activation by a PRR, innate immune cells perform effector functions quickly, on a 
timescale of seconds to hours, without any need for presensitization. As another contrast to 
adaptive immunity, innate immunity has not conventionally been considered to have the capacity 
for memory responses. However, recent data suggest that cellular activation can induce 
epigenetic changes within innate immune cells, leading to durable enhancements of cellular 
function reminiscent of memory, called trained immunity (9, 10). Furthermore, both human and 
mouse NK cells are now recognized to undergo clonal expansion in response to some stimuli, 
though this does not appear to be a shared feature among innate immune cells (11-13). 
Therefore, innate immunity is predominantly characterized by the absence of recombined 
antigen receptors that are expressed by adaptive immune cells. The lack of these receptors leads 
to substantially faster immune responses induced directly by PRRs that do not require clonal 
memory features. 
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 Some lymphocyte populations have intermediate characteristics of innate and adaptive 
immunity (14-19). Natural Killer T (NKT), mucosal-associated invariant T (MAIT), γδ T, 
Marginal Zone (MZ) B, and B-1 cells each belong to either the T or B cell lineage and thus 
express recombined antigen-specific TCRs or BCRs. However, the receptor repertoire of these 
cells is substantially more limited than conventional adaptive immune cells, leading to 
differences in the types of antigens they recognize and how they are activated. Additionally, 
reactivity to self does not necessarily cause elimination of these cells and may rather be a critical 
component to their function (14, 19).  
In the T cell lineage, NKT cells, MAIT cells, and γδ T cells are not MHC restricted, 
meaning that they are not functionally required to recognize peptide antigens bound to MHC. 
Instead, NKT cells recognize lipids antigens bound to the MHCI-like molecule CD1d (14, 18) 
and MAIT cells recognize microbial metabolites bound to another MHCI-like molecule, MR1 
(17). γδ T may have a more diverse recognition of antigens including MHC-presented peptides, 
MHCI-like molecules, and perhaps even structural epitopes reminiscent of conventional B cells 
(16). Still, NTK and γδ T are similar to adaptive CD4+ T cells in their capacity to polarize to 
Th1, Th2, and Th17-like cells, though they do not polarize to Treg-like cells (14, 16). 
  In the B cell lineage, MZ B cells express poly-reactive BCRs reminiscent of PRRs (15), 
while B-1 cells express BCRs with low-affinity and broad cross reactivity that are secreted in 
steady state as natural antibodies (19). These cells do not appear to require singling through the 
BCR for function or T cell help, instead relying on innate signaling modalities from PRRs and 
cytokines to induce their function. Yet, like conventional B cells, MZ B cells and B-1 cells still 
produce secreted antibodies as a core function.   
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Beyond their restricted receptor repertoire, NKT, MAIT, γδ T, MZB, and B-1 B cells are 
also a more similar to innate immune cells in their activation kinetics and propensity for clonal 
expansion. After generation, these cells home directly to tissues, rather than SLOs, where they 
are can respond quickly to stress antigens without substantial clonal expansion. Limited diversity 
and tissue residency ensures appropriate signal strength without the need for regulated clonal 
expansion. Furthermore, although at least some of these subsets have the capacity to form 
memory responses, these appear to be less effective than those of conventional T and B cells (3, 
14). Thus, based on their “adaptive” expression of recombined antigen receptors, but limited 
receptor repertoires, fast kinetics, and reduced clonal memory responses, these cells are now 
collectively called innate-like lymphocytes (ILLs).  
 
1.2 ILCs: The New Kids on the Block 
Over the past several years, the universe of lymphocytes has rapidly expanded with the 
recognition and subsequent investigation of a new major class of immune cells in mouse and 
human, called innate lymphoid cells (ILCs) (20-26). Developmental origins, including reliance 
on the master lymphocyte cytokine receptor Interleukin-2 receptor common gamma chain (IL-
2rg, γc), clearly place ILCs in the lymphoid lineage (21, 23). Yet, their lack of recombined 
antigen-specific loci and other lineage markers distinguish them from conventional T and B cells 
as well as ILLs. Thus, unlike other mature lymphocytes, ILCs are present and even expanded in 
Rag1- and Rag2-deficient mice, which lack DNA recombination machinery. With regard to 
localization, ILCs are more similar to ILLs than conventional populations as they are 
predominately a tissue-resident population (18), located in greatest number and frequency at 
mucosal barriers such as the small intestine lamina propria (siLP) (21-23, 27).  
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Before 2008, two members of the ILC class had already been discovered, namely NK 
cells and lymphoid tissue inducer (LTi) cells. NK cells recognize virally infected cells and tumor 
cells and kill them via release of lytic granules (28-30). In addition to their cytolytic activity, NK 
cells also secrete cytokines such as Interferon-gamma (IFN-γ), GM-CSF and TNF-α (28-30). 
Mechanistically, NK cells function through germline-encoded families of receptors with both 
inactivating and activating variants. These receptors coordinate to optimally respond to danger 
without inappropriate responses to self by requiring both loss of inhibition and an activating 
signal to function (28). To this end, inhibition by self-MHC I is a key factor for appropriate NK 
cell function, accomplished by the convergently evolved human KIR gene family within the Ig 
superfamily and mouse C-type lectin Ly49 family (28). Other NK cell receptors include the 
CD94/NKG2 family members, which are conserved between human and mouse, and bind non-
classical MHC I molecules, such as HLA-E in human and Qa-1 in mouse (31-34). Another type 
of ILC, the LTi cell, was known for some time to uniquely orchestrate the generation of 
lymphoid organs during fetal development (35, 36). LTi cells express the cell surface 
heterotrimer lymphotoxin-α1β2 (LTα1β2). This acts on LTβR+ stromal organizer cells to induce 
lymph node and Peyer’s patch (PP) organogenesis by stimulating the production of chemokines, 
which in turn attract lymphocytes to form secondary lymphoid organs (37).  
After 2008, additional ILC subtypes were identified in human and mouse and grouped 
together based on shared developmental requirements and functional cytokine production (20): 
T-bet+ Eomesodermin– (Eomes) ILC1 produce IFN-γ, like Eomes+ NK cells; GATA3hi ILC2 
produce IL-5, IL-13, IL-9 and amphiregulin; and RORγt+ ILC3 produce IL-22, GM-CSF and/or 
IL-17.  In mice, the distinction between ILC1 and NK cells is controversial, as cell-surface 
markers defining these cells vary between tissues and overlap with NK cells; thus, ILC1 are 
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currently best defined by their lack of Eomes expression within NKp46+ NK1.1+ cells (38). 
ILC3s are a particularly diverse class of cells. In adult mice these cells include: A cellular subset 
phenotypically similar to fetal LTi cells, referred to as LTi-like cells or NKp46–CCR6+ ILC3 
cells, which express MHC-II and produce IL-22, IL-17a, IL-17f, and LT-α (39-44); T-betlo 
NKp46–CCR6– ILC3 or double negative (DN) ILC3, which expresses IL-22, GM-CSF, and IL-
17a (45, 46); T-bet+ NKp46+CCR6– ILC3, which express IL-22 and GM-CSF (42, 45-50); and a 
T-bet+NK1.1+NKp46+ ILC3 transitional subset, which has downregulated RORγt and produces 
IFN-γ, like ILC1 (51). Recently, single-cell sequencing of human ILC3 has similarly identified 3 
cellular clusters based on shared and distinct transcriptional programs, including NKp44+ ILC3, 
a CD62L+NKp44– “naïve” ILC3, and HLA-DR+ LTi-like ILC3, reminiscent of diversity found 
among mouse ILC3 (52). However, the functional heterogeneity of ILC3 may vary depending on 
expression of other cell-surface molecules and the method of stimulation.  
Developmental studies have been instrumental to demarcate the major ILC classes and 
subsets. Like other lymphocytes, ILCs develop downstream of the common lymphoid progenitor 
(CLP) from a series of progenitors with progressively restricted fates (21, 23). In mouse, adult 
bone marrow contains many multipotent ILC progenitors: Tcf7+ Early innate lymphoid 
progenitors (EILPs) (53) and alpha-lymphoid progenitors (αLPs) (54) give rise to all ILCs, but 
not T or B cells; Common helper ILC precursors (CHILPs) generate ILCs but not NK cells (51); 
and Plzf+ ILC precursors (ILCPs) differentiate into ILC1, ILC2, NKp46+ ILC3, and DN ILC3 but 
not CCR6+ LTi-like ILC3 (55). Thus, NK cells, CCR6+ LTi-like ILC3, and other ILCs are each 
developmentally distinct lineages.  
Adult bone marrow further contains unipotent immature progenitors for ILC2, NK cells, 
and ILC1, but not obviously for ILC3. ILC2 precursors (ILC2Ps) are a relatively large 
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population in the bone marrow, first identified as a cell with unknown function before the 
recognition of ILC2, and later described to selectively generate ILC2 (56, 57). Precursors for NK 
cells have long been recognized in the bone marrow, identified in sequence as pre-pro-NK, pre-
NK precursor (pre-NKP), refined NKP (rNKP), and immature NK (iNK) (58). To determine if 
this sequence gave rise specifically to NK cells or also included other ILC subsets, these 
developmental stages were recently reevaluated for expression and fate-mapping of Plzf, 
indicative of ILCP origin. These results demonstrated that NK cell precursor stages substantially 
overlapped with other ILCs, with the most restricted iNK generating significantly more ILC1 
than NK cells (59). Thus, the bone marrow contains ILC2 as well as ILC1 and NK cell 
progenitors, but similar to their mature counterparts, ILC1 and NK cell progenitors express 
overlapping cell-surface phenotypes and can only be differentiated using reporter mice. 
In the absence of antigen-specific receptors, ILCs respond quickly to cytokine signals, 
including an IL-1 family danger signal and an additional STAT-activating cytokine: IL-12, IL-18 
and IL-15 stimulate ILC1; IL-25, thymic stromal lymphopoietin (TSLP) and IL-33 trigger ILC2; 
and IL-23 and IL-1β stimulate ILC3 (21, 23, 27). Thus, ILCs are rapidly acting, innate source of 
cytokines that are sensitive to, and respond to, changes in the cytokine microenvironment. This 
principle explains three key roles for ILCs that have emerged: 1) homeostatic functions, likely 
due to constitutive cytokine production and/or effective antigen-independent responses to subtle 
homeostatic perturbations; 2) robust and emergent responses to danger stimuli, such as early 
infection, leading to temporary control; and 3) crosstalk with other innate immune cells and 
regulation of the adaptive immune response.  
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Remarkably, the functional specializations of ILCs as well as their developmental 
programs resemble those previously recognized in CD4+ T helper cell subsets (21). Therefore, 
ILC1, ILC2 and ILC3 are considered the innate counterparts of Th1, Th2 and Th17, while NK 
cells are the innate counterpart to CD8+ cytotoxic T cells (21, 60). To date, there is no recognized 
ILC counterpart to Treg. The similarities between ILCs and T cells raise the intriguing 
possibility that all lymphocytes, including those of fundamentally distinct lineages, may share 
core “modules of immunity” that encompass transcriptional circuitry and effector functions, but 
utilize non-redundant, complementary mechanisms of pattern recognition to enact effector 
functions. Here, we focus on modules currently known to be shared by ILCs. Unless otherwise 
stated, for all modules discussed below, T cell comparisons are made with effector memory 
subsets, rather than naïve cells unless otherwise stated, the latter of which have fundamentally 
different profiles (3). 
 
1.3 Cytotoxicity  
NK cells and CD8+ T cells are grouped together in the same immune module based on 
their shared function as cellular assassins. Cells in this module share cytotoxic potential 
produced through overlapping mechanisms, namely, mutual expression of perforin, granzymes, 
Fas ligand (FasL), and TNF-α, as well as production of the cytokine IFN-γ (discussed more 
extensively in Module 1) (61). In humans, these cells also express an additional factor, 
granulysin, that is not conserved in mouse (62). This module is critically regulated by the 
cytokines IL-12, IL-18, and IL-15. The expression of two transcription factor (TFs) in the T-box 
family, T-bet and Eomesodermin (Eomes), also characterize this module. 
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Perforin, granzymes, and granulysin all act in the same secretory pathway. Activated 
cytotoxic cells form immunological synapses with target cells and release granules containing 
these effector molecules. Perforin demonstrates substantial structural homology to the 
complement Membrane Attack Complex (MAC), and likewise, inserts into the membrane 
forming large holes through which granzymes and granulysin can enter (61). Granzymes are a 
family of serine proteases that differ in their substrate specificity and the extent to which they 
cause cellular damage. In human and mouse, granzyme B is the strongest pro-apoptotic member 
of the family, followed by granzyme A. However, the mechanism by which granzyme B leads to 
apoptosis differs between species, as it directly activates intracellular caspase cascades in mouse, 
but preferentially cleaves BID to induce the mitochondrial apoptosis pathway in human (62). 
Meanwhile, the antimicrobial molecule granulysin directly targets any intracellular pathogens 
living in endosomal compartments of infected cells (62).  
FasL and TNF-α are both homotrimeric proteins that belong to the tumor necrosis factor 
(TNF) superfamily and can induce cellular apoptosis by engaging their respective receptors, Fas 
and TNF-R1. TNF-α also ligates TNF-R2, but this pathway does not cause apopotosis, instead 
leading to increased cell proliferation and survival. Based on their shared expression of 
intracellular death domains (DD), Fas and TNF-R1 along with four other members in the TNF 
superfamily form the death receptor subfamily (63-65). Upon ligation, Fas and TNF-R 
oligomerize and can recruit adaptors through mutual DDs, which in turn recruits initiator 
procaspase 8 into the death-inducing signaling complex. Autoproteolysis of caspase 8 leads to its 
subsequent proteolysis of effector procaspases -3, -6, and -7, and downstream cleavage of BID 
leading to mitochondrial apoptosis. Both FasL and TNF-α exist as cell-surface and secreted 
forms. For FasL, it is the cell-surface form of the molecule that generates cytotoxic potential, 
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whereas the secreted form acts as cytokines that induce the master immune transcription factor 
NFκB. For TNF-α, both cell surface and secreted forms are able to induce either apoptosis or 
NFκB, though cell-surface TNF-α preferentially binds non-apoptotic TNF-R2 (66-68). 
The TFs Eomes and T-bet are essential regulators of the cytotoxicity module in mouse 
and likely also in human based on their conserved pattern of expression (69). As members of the 
same T-box family, Eomes and T-bet have somewhat redundant functions, allowing each TF to 
partially compensate for the other (70, 71). Therefore, the cytotoxic program fails to develop 
only in the absence of both molecules, leading to the selective ablation of CD122hi (marking IL-
15 receptor beta, IL-15rβ) memory CD8+ T cells and NK cells, and the aberrant expression of 
IL-17 by remaining CD8+ T cells upon their activation (72, 73).  
The regulation and specific functions of Eomes and T-bet appear to differ. In CD8+ T cell 
effector differentiation, T-bet expression temporally precedes that of Eomes (74), with the 
highest T-bet to Eomes ratio in early effector cells and the lowest ratio in memory cells. While 
T-bet induces IFN-γ and IL-12Rβ2, Eomes superiorly induces perforin and granzyme B 
expression (71, 74, 75). Initially, this developmental sequence appeared to be conserved in NK 
cell differentiation, with T-bet sustaining immature NK cells and Eomes sustaining mature cells 
(73). Yet, evaluation of mice deficient for T-bet and Eomes in addition to transfer studies have 
demonstrated that Eomes is uniquely required for NK cell development, while T-bet is in fact 
required for the development of ILC1 (51, 76, 77). Moreover, when ectopically expressed, 
Eomes skews ILC1 to a cytotoxic NK cell profile with enhanced Ly49 expression; T-bet 
overexpression similarly results in the increased production of Eomes– phenotypic ILC1 (76, 78). 
These data suggest that Eomes and T-bet might achieve balance through mutual repression. 
Developmentally, the exogenous factors that lead to differential regulation of Eomes and T-bet 
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remain an active area of investigation, but likely include tissue factors such as TGF-β (79). In 
sum, both Eomes and T-bet together physiologically define the cytotoxic module, but Eomes is 
particularly critical for NK cells. 
 
1.4 Module 1: Intracellular Pathogens and Viruses 
 
 ILC1 and Th1 are grouped together based on their shared production of IFN-γ and TNF-
α, and, critically, their absence of granular cytotoxicity.  In mouse, some ILC1 additionally 
appear to share expression of the pro-apoptotic molecule TRAIL (76, 80). Underscoring the 
similarity in cytokine production with the cytotoxicity module, Module 1 is similarly defined in 
mouse by the TF T-bet (76, 77, 81). Furthermore, cells in this module are similarly regulated by 
the cytokines IL-12, IL-18, and IL-15. Engagement of this module is physiologically associated 
with viral and intracellular pathogen immunity, but it is deregulated in Crohn’s disease and some 
forms of autoimmunity such as Type 1 Diabetes (23). 
 IFN-γ is the only member of the Type 2 Interferon family and the prototypic cytokine 
produced by cells in Module 1. IFN-γ ligates the heterodimer composed of IFNGR1 and 
IFNGR2, which transduce signals through their respective tyrosine kinases, JAK1 and JAK2, to 
ultimately phosphorylate and activate STAT1 (82). A classic role of IFN-γ signaling is 
macrophage activation, leading to increased MHC I and MHC II antigen presentation and the 
production of reactive oxygen species via NADPH oxidase induction (82, 83). Along with 
additional the anti-proliferative signals generated by IFN-γ, macrophage activation supports the 
clearance of intracellular pathogens as well as antiviral responses. Beyond macrophages, IFN-
γ also increases leukocyte trafficking by inducing chemokines on the epithelium and strengthens 
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Th1 polarization (82, 83). Many signals generated by IFN-γ overlap with TNF-α and these two 
Module 1 cytokines synergize for enhanced function (82). 
 T-bet has long been recognized as a key driver of Th1 differentiation, and is more 
recently recognized as a necessary factor for ILC1 differentiation (51, 76, 77, 81, 84). In the 
absence of Th1, naïve T cells do not produce IFN-γ, and instead polarize to a Th2 effector 
program (85). The fate of ILC precursors unable to engage T-bet is currently unclear. 
Functionally, T-bet binds to the promotor and regulatory elements of Ifng (86). It also directly 
induces the expression of Runx3, an additional Ifng-activating TF. Supporting the role of Runx3 
in Module 1, Runx3 deficient mice also fail to generate ILC1 (87).   
While T-bet clearly has an important role in Module 1, the role of Eomes is more 
controversial. In mice, ILC1 are currently best defined by their lack of Eomes expression. 
However, in the absence of an Eomes fate-mapping mouse, it unclear if ILC1 always lack Eomes 
expression, or if they may sometimes express it. Indeed, ATACseq data from mouse ILCs 
demonstrate a graded expression of ATAC peaks surrounding Eomes, with highest expression in 
NK cells, lower expression in ILC1, and even less expression in ILC2 and ILC3 (88), suggesting 
the potential to express Eomes is not gone in ILC1.  Furthermore, the “Eomes negative” 
definition of the module cannot be universally true, as both mouse and human Th1 cells can 
express Eomes when activated (89, 90). In human, two ILC1 subsets have been identified, one in 
the lamina propria (LP) that exclusively expresses T-BET and another among the intraepithelial 
lymphocytes (IELs) that expresses T-BET and intermediate levels of EOMES compared to NK 
cells.  Notably, IELs are in direct contact with the epithelium, constitutively sensing foreign 
metabolites and antigens, and are well known to express highly activated phenotypes in steady-
state (91). Collectively, these data suggest that cells in Module 1 rely on T-bet, likely for this TFs 
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preferential induction of cytokine versus cytolytic machinery, but may express Eomes in some 
circumstances, such as activation. Regardless, Eomes is unlikely to be a core regulator of the 
module.  
 
1.5 Module 2: Barrier Maintenance and Helminthes 
ILC2 and Th2 share the same functional module based on their mutual production of IL-
4, IL-5, and IL-13 (92). Other factors associated with this module include IL-9, GM-CSF, and 
the epidermal growth factor family member amphiregulin (93, 94) Transcriptionally, the core TF 
driving Module 2 polarization and function is GATA3 (56, 95, 96), while IL-25, IL-33, and 
TSLP are conserved cytokine regulators. Type 2 cytokines support tissue remodeling and the 
response to helminth infections, but are deregulated in the development of allergy and asthma 
(23). 
IL-4 and IL-13 are structurally similar cytokines that have overlapping but distinct 
functions. IL-4 ligates two STAT6-activating receptors: Type 1 IL-4R is composed of IL-4Rα 
and γc, while Type 2 IL-4R comprises IL-4Rα and IL-13Rα1 (97, 98). IL-13 also binds to the 
Type 2 IL-4R, but can also bind to a decoy receptor with no signaling function, IL-13Rα2 (97, 
98). In human, Type 2 receptors are broadly expressed by immune and non-immune cells, 
though not by T cells (98). Overlapping functions of IL-4 and IL-13 include: B cell class switch 
to IgE and IgG1, inhibition of Module 1 immunity, and alternative activation of macrophages that 
support tissue repair and wound healing. IL-4 has a specialized function to induce Th2 
development, and in turn, is produced in greater quantities by Th2 (99, 100). Meanwhile, IL-13 
acts directly on epithelial stem cells to induce goblet cell and tuft cell hyperplasia (101-103), 
which can cause airway remodeling associated with asthma (98). During helminth infection in 
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mouse, tuft cell-produced IL-25 activates IL-13 production from ILCs, leading to a feed-forward 
loop caused by even greater tuft cells generation (101-103). 
IL-5 is a cytokine in that promotes eosinophil development, survival, and activation as 
well as B cell activation (104). IL-5 ligates a heterodimeric receptor composed of IL-5Rα and 
the common β−chain, the latter of which is shared by the myeloid growth factors GM-CSF and 
IL-3 (104). In mice, ILC2 constitutively express IL-5, which is further enhanced during helminth 
infection and after feeding (105). While eosinophil degranulation combats helminthes, it causes 
airway remodeling in asthma (106). 
 GATA3 is the master TF regulating Module 2 and is required for the development of 
ILC2 and Th2 (56, 95, 107, 108). In both human and mouse, Il4, Il5, and Il13 are located in a 
gene cluster on the same chromosome and are mutually regulated by the locus control region 
within an intervening gene, Rad50 (92, 109, 110); Csf2 (encoding GM-CSF) is also located 
nearby on the same chromosome. GATA3 binds regulator elements within this gene cluster and 
in the Rad50 locus control region as well as directly to the promoter of IL-5 and IL-13 (111). 
Consistent with the minimal expression of IL-4 by ILC2, GATA3 does not appear to bind 
directly to the IL-4 promoter and conditional deletion experiments demonstrate that it is not 
required for expression after Th2 development (111, 112). However, GATA3 conditional 
depletion demonstrates a common role for this TF in Moddule 2 production of IL-5, IL-13, and 
Amphiregulin (99, 112). 
 
1.6 Module 3: Extracellular Bacteria and Fungi 
 All ILC3 subsets, Th17, and Th22 belong to Module 3, based on production of cytokines 
IL-22, IL-17a, and/or IL-17f. IL-26 is produced in human but is not conserved in mouse. Unlike 
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other modules, cytokine production is not shared between all cells in the module, but is 
compartmentalized: NKp46+ ILC3 and Th22 produce only IL-22, DN ILC3 produce IL-17a and 
IL-22, and CCR6+ ILC3 and Th17 produce all Module 3 cytokines (42). Th22 also produce IL-
10, which is not made in substantial quantities but other cells (113). Yet, Module 3 shares 
additional factors, including regulation by the cytokines IL-23 and IL-1, expression of the 
lineage-defining TF RORγt, and an important role for the TF AHR (Aryl Hydrocarbon 
Receptor). Another feature of this module is inherent plasticity, particularly to Module 1. Module 
3 is conventionally associated with immunity to extracellular pathogens and fungi, but also 
recognized to have a role in tissue homeostasis. It is deregulated in the development of psoriasis, 
Chron’s disease, and some forms of autoimmunity such as the multiple sclerosis model 
experimental autoimmune encephalomyelitis (EAE).  
 IL-17a and IL-17f are pro-inflammatory cytokines that belong to the IL-17 family, of 
which IL-17a is the founding and best understood member (114). Both cytokines are 
homodimers that function by ligating the heterodimeric receptor composed of IL-17RA and IL-
17RC, but IL-17f binds IL-17RA with lower affinity; IL-17a/f can also function as a heterodimer 
(115). IL-17 receptors each express a SEFIR (similar expression of fibroblast growth factor 
genes and IL-17Rs) domain, which has sequence homology to the TIR (Toll/Interleukin-1) 
domain expressed by TLRs (Toll Like Receptors) and members of the IL-1R family (116). This 
domain recruits the adaptor and ubiquitin ligase Act1, which further recruits, then activates 
TRAF6 (TNF-R associated 6), leading to NFκB and C/EBP activation (114, 116-118). 
Functionally, IL-17a and IL-17f predominantly act on epithelial and stromal cells to induce 
chemokines that recruit neutrophils and other leukocytes, pro-inflammatory cytokines such as 
IL-6, and antimicrobials such as β-defenensins. In humans, IL-17 is critically important for 
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control of the commensal fungi C. albicans, but it has a wider role to control many extracellular 
bacteria and fungi in mouse (114, 116, 117). 
 IL-22 and IL-26 belong to the IL-20 subfamily of the IL-10 superfamily of cytokines 
(119). As IL-26 expression is restricted to human, the functions of IL-22 are better understood.  
Both cytokines utilize the shared co-receptor IL-10RB, but ligate different heterodimeric 
receptors, with IL-22 binding IL-22RA1 and IL-26 binding IL-20RA (119). IL-10RB is 
expressed in many cell types, but hematopoietic cells do not express IL-22RA1; actions of IL-22 
are therefore restricted to non-hematopoietic cells such as stromal and epithelial cells, where it is 
broadly expressed (120). Signaling through JAK1/TYK2 strongly activate STAT3, as well as 
engage MAPK (120). In the small intestine, IL-22 is predominantly produced by ILC3 in steady 
state, and directly activates the epithelium to produce anti-microbials including defensins, S100 
proteins, and pro-growth Reg (Regenerating) family proteins (120-122). In mouse, this function 
is required for early defense against C. rodentium, an attaching-and-effacing model of E. coli 
infection (121). Interestingly, IL-26 was recently reported to have direct antimicrobial features 
through pore formation (123). As a pro-growth and immune-activating cytokine, the impact of 
IL-22 is highly context dependent, leading to homeostatic roles in barrier maintenance and 
wound repair, but also pro-inflammatory, colitogenic, and tumor-supporting roles when 
deregulated (119, 120, 124-126). 
 The master transcription factor regulating Module 3 identity is RORγt because in its 
absence, Th17 and ILC3 do not develop (42, 127). After development, however, RORγt directly 
regulates few genes, though in Th17, these include the signature cytokines IL-17a and IL-17f as 
well as receptors for key regulatory cytokines IL-23 and IL-1 (128). In ILC3s, RORγt may have 
an even smaller effect, as conditional deletion of RORγt as well as pharmacologic blockade 
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revealed no difference in IL-17a production, but did reduce IL-17a production in Th17 (129). 
Many other factors have been shown to regulate Th17, but the TF AHR in particular appears also 
to be shared by ILC3 (48, 130, 131). AHR is a ligand-dependent TF that binds pollutants, dietary 
metabolites, and bacterial metabolic byproducts (132). In conjunction with RORγt, AHR is 
required for the development of Th-22 and post-natal ILC3 and also directly controls IL-22 
production (48, 130, 131, 133). 
 
1.7 γc Cytokines and Lymphoid Development 
Lymphocyte development is critically dependent on γc, a pleiotropic cytokine co-receptor 
that is shared by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, and that is required for the function of 
these molecules (134). Thus, these cytokines are collectively called γc-family cytokines. In 
mouse, all lymphocytes require γc for normal development (24, 134, 135). In human, T cells and 
NK cells similarly require γc; B cells do not share this developmental requirement due to a 
species difference in IL-7 during B cell generation, although γc-deficient B cells appear to have 
cell-intrinsic functional impairments (136). As other ILCs have not been analyzed in patients 
with mutations in the gene encoding γc, IL2RG, the human requirement for γc in ILC1, ILC2, and 
ILC3 development is currently unknown.  
γc-family cytokines engage three primary pathways: JAK/STAT, PI3K/AKT, and 
RAS/MAPK. Generally, JAK/STAT activation induces the effector functions related to γc 
cytokines, while all three pathways converge on increased cell survival and proliferation (134).  
The contribution of γc is conserved between cytokine receptors, and is functionally mediated by 
the tyrosine kinase Jak3. γc constitutively associates with Jak3, with its carboxy-terminal binding 
to the Jak3 amino-terminal FERM domain (137).  Upon activation, Jak3 phosphorylates Jak1 
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carried by the other γc-family cytokine co-receptor, leading to downstream function. Thus, in the 
absence of Jak3, γc-family receptor Jak1 activation is also blocked.  
Among γc-family cytokines, IL-7 and IL-15 are the most important factors for 
lymphocyte development in the bone marrow, though other family members regulate aspects of 
lymphocyte function such as T-cell polarization and B-cell class switch (134). In mice, IL-7 is 
primarily responsible for T cell, B cell, ILC2, and ILC3 development, while IL-15 is a critically 
required for NK cell and ILC1 development (24, 135, 138). Both IL-7 and IL-15 directly induce 
pro-survival machinery, including Bcl-2, an anti-apoptotic factor in the mitochondrial membrane 
that prevents cytochrome c release, as well as other Bcl-2 family members such as Mcl-1 and 
Bcl-xL (139, 140).  
The mechanism by which γc-family cytokines sustain different lymphocyte populations is 
somewhat different. For T cells, IL-7 sustains development directly by increasing cellular 
survival. Residual T cells are more apoptotic in the absence of Jak3, and their development is 
rescued by transgenic expression of pro-survival Bcl-2 in Jak3 deficient mice (141). However, 
this approach is unable to rescue B and T cell differentiation, suggesting a greater role for γc 
cytokines in mouse B and NK cell lineage identity. For NK cells, IL-15 maintains NK cells in 
the periphery after their development by promoting cell survival, as Bcl-2 transgenic but not 
wildtype NK cells are able to persist in IL-15 deficient mice (142). Interestingly, original 
experiments demonstrated that Bcl-2 transgenes can further rescue IFN-γ−producing, non-
cytotoxic NK1.1+ cells in IL-15rβ deficient mice, which lack the co-receptor for IL-15 and IL-2 
(143). From a modern perspective, given their lack of cytotoxicity, it is unclear if these cells are 
in fact NK cells or rather ILC1. Furthermore, it remains unclear the extent to which other ILCs 
rely on IL-7 or IL-15 mediated Bcl-2 signals for their development and/or maintenance. In 
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summary, γc-family cytokines function as survival factors, which act at different stages in 
different lymphocyte populations. 
  
1.8 Perspectives 
 The modular immunity model posits that lineage primarily guides activation pathways, 
while mutual expression of core, conserved transcriptional modules guides function. But to what 
extent does this model represent true biology? Are ILCs totally redundant with conventional 
CD4+ T cells and ILLs, with the exception of their activation kinetics and tissue location? Or do 
lineage determinants differently regulate the ability of cells to engage certain effector programs?  
There are several requirements to determine the completeness of the modular immunity 
module. First, as ILCs are a newly discovered class of cells, the breadth of their function must 
first be assessed. These data may have further utility to determine controversial subset 
designations within the ILC lineage, in particular, that of NK cells and ILC1.  Second, to 
establish the extent to which lineage determinants alone provide unique functions to 
lymphocytes, ILCs and T cells must be directly compared. Third, new mouse models that 
specifically lack ILCs are required to experimentally test their function, which compels a better 
understanding of ILC development.  
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CHAPTER 2 
 
Transcriptional Programs Define Molecular Characteristics  
of ILC Classes and Subsets 
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2.1 Abstract 
Innate lymphoid cells (ILCs) serve as sentinels in mucosal tissues, sensing release of 
soluble inflammatory mediators, rapidly communicating danger via cytokine secretion, and 
functioning as guardians of tissue homeostasis. The diversity of these cells is rapidly expanding. 
In mouse and human, three ILC classes have emerged, ILC1, ILC2, and ILC3, with ILC1 and 
ILC3 including several subsets. The classification of some subsets is unclear and it remains 
controversial whether NK cells and ILC1 are distinct cell types. To address these issues, in part 
one, we analyzed ILCs and NK cells gene expression within mouse small intestine, spleen, and 
liver, as part of the Immunological Genome Project.  As much less is know about ILCs in 
humans compared to mouse, in part two, we also transcriptionally profiled human tonsillar iILC1 
and ILC3. To test the lineage and functional kinships to cytokine-secreting T helper cell 
counterparts, we make further comparisons to the respective adaptive counterparts of these ILCs, 
Th1 and Th17, isolated from the same tissue microenvironment. 
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2.2 PART 1: Mouse Transcriptional Profiles 
2.2.1 Introduction 
The Immunological Genome (ImmGen) Project is a collaborative effort of immunologists 
and computational biologists that seek, through rigorously controlled protocols for data 
generation and analysis, to dissect gene expression patterns of cell types across the immune 
system to better understand the immune response and comprehensively define its regulatory 
networks (144). In this context, we interrogated the global gene-expression profiles of innate 
lymphoid cells (ILC) from mice following ImmGen’s stringent standards (144).  
While shared TFs, cell-surface markers, and functional properties of cytokine production 
define the classes of ILC1, ILC2, and ILC3, deviations in one or more categories by 
subpopulations define subsets of ILCs within the larger class. In mouse, ILC2 appear to be the 
most homogenous class thus far, defined by expression of the IL-7 receptor (IL-7R, CD127), 
stem cell antigen-1 (Sca-1), the inhibitory receptor KLRG1, and the IL-33 receptor ST2 (24). In 
comparison, at least five subsets of mouse ILC3 have been reported. These include CD4+ and a 
CD4– subsets of Nkp46– RORγt+ lymphoid tissue inducer-like (LTi-like) cells (42); RORγt+, T-
bet+, Notch-dependent Nkp46+ ILC3 (42, 45, 47-50); a ILC3èILC1 transitional subset with 
downregulated RORγt, which expresses T-bet and higher amounts of NK1.1 and produces IFN-γ 
(‘ex-RORγt+ ILC3’)(51); and IL17-producing RORγt+ Nkp46– ILC3 in the large intestine (44). 
ILC1 have the most complicated and controversial distinction of both the ILC class itself 
and between subsets within the class (38). ILC1 and NK cells have functional similarities, 
primarily IFN-γ production, and share expression of T-bet and many cell-surface markers, such 
as NKp46 and NK1.1. However, NK cells are currently thought to have more cytotoxic potential 
than ILC1. IL-7R and CD49a surface expression are used to distinguish ILC1 from NK cells in 
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many but not all mouse tissues, as there is considerable diversity of ILC1 subsets between tissues 
(21, 38). Lineage-tracing experiments have shown that ILC1 and NK cells originate from distinct 
progenitors (51, 55), and mature NK cells are dependent on the transcription factor Eomes while 
ILC1 are not. However, immature NK cells also share many ILC1 markers and lack expression 
of Eomes (38, 58, 73).  
The breadth of polarization and relationship among ILC subsets remain incompletely 
understood. To better understand the functional differences between ILC classes and reported 
subsets within a class, we discriminated 7 populations of ILCs in the siLP (NK cells, ILC1, ILC2, 
and 4 subsets of ILC3), 3 additional subsets of ILC1 from liver and spleen, and small intestinal 
intraepithelial lymphocytes (siIEL), and 2 NK cell subsets from liver and spleen. Our findings 
provide a molecular definition of ILC classes and subsets, as well as identify a core signature in 
ILCs compared to NK cells. We also identify novel targets for future investigation and generate a 
comprehensive high quality and publically available resource of ILC transcriptomes. 		
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2.2.2 Materials and Methods 
Mice 
Consistent with ImmGen standards, six-to-nine week old male C57BL/6J mice and male 
B6.129P2(Cg)-Rorctm2Litt/J (with the sequence encoding enhanced green fluorescent protein 
(EGFP) inserted into the locus encoding RORγt) obtained from Jackson Laboratories and 
maintained at Washington University School of Medicine (WUSM) under specific pathogen-free 
conditions were used for cell sorting and validation experiments. B6.129P2-Cxcr6tm1Litt/J mice 
with the sequence encoding EGFP inserted into the locus encoding CXCR6 obtained from 
Jackson Laboratories were used for validation experiments in which mice were littermates or 
age-matched, gender-matched, and co-housed when possible. Il-22 tdTomato reporter BAC 
transgenic mice were used for validation experiments.40 The WUSM animal studies committee 
approved all experiments.  
 
Antibodies and flow cytometry 
Anti-CD3e (145-2C11; 145-2C11), anti-CD19 (eBio1D3), anti-CD27 (LG.7F9), anti-
CD49b (HMa2; DX5), anti-gamma delta (UC7-13D5; eBioGL3), anti-CD127 (A7R34; 
eBioSB/199), anti-CD49a (HMa1), anti-Nkp46 (29A1.4), anti-CD304 (3DS304M), anti-CD45 
(30-F11), anti-NK1.1 (PK136), anti-Sca-1 (D7), anti-ST2 (RMST2-2), anti-TRAIL (eBioN2B2), 
anti-CD4 (GK1.5), anti-KLRG1 (2F1), anti-RORγt (AFKJS-9), anti-Eomes (Dan11mag), SAv-
PE/Cy7, and isotype-matched control monoclonal antibodies were obtained from eBioscience. 
Antibody to CD25 (PCB1) and 7-AAD were obtained from BD Biosciences. Antibody to CD45 
(30-F11) was obtained from Miltenyi Biotec. LIVE/DEAD Fixable Aqua and SAv-APC were 
obtained from Life Technologies.  Monoclonal anti-NKp46 (Cs96, rat IgG) was produced and 
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biotinylated in our lab.  Fc receptors were blocked before surface staining using supernatant from 
anti-CD32 mAb-producing hybridoma cells (HB-197, ATCC). For intracellular staining, the 
FOXP3 staining kit (eBioscience) was used. Data were acquired on a BD FACSCanto II and 
analyzed using FlowJo software (Treestar).  
 
Cell identification, isolation, and microscopy 
Cells were isolated from between 3 to 15 mice per sample. For siLP and siIEL isolation, 
small intestine beginning half a centimeter after the pylorus and ending half a centimeter before 
the cecum with PP removed was dissociated using the Miltenyi Lamina Propria Dissociation kit, 
which includes 2 DTT/EDTA washes and an enzymatic digestion step of 30 minutes. For liver 
and spleen isolation, mice were perfused with 20 mL cold PBS and tissue was dissociated 
through a 70 µm cell strainer. Lymphocytes were enriched at the interface between a gradient of 
40% and 70% Percoll in HBSS. siIEL were further pre-enriched by negative selection with anti-
CD8 MicroBeads (Miltenyi). Liver and spleen were pre-enriched by negative selection with anti-
CD19 and anti-CD4 MicroBeads (Miltenyi). Cells were double-sorted directly into TRIzol with a 
Becton-Dickinson FACSAria II. The data browser of the ImmGen Project website shows flow 
cytometry plots from gating strategies and purity from the first round of sorting. These methods 
following the published standard operations protocol, reproduced from the ImmGen website 
here:  
The success of the ImmGen project depends on the reproducible generation of cell 
populations in a consistent and reproducible manner, minimizing site-to-site differences. It is 
thus essential that all cell preparations intended for ImmGen profiling strictly follow the steps 
and limits described below. To achieve >99% sort purity, preparations will involve either a round 
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of negative magnetic selection followed by a single flow sorting step, or 2 rounds of sorting. 
Reagents Phenol-red free DMEM (Sigma-Aldrich D1145) ACK Lysing Buffer (Lonza 
BioWhittaker 10-548E – order from Fischer Scientific) Propidium Iodide (Sigma-Aldrich P4170) 
Trizol (Invitrogen 15596-026) Staining Medium Staining and cell prep medium: Phenol-red free 
DMEM, 0.1% azide, 10 mM HEPES, 2% FCS Time tables 1. Total cell preparation time, from 
euthanasia to Trizol, must be held around 4 hours for “short preparations” or 6-7 hours for more 
intricate preparations. 2. Replicate sorts should be performed on separate days to smooth out 
variations across parallel samples.  3. Mice housed in SPF conditions 4. All mice used are males. 
In most instances, the mice used will be C57Bl/6J shipped from the Jackson Laboratory, Maine, 
and used 6 to 10 days from reception. 5. Tissues should be pooled from 3 (or more, but not less) 
mice for each batch. Positively verify gender of all animals. 6. Euthanize all mice between 8:30 
and 9:30 am by cervical dislocation (no CO2), sorter booked in consequence. Harvesting tissues 
1. Dissect organs and place in ice-cold medium within 5 minutes of euthanasia. 2. For 
preparation of cells from non-lymphoid tissues, perfuse tissues with cold PBS or collagenase-
containing medium. 3. If harvesting cells from non-lymphoid tissues (and thymus), ensure that 
tissues are picked clean of attached lymph nodes.  
Cytospins were prepared following the same ImmGen standards, except from only 1 to 3 
mice; splenic samples were positively pre-enriched by using DX5-coated beads (Miltenyi). 
Sorted cells were spun onto slides, left to dry overnight, and then fixed and stained with Diff-
Quik. Pictures were taken at 60x with oil-immersion using a Nikon Eclipse E800 and Leica 
Application Suite software.  
 
Microarray and data analysis 
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Two to three replicates of RNA were obtained from each sample that passed quality 
control. RNA amplified and hybridization to the Affymetrix Mouse Gene 1.0 ST array was 
carried out by ImmGen following a standardized TRIzol extraction protocol.Data generation and 
quality control documentation also followed the ImmGen protocols. QC data, replicate 
information, and batch information from each ImmGen sample are available on the ImmGen 
website, at www.immgen.org. Data were analyzed using GenePattern software (145) (Broad 
Institute). Raw data were normalized using RMA.  
Differences in gene expression were identified using the Multiplot Studio function of 
GenePattern, from a filtered subset of genes with coefficient of variation less than <0.1 in all 
samples and expression of at least 120 relative units in one subset by the class mean functions, a 
value that corresponds to a 95% confidence of true expression across the ImmGen dataset. For 
gene expression signatures of individual subsets, pairwise comparisons were made between 
subsets, filtering for fold-changes of 2 or 4-fold, as indicated. For comparisons between 2-4 
samples, probe sets were considered to have differences of expression for transcripts expressed 
>120 relative units, with > 2-fold change and P value of <0.05 (Student’s t-test), except between 
siLP ILC1 and siLP NK cells where P value was not considered.  
Volcano plots and fold-change-by-fold-change plots were produced in Multiplot, and 
degree of overlapping genes between subsets was calculated in MATLAB. Heat maps were 
generated using Gene-E (http://www.broadinstitute.org/cancer/software/GENE-E/). Data were 
log2-transformed, visualized by ‘Relative’ expression per row or ‘Global’ expression in the heat 
map, as indicated, and rows were clustered using the Hierarchical Clustering function with the 
Pearson correlation as a metric. Where more than one probe set with the same gene annotation 
was found, the probe set with highest average expression was used. For PCA, the top 10% of 
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most variable probe sets was calculated using PopulationDistances PCA program (Scott Davis, 
Harvard Medical School, Boston MA). This program identifies differentially expressed genes by 
ANOVA using the geometric standard deviation of populations to weight genes that vary in 
multiple populations. The top 10% of most variable genes dataset was log2-transformed in 
MATLAB and used to generate a PCA with the functions pca and scatter3. Hierarchical 
clustering of sample replicates was carried out in Gene-E from the same dataset using the 
Pearson correlation as a metric. For RNAseq analysis, data from GEO accession GSE52043 were 
visualized in IGV and aligned to the mm9 genome, as described previously (77).  
 
Statistics 
Prism (GraphPad Software) was used for statistical analysis of flow cytometry data. Data were 
tested using either one-way or two-way ANOVA, as appropriate. Error bars are shown as mean 
+/- SEM.   
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2.2.3 Results 
Analysis of ILC frequency and diversity  
We isolated all reported ILC subsets in the siLP from young adult C57BL/6 male mice. 
ILC2 were isolated from wild-type C56BL/6 mice and all other subsets were isolated using 
RORγteGFP reporter mice. These subsets included CD127– NK cells, CD127+ ILC1, CD4– and 
CD4+ NKp46– LTi-like ILC3, NKp46+ RORγthi ILC3, and NKp46+ RORγtlo ILC3 (Figure 1A). 
Notably, NKp46+ RORγthi and RORγtlo ILC3 cannot be discriminated by intracellular RORγt 
staining in wild-type C56BL/6 mice, in which only one NKp46+ RORγt subset is detectable; 
thus, the use of RORγteGFP reporter mice provided the unique opportunity to profile RORγtlo and 
RORγthi subsets, as previously described (146). As the RORγtlo ILC3 subset expresses higher 
amounts of NK1.1 compared to RORγthi ILC3 (Figure 1B-D), we reasoned this would be 
enriched for converted or actively converting ‘ex-RORγt+ ILC3’. We also profiled 
CD49b+TRAIL– NK cells and CD49b–TRAIL+ ILC1 in the liver, and CD127– NK cells from 
CD127+ ILC1 in the spleen, the last of which has been reported but has not previously been 
called ILC1 (147). siIEL ILC1 were isolated from the intestinal epithelium as NK1.1+NKp46+. 
They are phenotypically distinct from NK cells due to TGF-β imprinting (148), although their 
developmental origin and transcriptional relationship to siLP ILC subsets remains unclear. 
Cytospins demonstrated that ILC subsets were morphologically pure lymphoid 
populations (Figure 1E). We assessed ILC frequency with regard to these 12 subsets within the 
lymphocyte population of small intestine, liver, and spleen in naive mice (Figure 2). ILCs were 
most abundant in the siLP, followed by liver and spleen; siIEL contained the lowest frequency of 
ILCs. Next, we sorted these populations following ImmGen’s standardized protocol for data 
generation and analyzed gene expression using whole mouse genome array. A principal 
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component analysis showed a greater degree of diversity generated by ILC2 and ILC3 subsets 
than ILC1 (Figure 3A-B). By hierarchical clustering, three pairs of ILC subsets were 
computationally indistinguishable (Figure 3C): splenic and liver NK cells, RORγthi and RORγtlo 
ILC3, and CD4+ and CD4– NKp46– ILC3 were intermixed. All ILC1 subsets clustered separately 
from NK cells from the same tissue. However, siIEL ILC1, siLP NK cells, and siLP ILC1 
clustered in a separate branch of the dendrogram from liver and spleen NK cells and ILC1 
subsets. We conclude that beyond classical polarizations, there are environmental factors in the 
small intestine that differentiate subsets from liver and spleen. 
 
Unique transcripts of individual ILC subsets 
We assessed the unique gene-expression profile of each sorted subset (Figure 4A-H). We 
found the greatest number of unique transcripts in the siLP ILC2, with 100 transcripts expressed 
more than 2-fold (Appendix 1A) and 34 transcripts expressed more than 4-fold higher compared 
to other subsets (Figure 4A). These included expected transcripts such as Il13, Il5, IL4, Il9r, and 
the IL-25 receptor Il17rb (94, 99, 149), as well as several novel transcripts, including Rxrg, 
Pparg, Mc5r, Dgat2, and Alox5. The transcriptional repressor retinoid X receptor gamma 
(RXRG), which binds the Vitamin A metabolite 9-cis retinoic acid (150), has not been 
previously described in ILC2. Vitamin A is known to directly inhibit ILC2 differentiation by an 
unknown mechanism (151), suggesting RXRG may mediate this effect. We also find previously 
unrecognized expression of peroxisome proliferator-activated receptor gamma (PPARγ), which 
forms heterodimers with RXRs and transcriptionally mediates lipid homeostasis (150). ILC2 
expressed several other genes implicated in lipid metabolism.  These include DGAT2, which 
mediates the final reaction of triglyceride synthesis, MC5R, a receptor that causes lipid 
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mobilization in adipocytes, and ALOX5, a lipoxygenase that catalyzes leukotriene A4 synthesis. 
While ILC2 are known to regulate immune cell function in visceral adipose tissues (152), our 
data suggest that ILC2 may also directly sense lipids as well as produce lipid mediators.   
NKp46– LTi-like ILC3 subsets expressed the second greatest number of unique 
transcripts. As suggested by clustering analysis (Figure 3C), CD4+ and CD4– LTi-like had 
overlapping gene expression patterns. Only 4 transcripts were 2-fold uniquely upregulated in 
CD4+ LTi-like cells, one of which was CD4, and none were uniquely expressed in CD4– LTi-like 
(Figure 4B).  However, 65 transcripts were expressed by both subsets more than 2-fold higher 
(Appendix 1A) and 9 transcripts expressed more than 4-fold higher compared to other subsets 
(Figure 4C). Eight additional transcripts were upregulated at least 4-fold by either CD4+ LTi-
like or CD4– LTi-like ILC3, with differences in expression between subsets likely due to 
replicate variation (Figure 4B). Unique transcripts shared by both LTi-like subsets included 
those encoding the chemokine receptor CCR6, which has previously been used as a marker for 
LTi-like ILC3 (45), and CXCR5. We also find several novel genes, including Gucy1a3, Cntn1, 
Slc6a7, Cacna1g, and Nrp1. Gucy1a3 encodes the alpha subunit of the soluble guanylate cyclase 
receptor, which transduces signals from nitric oxide; however, we found no expression in LTi-
like ILC3 of the other gunaylate cyclase receptor components (data not shown). Interestingly, 
immune expression of CNTN1, a GPI-linked member of the immunoglobulin family best known 
for its role in regulating axonal guidance and neural system development was also detected. The 
L-proline transporter SLC6A7 and voltage gated calcium channel CACNA1G are similarly 
atypical, and not expressed in other immune cells (www.immgen.org). We conclude LTi-like 
ILC3 specifically express several unique transcripts compared with the entire immune system, 
including putative factors involved in neural crosstalk. 
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The remaining ILC subsets had less candidate unique markers, likely due to multiple 
comparisons with other subsets in the same class. As indicated by PCA, siLP NKp46+ RORγthi 
ILC3 and siLP NKp46+ RORγtlo ILC3 had overlapping gene expression profiles. When 
compared to all other profiled ILCs except NKp46+ RORγtlo ILC3, 16 transcripts were expressed 
2-fold higher in NKp46+ RORγthi ILC3, though a heat map reveals that most of these genes are 
also expressed by other siLP subsets at lower levels (Figure 4C). Liver and splenic ILC1 each 
expressed some unique transcripts with greater than 2-fold change compared to all other subsets 
(Figure 4D-E), but we found no unique transcripts expressed by siLP ILC1. This suggests there 
are few unique factors expressed by ILC1 subsets among all ILCs and NK cells. Surprisingly, the 
only unique transcript expressed by IEL ILC1 was Itgae, which encodes CD103 (Figure 4F). 
CD103 protein is expressed in human IEL ILC1 (148), but was not previously known to be 
expressed by mouse IEL ILC1, which lack surface protein CD103 expression, suggesting post-
transcriptional regulation in the IEL. Focusing on NK cells, we identified 4 genes that were 
expressed 2-fold higher in siLP NK cells than in all ILCs (Figure 4G). Splenic and liver NK 
cells expressed no unique transcripts. However, when both liver and spleen NK cells were 
compared as a group to all other subsets, 25 transcripts were 2-fold more highly expressed, 
although siLP NK, IEL ILC1, and splenic ILC1 show lower expression of these genes (Figure 
4H). We conclude that ILC2 and LTi-like ILC3 mRNA profiles are quite unique, while NKp46+ 
ILC3, ILC1, and NK cells profiles show considerable overlap. 
 
A transcriptional signature shared by all siLP subsets 
We next asked whether there are any uniquely expressed transcripts between profiled 
tissues of siLP, liver, and spleen. Given that siLP NK cells and ILC1 cluster further from liver 
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and splenic subsets by hierarchical clustering and PCA, we focused on the siLP (Figure 3A-C) 
Pairwise comparisons of all subsets from the siLP to remaining subsets from liver and spleen 
revealed that all siLP subsets expressed a core 35-transcript signature (Figure 5), which included 
several transcription factors such as Rora, Atf3, Nr4a1, Maff, Epas1, Bhlhe40, and Per1. 
Furthermore, all siLP-resident ILCs expressed high transcript levels of the activation marker 
Cd69 and varied levels of Csf2, which encodes GM-CSF. Although production of GM-CSF by 
ILC2 (95), ILC3 (40, 153, 154), and NK cells (155) is known, production by ILC1 has not been 
reported. Thus, ILC subsets in the siLP appear to be more activated than ILCs in other tissues, 
likely reflecting their constant exposure to varied environmental signals from the microbiome 
and incoming nutrients, including well-documented transcriptional activators such as Vitamin A 
(151, 156) and AhR ligands (48, 130). 
 
Transcription factors, cytokines, and chemokines expressed by ILC subsets 
To address broad patterns of gene expression between ILC subsets and classes, we 
interrogated expression of previously reported and novel TFs, chemokines, cytokines, and other 
secreted factors. The TFs expressed at the highest relative levels included well-documented ILC-
defining Id2, ILC3 class-defining Rorc, ILC1 and NKp46+ ILC3-defining Tbx21 and NK cells-
defining Eomes (Figure 6A). ILC2-defining TFs Gata3 and Rora were enriched in ILC2 but also 
expressed in all ILCs, consistent with an early role in ILC development, at least for GATA-3 
(99). Nfil3, which is required for NK cells (157, 158), ILC3, and ILC2 (80, 159) development, 
was expressed most highly in siLP subsets; NKp46+ ILC3, ILC1, and NK cells showed highest 
transcript levels, followed by LTi-like ILC3 and ILC2, and much lower transcript levels were 
present in the liver and spleen ILC1 and NK cells. Furthermore, TFs identified in the siLP 
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signature Atf3 and Nr4a1 (Figure 5), were expressed at levels similar to lineage-defining TFs. 
Collectively, these data suggest a marked role of the intestinal microenvironment in the 
expression of certain TF, which subsequently can have diverging roles between ILC classes.   
Analysis of chemokines and chemokine receptors (Figure 6B), as well as cytokines and 
cytokine receptors (Figure 6C), revealed shared and distinct expression patterns. Beyond known 
signature cytokine and chemokine circuitries, we identified a novel candidate feed-forward loop 
for ILC2, which expressed both CCR8 and its ligand CCL1. We also identified the novel ILC2 
expression of Bmp7 and Bmp2, the latter of which is known to modulate intestinal peristalsis by 
binding the BMP receptor on enteric neurons (160). Interestingly, we found Il2 expression in 
several ILC populations, which suggests that ILCs may be able to activate T cells or other ILCs 
through IL-2R signaling. 
 
Shared transcriptional profiles between siILC subsets 
We next focused our analysis of transcriptional profiles to the four major CD127+ ILC 
subsets within the siLP: ILC1, ILC2, NKp46+ RORγthi ILC3, and CD4– LTi-like ILC3 (Figure 
7A).  Comparison of siLP ILC subsets revealed that ILC subsets had overlapping patterns of 
gene expression that were not identified in unique signatures (Appendix 1B). For example, ILC2 
and LTi-like ILC3 shared 17 transcripts including Arg1 and Ret. Arginase-1, encoded by Arg1, 
which marks fetal and adult ILCs and facilitates the identification of developing ILCs in the siLP 
(161). The receptor tyrosine kinase Ret is also expressed by fetal CD11c+ lymphoid tissue 
initiator (LTin) cells and is required for PP development (162), but has not been previously 
reported to be expressed by fetal or adult ILCs, including LTi or LTi-like ILC3. Together, these 
results suggest that ILC2 and LTi-like ILC3 share a common transcriptional program, though the 
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functional relevance of this program remains to be investigated. ILC1 and ILC2 also shared 19 
transcripts, including Ets2. Ets-1 and Ets-2 interact with Id proteins, and while Ets-1 has been 
implicated in ILC2 (163) and early NK cell (164) development, Ets-2 has not. Thus, Ets-2 may 
be relevant in ILC1 and ILC2 development or maintenance.  
NKp46+ and LTi-like ILC3 have long been recognized to share many characteristics due 
to mutual production of IL-22 and expression of RORγt. Yet NKp46+ ILC3 shared an even 
greater number of transcripts with NKp46+ ILC1 than with LTi-like ILC3 (Figure 7A, 
Appendix 1B). These comprised Tbx21, Ifng, and Il12rb transcripts. While T-bet is required for 
NKp46+ ILC3 development (45, 49, 50), these cells produce little IFN-γ protein in response to 
IL-12 and IL-23 (data not shown). Because IFN-γ is well documented to be post-transcriptionally 
regulated (165), finding the Ifng transcript in Nkp46+ ILC3 suggests that T-bet may be sufficient 
to induce transcription, but other factors are needed for protein production, such as bacterial 
infections in vivo (45, 51). In addition to shared transcripts, NKp46+ ILC3 and NKp46+ ILC1 
showed 213 genes differentially expressed, with the NKp46+ ILC3 upregulated genes including 
many genes shared with LTi-like ILC3 (Figure 7B). Thus, NKp46+ ILC3 have a transcriptional 
profile with intermediate characteristics between those of NKp46– LTi-like ILC3 and NKp46+ 
ILC1, which may enable functional plasticity. Their functional polarization towards ILC3 or 
ILC1 most likely depends on the tissue microenvironment.  
Although a pairwise comparison failed to identify unique siLP ILC1 transcripts, when 
compared to other ILC subsets within the siLP, ILC1 demonstrated higher cytotoxic capacity, as 
evidenced by expression of Gzma and Prf1, encoding granzyme A and perforin. It is possible this 
is due to imperfect distinction between siLP ILC1 and NK cells (see below).  ILC1 also strongly 
expressed Il21r, a member of the common gamma chain cytokine family (Figure 7A). When an 
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additional comparison between ILC1 and NK cells in the siLP was included, ILC1 expressed 
only 4 unique transcripts, including Gpr55, Trat1, Mmp9, and Cpne7 (Appendix 1B). Thus, 
while siILC1 are more NK-like than other siILC subsets, they show no obvious unique markers 
when NK cells are included in the comparisons using our sorting strategy.  
 
Defining novel transcripts within ILC3 
Pairwise comparison of all ILC3 subsets versus other profiled cells revealed a 42-
transcript ILC3 signature (Figure 8A). This signature included well-studied transcripts such as 
Il23r, Rorc, and Il22, as well as several novel molecules such as the highly and quite specifically 
expressed retinoic acid target and JNK activator, Pram1. This result supports a role for retinoic 
acid in ILC3 development (151, 156). Remarkably, Il17 was not among the transcripts with 
higher than 2-fold expression in ILC3 than in other ILCs, nor was it expressed uniquely by any 
individual ILC3 subset (Figure 4B-C). This result suggests that IL-17 is not a major ILC3 
product in the small intestine, at least in adult mice at steady-state. 
Comparison of the major adult LTi-like population, CD4– LTi-like ILC3, and NKp46+ 
RORγthi ILC3 revealed 508 total significant differences greater than 2-fold (Fig. 8B, Appendix 
1C). Among the transcripts most highly and most significantly upregulated by CD4– LTi-like 
ILC3, we found Nrp1. Also identified as part of our LTi-like ILC3 signature (Figure 4B), Nrp1 
is a co-receptor for several ligands, including VEGF, TGFβ1, and semaphorins, and may have 
functional roles in negatively regulating the immune response in part through enhanced Treg cell 
survival (166). It is also one of a few markers that differentiate natural Treg cells from 
peripherally generated mucosal derived iTreg cells (167, 168). However, Nrp1 has never 
previously been reported to be expressed by LTi-like ILC3. We confirmed by flow cytometry 
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that Nrp1 is expressed at higher amounts on LTi-like ILC3 than other siLP subsets (Figure 8C). 
We also found CD25 protein expression is higher on LTi-like ILC3 than other siLP subsets 
(Figure 8C). Gating on Nrp1+ CD25+ cells within CD3– CD19– siLP lymphocytes results in a 
cell population highly enriched for LTi-like ILC3 (Figure 8D) and IL-22 production from naïve 
IL-22 reporter mice (169) (Figure 8E).  
Between LTi-like ILC3, distinctions between CD4+ versus CD4– subsets were not robust 
and unlikely to have functional significance (Figure 8F), although they may reflect different 
developmental lineages (42). Similarly, comparison of siLP NKp46+ RORγtlo ILC3 to siLP 
NKp46+ RORγthi ILC3 revealed substantial overlap with few differences (Figure 8G, Appendix 
1C). Because siLP RORγtlo ILC3 expressed more NK cells-like transcripts such as Ccl5 and 
Klrd1 than siLP RORγthi ILC3, the siLP RORγtlo ILC3 may include a minor ILC3 population 
‘converting’ into ‘ex-RORγt+ ILC3’. Robust identification of ‘converting’ ILC3 can be 
established only using fate mapping experiments, as recently described (51, 138). 
 
Transcriptional differences between ILC1 and NK cells 
One area that has been particularly controversial is the difference between ILC1 and NK 
cells, in part due to a lack of unique and consistently expressed markers between NK cells and 
ILC1 in different organs. As such, we used different sorting strategies in each tissue to 
discriminate between ILC1 and NK cells, consistent with what has been reported previously (21, 
76). We achieved the best separation of subsets in the liver and the worst in the siLP  (Figure 
9A). Comparisons of NK cells to ILC1 in liver, spleen, and siLP reflected the degree of 
separation between populations during sorting, with the most number of significant differences 
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in the liver and the least in the siLP. ILC1 replicates clustered together and were distinct from 
NK cells in liver, spleen, and siLP (Figure 9B, Appendix 1D).  
As expected, Eomes expression was significantly different with greater than 2-fold 
expression between NK cells and ILC1 in all analyzed tissues. Levels of transcripts encoding 
proteins of cytotoxic machinery were generally higher in NK cells than in ILC1. However, in the 
siLP, perforin transcripts were only 1.7-fold increased compared to ILC1, while in the liver only 
granzyme K was differentially expressed between NK cells and ILC1. In fact, granzyme A and C 
were expressed more highly in liver ILC1 than in liver NK, consistent with the reported cytolytic 
activity of liver ILC1 (77). Liver and spleen ILC1 selectively expressed transcripts for known 
cell surface markers.  In liver ILC1, these transcripts included Itga1 and Tnfrsf10 encoding 
Cd49a and TRAIL, respectively, which have been used for separating liver ILC1 from NK cells 
(38). Splenic ILC1 highly expressed IL2ra and IL7r, which encode cytokine receptors that 
collectively enable this population to escape Treg cell regulation (147). The most highly and 
significantly expressed transcripts in siLP ILC1 compared to siLP NK included only previously 
uncharacterized transcripts such as Tmem64, Npas2, and Lmo4. However, these transcripts were 
expressed in other siILC, and therefore are unlikely to provide useful markers.  
A comparison between the splenic and liver ILC1 subsets revealed that splenic ILC1 
expressed markers of immature and mature NK cells, including CXCR4, c-Kit, and Eomes (73, 
76) (Figure 9C). These differences in transcription could be explained by the finding that our 
sorting strategy based on CD127 and CD27 included an Eomes+ subset within the splenic ILC1 
(Figure 9D). We also noted that the siLP NK cells subset identified using cell surface markers 
contained a large population of Eomes– cells. Thus, NK cells and ILC1 cannot be discriminated 
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by CD127 alone and/or CD27 in the spleen and siLP. Use of EomeseGFP reporter mice may be 
useful in the future to better discriminate NK cells from ILC1, as recently described (76). 
 
A core, NK-distinct, ILC signature  
If ILC1 are different from NK cells as a class, we reasoned that there should be shared 
transcripts between ILC1 from all tissues compared to NK cells and visa versa (Figure 10A). 
Spleen and liver ILC1 shared expression of reported ILC1 genes, such as Tnfsf10, Tnf, and Il2, 
although Il2 was filtered out following our methods due to variability between replicates 
(Appendix 1E). Meanwhile, NK cells transcripts were enriched for Eomes, Itgam (encoding 
CD11b), and members of the Klra family of genes (encoding Ly49 receptors) (Appendix 1E). 
This NK specific signature is consistent with that previously identified in a more limited dataset 
by comparing NK cells to ILC1 and ‘ex-RORγt+ ILC3’ within the siLP (51).  
Visualization of genes differentially expressed in liver, spleen, and siLP in the entire 
dataset revealed that with few exceptions, genes upregulated in ILC1 over NK cells were even 
more highly expressed in many other ILC subsets (Figure 10B). Genes upregulated in all NK 
cells were consistently not expressed in other ILCs (Figure 10C), except for low transcript levels 
in ILC1. Unexpectedly, the transcripts most highly expressed by ILCs compared to NK cells 
(Figure 10A) were Tcrg-V3, Tmem176a, Tmem176b, Il7r, and CXCR6 (Figure 10B, Appendix 
1F). We validated by flow cytometry that the TCRδ chains were not expressed in any of our cell 
types, either extracellularly or intracellularly (Figure 11A-B), suggesting that they lacked a 
functional TCRγδ receptor. Furthermore, from a published RNAseq dataset that included liver 
ILC1, liver NK cells, and spleen NK cells from Rag1-/- mice (77), we found high levels of the 3’ 
end of the TCRγ locus, annotated as Tcrg C4 transcript, present in liver ILC1 but not NK cells 
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from liver or spleen (Figure 11C). As STAT5-activating cytokines IL-7 and IL-15 are well 
known to mediate germline TCRγ expression (170, 171), we conclude that ILCs have open 
chromatin at the Tcrγ locus and germline transcription, likely due to signaling through IL-7.  
We also assessed the ability to use CXCR6 as an ILC marker using a CXCR6eGFP reporter 
mouse. Although we found statistically significant differences between ILC1 and NK cells in the 
percentage of CXCR6+ cells, it failed to label all ILCs (Figure 12A-B). Additionally, in steady 
state, CXCR6 was not required for ILC development or tissue homing, as we found no difference 
in ILC frequency between CXCR6eGFP/+ and CXCR6eGFP/eGFP mice (Figure 12C). Thus, CXCR6 
is expressed more highly in ILCs compared to NK cells, but its expression does not cleanly 
separate the two lineages. 
 
IEL ILC1 have an intermediate expression profile between ILC1 and NK cells 
Finally, we asked whether intestinal intraepithelial ILC1 should be classified as an ILC1 
or NK cell population, as this population has unique transcription factors and cell surface 
markers, preventing it from fitting clearly into an ILC1 or NK cell designation (148). 
Comparisons between IEL ILC1, siLP ILC1, and siLP NK cells revealed that IEL ILC1 
expressed transcripts characteristic of both NK cell and ILC1 populations. While NK-signature 
transcripts Eomes and Klra3 (Figure 10B) were more highly expressed by IEL ILC1 than in 
siLP ILC1, ILC1-signature transcripts Tcrg-V2 and Tcrg-V3 (Figure 10B) were more abundant 
in IEL ILC1 than in siLP NK (Figure 13). It remains unclear whether IEL ILC1 are a single 
unique subset with distinct developmental and functional characteristics, or whether siLP NK 
cells and ILC1 both traffic to the epithelium, where they become phenotypically 
indistinguishable, possibly in response to tissue factors in the epithelium. 
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2.2.4 Discussion 
 
Here we have provided the first comprehensive transcriptional analysis of the spectrum of 
ILC subsets reported in siLP, liver, and spleen. The transcriptional programs we found will allow 
a better definition of the individual ILC classes, as well as ILC subsets, within a class. ILC2 was 
the most homogeneous and distinguishable ILC class, which expressed the most unique genes, 
with well-documented factors as well as novel genes including the nuclear receptors Rxrg and 
Pparg, and several others involved in lipid metabolism. Within ILC3, LTi-like ILC3 expressed 
several unique genes, previously unknown to be expressed in immune cells, including Cntn1, 
Slc6a7, Cacna1g. They were distinct from NKp46+ ILC3 and were effectively marked by the 
previously unreported LTi-like factor Nrp1, as well as CD25. The definition of ILC1 was the 
most problematic, because compared to all ILCs and NK cells, we found no unique markers for 
siLP ILC1 and few for liver and spleen ILC1. CD103 was a surprising unique transcript for 
siIEL ILC1, given that it was not found as a protein in this subset in mouse but only in human16. 
Among siLP subsets, we also found a previously unrecognized “intestinal” gene signature 
composed of activation markers like Cd69 and many transcription factors including Rora, Atf3, 
Nr4a1, and Maff, which likely reflects continuous environmental exposures. 
Besides unique factors, ILC classes also shared many transcripts. For example, siLP 
NKp46+RORγt+ ILC3 shared many transcripts with siLP ILC1, including Ifng and Il12rb2. These 
data, which are consistent with previous reports (51, 146), provide a basis for the functional 
plasticity of siLP NKp46+RORγt+ ILC3, which become similar to ILC1 in certain conditions yet 
to be defined. Furthermore, ILC1 and ILC2 shared expression of the TF Ets-2, which suggest 
new transcriptional pathways shared by ILC1 and ILC2. Interestingly, ILC2 and LTi-like ILC3 
expressed genes that suggest a function in neural and glial crosstalk. ILC2 expressed Bmp2, 
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which was recently found to modulate enteric motility in response to the microbiota (160); given 
the importance of motility in clearing helminth infections, this observation might reveal a novel 
mechanism of innate defense. We discovered that both ILC2 and LTi-like ILC3 also expressed 
Ret, encoding a receptor for the glial derived neurotrophic family (GDNF) of molecules, known 
to drive PP development (162), but unstudied in ILCs. Thus, in the siLP, ILCs may engage in 
crosstalk with neurons and glia during steady-state and an immune response. 
We generated a core ILC signature that includes 17 genes, with highest expression of 
TCRγ germline transcripts, Cxcr6, Tmem176a, Tmem176b, and Il7r. Surprisingly, the most 
highly expressed gene by all ILCs compared to NK cells was TCRγ-V3 germline transcript, 
which has not previously been reported in ILCs but was recently reported in a putative ILC3 cell 
line (172). We postulate that this reflects signaling by IL-7R (170), which is expressed by all 
ILCs but not by mature NK cells. In our study, we validated that all ILCs express CXCR6 at 
higher amounts than NK cells. Interestingly, two recent studies interrogated CXCR6 expression 
in ILCs. The first study demonstrated that a CXCR6+ early progenitor gave rise to both NK cells 
and ILC, but not T cells (54). The second study found that CXCR6 deficiency preferentially 
affects NKp46+ ILC3 frequency and function by preventing appropriate interactions with 
CD11b+ intestinal dendritic cells (173). However, we found that CXCR6 neither marks the entire 
population nor were any ILC frequencies affected by its loss, though it is possible that CXCR6 
loss affects ILC function, which should be tested across ILC classes. Notably, Tmem176b was 
previously reported to be a marker of innate lymphocytes as one of only 3 transcripts shared 
between NK cells, NKT cells, and γδT cells (174), though in our dataset, we find that ILC1, 
ILC2, and ILC3 express significantly higher levels of Tmem176b than do NK cells. These data 
45	
suggest that the core ILC signature identified here most likely also extends to other innate and/or 
tissue resident lymphoid cells.  
IFN-γ-producing ILC1 and NK cells can develop from different progenitors, and are 
independent or dependent of Eomes, respectively (51, 55, 76). However, in tissues they show 
overlapping phenotypes and functional programs. While NK cells are well known to have 
cytolytic capacity, liver ILC1 express granzyme A and C and were also shown to be 
cytolytic(84). While liver ILC1 were identified by TRAIL and CD49a, other cell surface markers 
such as CD127 and CD27 were insufficient to discriminate Eomes– ILC1 from Eomes+ NK cells 
in siLP and spleen. Thus, transcriptional data generated using Eomes reporter mice will be a 
useful comparison to our dataset (51, 76). Moreover, the induction of cytokines like IL-15 and/or 
IL-2 in certain pathologic conditions may further increase the phenotypic and functional 
similarity of ILC1 with NK cells. Thus, it remains unclear whether ILC1 and NK cells are truly 
distinct lineages or a spectrum of cells within the same lineage, which includes ILC1, immature 
NK cells and mature NK cells.  
Our data offers the most complete transcriptional profile of ILCs and NK cells to date 
and provides a comprehensive view of the relationship between ILC subsets in the steady state. 
Our findings will help define new avenues of research and should aid in the production of new 
tools to study ILCs, especially with the identification of several molecular targets expressed at 
high levels among all ILCs. Finally, they will also be a valuable resource to the scientific 
community, with accessibility to our data set and comparisons to other published datasets 
generated under the same rigorous conditions provided by the ImmGen Project.  
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2.2.5 Figures 
 
 
 
FIGURE 1: Sorting Strategy for Mouse ILCs   
 
(A) Sorting strategy for array analysis after gating on live CD45+ and CD3–CD19– cells. (B)	Gating	 strategy	 for	 siLP	 ILC1,	 NK,	 Nkp46+	 ILC3,	 and	 Nkp46–	 LTi-like	 ILC3	 subsets	 after	gating	on	 live	CD45+	 and	CD3–CD19–	 cells	 in	C56BL/6	mice	or	RORγteGFP/+	reporter	mice.	ILCs	are	gated	on	intracellular	RORγt+	staining	or	RORγteGFP+	cells,	representative	of	at	least	n	=	10	experiments.	For	microarray	analysis,	the	gating	strategy	as	shown	on	the	right	was	used.	 (C-D)	Histograms	 of	 (C)	NK1.1	 and	 (D)	 CD45	 expression	 from	 sorted	 siLP	 subsets	used	in	array	generation,	representative	of	n	=	3	experiments	from	5	pooled	mice	each.	 (E) 
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Cytospins of cells using the indicated sorting strategy for each population. Each individual panel 
is 14.6µm in length. 
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FIGURE 2: Mouse ILC Frequency Among Lymphocytes 
  
(A) Flow cytometric analysis of ILC percentage in each tissue among the lymphocyte 
population. To differentiate CD3+ T cells, CD19+ B cells, and ILCs within the same sample, the 
same gating strategy in (1A) was used except: the siLP ILC2 marker KLRG1 and spleen ILC1 
marker CD27 were excluded and liver ILCs were distinguished using NKp46, CD49b, and 
CD49a. Data from two independent experiments and n = 2-4 mice per tissue are shown.   
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FIGURE 3: Mouse ILC Diversity  
(A) PCA of gene expression by ILC and NK cells subsets. Numbers in parentheses indicate 
relative scaling of the principal variables. ImmGen sample nomenclature is used: spleen NK = 
NK.CD127–.Sp, liver NK = NK.CD49b+.Lv, siLP NK = NK.CD127–.SI, siIEL ILC1 = 
ILC1.IEL.SI, spleen ILC1 = ILC1.CD127+.Sp, liver ILC1 = ILC1.CD49b–.Lv, siLP ILC1 = 
ILC1.CD127+.SI, siLP NKp46+ RORγtlo ILC3 = ILC3.NKp46+.RORγtlo.SI, siLP NKp46+ 
RORγthi ILC3 = ILC3.NKp46+.RORγthi.SI, siLP NKp46– CD4– LTi-like ILC3 = ILC3.NKp46–
.4–.SI, siLP NKp46– CD4+ LTi-like ILC3 = ILC3.NKp46–.4+.SI, and siLP ILC2 = ILC2.SI.	 (B)	Two-dimensional	views	of	PCA. (C) Hierarchical clustering of ILC and NK cells subsets based 
on the 10% of genes with the greatest variability. Data are combined from 3-7 experiments per 
sample, with cells pooled from 3-15 mice each.  
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FIGURE 4: Unique Transcripts of Individual ILC Subsets 
(A-H; and full gene lists in Appendix 1A) mRNA transcripts upregulated more than 4-fold (red 
font) or 2-fold (black font) in individual subsets (A,D,E,F,G) or two similar subsets (B,C,H) 
were generated based on pairwise comparisons between the index subset(s) labeled in bold above 
the heat map compared to all other subsets. Between similar ILC3 subsets consisting of (B) 
NKp46– CD4+ LTi-like and CD4– LTi-like or (C) NKp46+ RORγthi and RORγtlo cells, some 
transcripts were expressed more than 4-fold or 2-fold higher in one subset, but not the other, in 
which case shared transcripts expressed by both subsets are indicated in blue. CD4+ LTi-like 
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ILC3 expressed 4 transcripts 2-fold more than CD4– LTi-like ILC3 and 4-fold more than all other 
subsets, shown in gray (B). 
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FIGURE 5: Small Intestine Lamina Propria Gene Signature 
mRNA transcripts upregulated more than 4-fold (red font) or 2-fold (black font) in all siLP 
subsets were generated based on pairwise comparisons between the index subset(s) labeled in 
bold above the heat map compared to all other subsets.  
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FIGURE 6: TFs, Cytokines, and Chemokines Expressed by ILCs 
 
(A) Heat map of selected transcription factors, normalized by expression within the entire heat 
map. (B-C) Heat map of selected (B) chemokine receptors and ligands and (C) and cytokine 
receptors and ligands, normalized by expression within each row. 
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FIGURE 7: Spectrum of Shared Transcriptional Profiles Between siLP ILCs 
(A; and full gene lists in Appendix 1B) Among selected siLP ILCs, transcripts upregulated by a 
single subset or 2 subsets are indicated, as described in the color-coded key above the plot. 
Numbers within the plot indicate transcripts upregulated at least by a 2-fold change in the 
indicated color-coded subset(s). (B) Volcano plot of RORγthi NKp46+ ILC3 (n = 3 replicates) 
compared to ILC1 (n = 2 replicates), with transcripts significantly upregulated at least 2-fold 
quantified in corners. P ≤ 0.05 (t-test).  
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FIGURE 8: ILC3-Specific Transcriptional Programs and Cell Surface Markers 
(A) Heat map of mRNA transcripts upregulated more than 4-fold (red font) or 2-fold (black font) 
in RORγt+ ILC3 subsets compared to all other subsets. (B; and full gene lists in Appendix 1C) 
Volcano plots comparing NKp46+ RORγthi ILC3 to CD4– LTi-like ILC3 with transcripts 
significantly upregulated at least 2-fold quantified in corners and color-coded according to key 
below plot. P ≤ .05 (t-test) (n = 3 replicates each) (C) Expression of Nrp1 and CD25 compared to 
other siLP ILC subsets from the RorγteGFP reporter mice. (D) Unbiased selection of Nrp1+ CD25+ 
cells gating only on CD45+ and CD3–CD19– cells, with percent enrichment of LTi-like in by 
intracellular RORγt staining from C56BL/6 wt mice. (E) Enrichment of IL-22 production from 
naive IL-22 reporter mice in Nrp1+CD25+ cells compared to other quadrants, gating on CD45+, 
CD3–CD19–, and NKp46– cells. (F-G; Appendix 1C) Volcano plots comparing (F) CD4+ LTi-
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like (n = 2 replicates) to CD4– LTi-like ILC3 (n = 3 replicates) and (G) NKp46+ RORγthi ILC3 to 
NKp46+ RORγtlo ILC3 (n = 3 each). P ≤ .05 (t-test). Data are representative of 3 experiments. 
 
57	
 
 
FIGURE 9: Transcripts Differentially Expressed Between NK cells and ILC1 
(A) Gating strategy of liver, spleen, and siLP ILC1 and NK cells after the first round of sorting 
from pooled samples. (B-C; and full gene lists in Appendix 1E) Volcano plots comparing (B) 
liver ILC1 to liver NK cells (n = 3 replicates each), spleen ILC1 to spleen NK cells, siLP ILC1 to 
siLP NK cells, and (C) liver ILC1 to spleen ILC1, with transcripts significantly upregulated at 
least 2-fold quantified in corners and color-coded according to the key below plot. P ≤ .05 (t-
test). (D) Expression of CD127 and Eomes in ILC1 and NK cells compared to isotype-matched 
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control Ig staining from liver, spleen, and siLP, color-coded according to the key on the left. 
Histograms are representative of 2 experiments.  
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FIGURE 10: Generation of a Core ILC Signature Distinct from NK Cells 
 
(A) Visualization of transcripts differentially expressed by ILC1 compared NK cells from 
different tissues. Transcripts upregulated by 2 or 3 subsets are indicated, as described in the 
color-coded key above the plot. Numbers within the plot indicate transcripts significantly 
expressed with at least a 2-fold change between liver and spleen ILC1 and NK cells (n = 3 
replicates each) or with an additional filter for at least a 2-fold change between siLP ILC1 and 
NK cells (n = 2 replicates each). P ≤ .05 (t-test). (B; and full gene lists in Appendix 1F) Heat 
map showing gene signatures generated and color-coded in (A); transcripts upregulated ≥ 4-fold 
in all 3 comparisons between ILC1 and NK cells are shown in red. 
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FIGURE 11: ILCs lack TCRδ protein but express TCR-γ transcripts 
 
(A-B) Representative plots from ILCs and positive control IEL γδ T cells stained extracellularly 
or intracellularly for TCRδ by flow cytometry; for intracellular stain, PE-conjugated anti-TCRδ 
mAb was used to stain positive control IEL extracellularly before intracellular staining with 
FITC-conjugated anti-TCRδ  (n = 2 independent experiments). Color-coded gates demonstrate 
percentage of indicated subsets positive for anti-TCRδ, except for control IEL γδ cells, which are 
shown as a percentage of CD45+ cells. (C) RNAseq data from a previous dataset (GEO accession 
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GSE52043), selecting the 3’ end of the TcRγ locus between 19426 kb and 19446 kb on 
Chromosome 13. 
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FIGURE 12: ILCs Express CXCR6 at Higher Levels Than NK cells 
 (A)	Representative flow plots of percentage of CXCR6+ cells from CXCR6eGFP/+ reporter mice. 
siLP NKp46– LTi-like ILC3, siLP ILC1, siLP NK, and siLP NKp46+ ILC3 percentages were 
analyzed after fixation of cells. Color-coded gates demonstrate percentage of indicated subsets 
that are CXCR6+. (B) Quantification of percentage of CXCR6+ cells within each ILC subset from 
CXCR6eGFP/+ reporter mice. (1-way ANOVA with multiple comparisons; error bars mean +/- 
SEM; * P ≤ .05). (C) Quantification of ILC frequency in CXCR6eGFP/+ and CXCR6eGFP/eGFP mice 
(2-way ANOVA with multiple comparisons; error bars mean +/- SEM; all comparisons are not 
significant). (A-C) Data are from 3-4 mice from each genotype per tissue.  
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FIGURE 13: IEL ILC1 Have Intermediate Characteristics Between ILC1 and NK cells 
 
Visualization of transcripts upregulated between siLP ILC1, siLP NK, and siIEL ILC1 by 1 or 2 
subsets are indicated, as described in the color-coded key above the plot. (n = 2-3 replicates 
each). 
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2.3 PART 2: Human Transcriptional Profiles 
2.3.1 Introduction 
 
Compared with the extensive characterization of mouse ILCs, human ILC subsets are 
under-characterized. Like mouse (175), human ILC1, ILC2, and ILC3 populations have been 
reported to reside primarily in tissue-resident locations. ILC1 and ILC3 are easily discriminated 
within human tonsil, intestinal epithelium, and intestinal LP, while ILC2 are rare in these 
locations (52). ILC2 are instead reportedly enriched in inflamed tissues such as nasal polyps 
from subjects with allergies (149), though we have been unable to reproduce these data 
(unpublished observations). Thus, we focus our analysis on ILC1 and ILC3.  
Human ILC1s include a major subset in mucosal epithelium (intraepithelial ILC1s, 
iILC1s), which produce IFN-γ in response to IL-15 and IL-12 (148). Unlike cNKs, iILC1s are 
unresponsive to IL-18, have limited cytolytic capacity, and express markers of intraepithelial 
residency, such as CD103, CD160, CD49a, and CD101. Like Th1s, most tonsillar iILC1s 
express T-BET and low amounts of EOMES. Fate mapping in mouse has shown that iILC1s are 
a distinct lineage from cNKs (55, 59). Although a second ILC1 subset has been reported in 
human (176), these IFN-γ producing cells are found at very low frequencies in mucosal-
associated lymphoid tissues. 
Human ILC3s are primarily defined by their ability to produce IL-22 in response to IL-23 
(177). Human ILC3s also produce GM-CSF and IL-26, as well as two other soluble mediators, 
LIF and BAFF, which are not substantially expressed by Th17 cells or mouse ILC3s (177). 
Although developmental data are limited, tonsillar ILC3s express RORC plus AHR, and appear 
to derive from a CD34+c-Kit+RORC+ hematopoietic progenitor (178). However, assignment of 
human ILC3s to a distinct lineage remains controversial due to reports that they are intermediates 
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in a linear differentiation pathway for cNKs (58, 179). Furthermore, ILC3s exhibit some 
functional plasticity under certain conditions in vitro that stimulate IFN-γ production (177). 
Although human ILCs appear to share core transcriptional circuitry and effector 
programs with adaptive immune CD4+ helper T cell counterparts, it is unclear the extent to which 
these cells have functionally overlapping profiles or distinct functions. Despite functional and 
ontogenic similarities, differences exist between ILC and helper T cell counterparts, especially 
their dependence on pathogen-derived antigens. For example, T helper cell priming requires 
signals from TCR and co-stimulatory receptors, which drive differentiation and cytokine 
expression. ILC effector responses depend solely on cytokine microenvironments, endowing 
them with more rapid response profiles (180). Distinctions in cytokine expression also exist 
between human ILC–T helper cell counterparts – Th17s produce IL-17 and -22, while ILC3s 
secrete only the latter. To identify the functions of human ILCs and determine their similarity or 
differences from T cells, we sought to transcriptionally profile ILCs compared to their respective 
adaptive T cell counterparts. We transcriptionally profiled ILC1, ILC3, Th1, and Th17 from the 
human tonsil, with CD56dim blood cNK cells as an external comparator. 
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2.3.2 Materials and Methods 
Sorting and Cytometric analysis. 
 Cells were sorted from 2-3 pooled donors for each replicate, as described (148, 177, 181). 
Briefly, inflamed pediatric human tonsil were homogenized to a single-cell suspension in 1mM 
EDTA in PBS and stored overnight on ice. T helper cells were enriched using anti-CD4 beads 
(Miltenyi) prior to sorting. Cells were stained with the following antibodies (Biolegend unless 
indicated): for ILC1 and ILC3, lineage included CD3ε-PerCpCy5.5 (eBioscience), CD19-
PerCpCy5.5 (eBioscience), CD34-PerCpCy5.5 and ITL3-PerCpCy5.5, and positive markers 
were NKp44-PE (BD-Pharmingen), CD196-BV421, CD103-BV605; for Th1 and Th17, lineage 
included CD45-AlexaFluor700 (Biolegend), CD19-FITC, CD25-FITC (Immunotech), and 
positive markers were CD4-APC780 (eBioscience), CXCR3-PE (BD-Pharmingen), CD196-
BV421. Blood NK cells were isolated using a Ficoll gradient, pre-enriched using CD56 beads 
(Miltenyi), and discriminated using CD3ε-FITC (BD-Pharmingen) and CD56-PE-Cy7 (BD-
Pharmingen). Sorting was conducted using a Becton-Dickinson FACSAria II. Data were 
analyzed by FlowJo software (TreeStar). 
 
Microarray generation and analysis 
 RNA was isolated using RNeasy Plus Micro Kit (Qiagen). RNA was amplified and 
hybridized to Affymetrix Human Gene 1.0 ST arrays by the Genome Technology Access Center 
(GTAC) at Washington University. RNA yields from each subset were comparable. Array data 
were analyzed as described (182) using the Multiplot Studio function of GenePattern(). 
Heatmaps were generated using GENE-E (). Unsupervised clustering was performed in R using 
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the hclust function. Ingenuity Pathway Analysis (IPA) was performed using the Top Network 
and Upstream Regulator functions.  
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2.3.3 Results 
 Human ILCs cluster separately from adaptive T cell counterparts 
To interrogate unique and overlapping pathways in ILC and T helper cells from a 
mucosal environment, we isolated lymphocytes from pediatric tonsils. This source provides a 
sufficient number of purified ILCs for transcriptome and low-input epigenome analyses. We 
divided lineage-negative cells that expressed CD56 and NKp44 into CD103+iILC1s and 
CCR6+ILC3s (Figure 14A). The latter subset produces IL-22 in response to IL-23, confirming 
its functional categorization (177). CD4-enriched tonsillar lymphocytes were divided into 
CXCR3+Th1 and CCR6+Th17 cells, as described (181, 183). ILC2 and Th2 subsets were at 
sparingly low abundance in tonsils and could not be analyzed. As a comparator for ILCs, we 
isolated the prototypic innate lymphoid subset, cNK cells (CD56lowNKp44–), from human blood. 
To explore relationships between cell types, we performed supervised principal 
components analysis (PCA) on expression array data, focusing on the top 15% most 
differentially expressed genes. A reproducible separation was observed between ILC3, ILC1, 
cNK, and Th cells (Figure 14B). Consistent with prior studies (181, 184, 185), gene expression 
in Th1 and Th17 replicates from different tonsils was highly related, with a single module of 
genes providing a primary distinction (PC3). PCA clearly segregated innate cells from their 
helper T cell functional counterparts; i.e., iILC1s were distinct from Th1s and ILC3s were 
distinct from Th17s. Thus, ILC and T lineage commitment dominated functional relationships in 
several transcriptional modules.  
 
Tonsillar cells express a unique transcriptional signature 
69	
PCA also revealed that blood cNKs segregated substantially from their functional 
counterpart, iILC1s. When comparisons were broadened to entire transcriptomes, unsupervised 
hierarchical clustering of array data separated all tonsillar subsets from blood cNKs (Figure 
15A). These analyses suggested that the mucosal microenvironment, in addition to lineage 
specification, had an influence on expression programs in lymphoid cells. Indeed, differentially 
expressed genes in iILC1s, when compared with blood cNKs, generated a signature that was 
present in all four tonsillar subsets (Figure 15B-C). As such, we restricted most comparisons to 
cells derived from tonsils, using blood cNKs as external comparators.  
 
Unique and overlapping transcriptional profiles between ILCs and T helper cells 
Although PCA underscored distinctions in transcriptional modules between innate and 
adaptive counterparts, ILC and T helper cell subsets share overlapping developmental pathways 
and functions. Therefore, we asked which genes were uniquely overexpressed by each subset and 
which were shared by multiple subsets. Comparisons of fold change expression profiles revealed 
important features of lineage specification and functional polarization. First, “unique” transcripts 
were most abundant in ILC3s (~100), followed by iILC1s, Th17s, and Th1s (Figure 16A). 
Second, the number of “unique” transcripts was far greater than that shared by any two subsets. 
Third, among the latter transcript category, ILC3+Th17 was dominant (19 transcripts). These 
data suggested that, despite similar functionality, ILC and T helper cell counterparts have 
fundamentally distinct transcriptional programs. Indeed, ILCs shared more differentially 
expressed genes with each other (118) than with their T helper counterparts (27) and vice versa 
(123) (Figure 16A-B). These data suggest that ILC and T lineage factors distinguish the identity 
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of cytokine-producing lymphocytes to a greater extent than factors governing their functional 
polarization. 
In this regard, Figure 17 highlights a set of genes whose expression distinguished innate 
and adaptive subsets, spotlighting six biological categories. ILC and T helper subsets both 
expressed genes associated with cellular activation, including MHC II, CD25, CD38, and CD69, 
consistent with their isolation from inflamed tonsils (Figure 15C, Figure 17). Importantly, genes 
encoding lineage determinants, receptors, and effector molecules aligned with the predicted 
functionality of each subset. For example, expression of RORC, CCR6, and IL26 was shared 
between ILC3s and Th17s, whereas CXCR3 and IFNG were shared between iILC1s and Th1s. 
Although TBX21, a “master” TF for Th1/ILC1 lineages, was expressed two-fold higher in iILC1 
than ILC3 cells, the probeset had low absolute values and fell below cut-off criteria. In addition, 
T cell markers, such as CD4 and CD28, were expressed by Th1 and Th17 cells, while many NK 
cell markers, such as KLRK1, NCR1, and CRTAM, were expressed by iILC1s and ILC3s. 
Several features of this analysis should be emphasized. First, consistent with patterns of 
“unique” genes (Figure 16A), ILC3s expressed a substantial number of “unique” TFs (Figure 
1E). These included not only known ILC3 factors (RORC, AHR), but also several whose roles in 
ILC3 biology were less clear (e.g., RUNX2, BACH2, and ZBTB34). Second, consistent with their 
primary activation modes (cytokines for ILCs, antigen for T cells), ILCs expressed more 
cytokine receptors at substantially higher levels than T helper cells, with a notable exception. 
Both T helper subsets specifically expressed IL6R and IL6ST, which form the IL6 receptor, 
suggesting that this proinflammatory cytokine should regulate T helper but not ILC responses. 
Third, when compared with T helper subsets, ILCs expressed a distinct set of metabolic genes, 
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particularly those encoding enzymes with anti-microbial functions (e.g., AOAH, BLVRA, and 
FUCA1). 
 
Pathway analysis of differentially expressed ILC transcripts 
We next performed Ingenuity Pathway Analysis (IPA) on genes with greater than two-
fold differences in ILC3s vs Th17s, iILC1s vs Th1s, or ILC3s vs iILC1s (Figure 18 A-C). These 
analyses indicated that Th-enriched genes connected to pathways for antigen signaling through 
the TCR, while ILC-enriched genes coordinated pathways for cytokine signaling or attenuated 
TCR signaling (Figure 18A-B). Pathway distinctions were more apparent when input transcripts 
were restricted to those differentially expressed by both ILC subsets compared to both T helper 
subsets, generating a network composed almost entirely of signaling molecules (Figure 18D). 
Differentially expressed transcripts created an innate activation module for ILCs centered on 
FCER1G (FcRγ) and TYROBP (DAP12), while the T helper module centered on components of 
the CD3 complex. Despite distinct receptor origins, both pathways converged on the MAP 
kinase, ERK. 
Distinct pathways also emerged when individual ILC-T helper subsets were compared. 
Pathways augmented in ILC3s versus Th17s were connected to ETS family TFs (designated as 
SPI1 by the IPA database), which are known to regulate cNK cell development (164), or the 
IL1β cytokine (Figure 18A). The known potential of human ILC3s to convert into ILC1s also 
became evident. Namely, IL15- and T-BET-regulated pathways emerged when ILC3s were 
compared with Th17 cells, albeit these pathways had a lower z-score than ILC3–iILC1 
comparisons (Figure 18A-C). Together, transcriptome arrays confirmed and revealed modules 
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of gene expression that coordinate lineage specification, signal transduction, and functional 
polarization of human ILC/T helper subsets in a mucosal microenvironment. 
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2.3.4 Discussion 
 
The importance of ILCs in mammalian immunity has emerged from in vitro studies in 
human and functional analyses in mice. However, many outstanding questions remain, especially 
with regard to ontogeny, functional relationships, ILC plasticity, and species distinctions. Here, 
we shed light on important facets of lineage and functional relationships between innate and 
adaptive T helper counterparts derived from a human mucosal tissue. 
In this study, we directly compare for the first time gene expression by ILC and T helper 
cell subsets. Among ILC subsets, we found that tonsillar iILC1, tonsillar ILC3, and blood cNK 
cells all exhibited substantial transcriptional differences. In fact, in a PCA, these cells clustered 
more distinctly than did Th1 and Th17, the latter of which failed to cluster by subset over donor 
using unsupervised clustering. As these data are similar to those published from blood Th1 and 
Th17 (181, 184, 185), this suggests that T helper cell polarization in human is less complete that 
of ILCs. However, because we did not profile blood Th1 and Th17 here, it remains possible that 
Th1 and Th17 polarization in the human tonsil could also be more incomplete. Comparing ILC1-
Th1 and ILC3-Th17 modules directly, we found that while matched pairs shared more transcripts 
with each other than those of mismatched pairs ILC3-Th1 and ILC1-Th17, lineage determinants 
were more effective at separating subsets; these predominantly included signaling molecules 
core to ILC versus T cell function. The partner study to this work comparing the epigenetic 
profile of mouse ILCs demonstrated that acute induction of Th2 and ILC2 by helminth infection 
induced a substantial overlap of effector programs (88). As our cells were profiled directly ex-
vivo, it remains possible that upon strong activation the transcriptional programs of ILC1-Th1 
and ILC3-Th17 modules would likewise grow more similar.  
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Ontogenic connections between ILC1 and cNK cells have remained controversial, 
particularly for human iILC1 profiled here, which express intermediate levels of EOMES. 
Lineage tracing in mice suggested that ILC1s, including iILC1s, developed from an 
ID2+ZBTB16+ precursor shared with other ILCs but not cNK cells (55, 59). While our study 
cannot resolve this issue completely, expression programs of iILC1s diverged significantly from 
blood cNK cells. Such divergence in gene circuitry renders it unlikely that iLC1s and cNK cells 
are the same cell type. Notwithstanding, microenvironmental factors, layered on top of lineage 
specification, may contribute to this divergent profile. In depth study of this issue will require 
extensive phenotypic characterization of the multiple IFN-γ producing cells that inhabit human 
mucosae.  
Recently, single-cell RNAseq of the second human ILC1 subset was reported, which 
unlike iILC1, does not express EOMES (52). These cells were isolated by a Lin–CD56–CRTH2–
cKit–CD127+CD161+ cell-surface phenotype and were not compared directly to adaptive 
immune cells. Unlike iILC1, these cells expressed many obvious T cell related genes, including 
α and β T variable region transcripts, CD4, CD8s, CD3s, as well as transcripts we identify here 
as part of the T cell signature such as CD5, CD28 and CD6. Similar to our results in mice, we 
found that largest epigenetic difference in human ILCs versus T cells was at the TCR-γ locus and 
not at other TCR loci (data not shown). Collectively, this suggests that immature or mature T 
cells likely contaminated human ILC1 profiled on a single cell level, while human and mouse 
iILC1 express germline transcripts induced by STAT5. 
Although we were unable to compare mouse and human ILC transcriptional profiles 
directly due to the low reliability of any such bioinformatics approach, we did note that some 
transcripts were maintained between modules in both mouse and human. For example, we noted 
75	
that all ILC3s in mouse as well as ILC3 and Th17 in human expressed the transcriptional 
repressor REV-ERBα, encoded by NR1D1. This conserved pattern of expression across RORγt 
expressing cells in two species suggests a potential core role for REV-ERBα in Module 3.  Thus, 
these data in conjunction with the data generated for mouse ILC transcriptomes, provide rich 
information for future functional study. 
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2.3.5 Figures 
 
 
FIGURE 14: Human ILCs Cluster Separately from Adaptive T cell Counterparts 
(A) Strategy for iILC1 and ILC3 sorting. (B) Supervised PCA of genes with most variable 
expression among iILC1, ILC3, Th1, Th17, and blood cNK cell replicates (top 15%). 
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FIGURE 15: Tonsillar Subsets Cluster Separately from Circulating Blood NK cells 
(A) Unsupervised hierarchical clustering of iILC1, ILC3, Th1, Th17, and blood cNK cell 
replicates used for analysis. (B) Volcano plot showing transcripts significantly upregulated (p-
value <.05) by two-fold between blood cNK cells (gray) or tonsillar iILC1s (blue). An additional 
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filter shows transcripts significantly upregulated by two-fold in all tonsillar subsets compared to 
blood cNK cells (white circles). Transcript numbers for each color-coded category are shown 
below the plot. (C) Heatmap shows gene expression levels of the tonsillar signature generated in 
B. In the bottom heatmap, selected housekeeping genes are shown as a control for gene 
expression levels, as compared to differentially expressed surface markers. 
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FIGURE 16: ILCs are Transcriptionally Distinct from T helper cells 
 
(A) Plot comparing the fold change of ILC3 and ILC1 to the fold change of Th17 and Th1 
depicts transcripts differentially expressed among ILCs and T helper subsets. Colored circles 
highlight transcripts expressed at least two fold higher in a single tonsillar subset compared with 
the other three subsets. Colored circles with black borders denote transcripts that are shared by 
both an ILC and Th subset with expression >2 fold higher than cells of their respective lineage. 
(B) Transcripts shared by ILC subsets that were increased by two fold compared to T helper 
subsets and vice versa. 
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FIGURE 17: Unique and Overlapping Transcriptional Profiles Between ILCs and T helper cells 
Heatmaps highlighting the average expression of selected transcripts that were differentially 
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expressed in each cell type as shown in panels C and D. Color coding at the left of each heatmap 
designates the categories of cell type-restricted expression patterns, retaining colors shown in 
Figure 16A-B. Transcripts that were both “shared” and “unique” are color-coded as “shared.” 
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FIGURE 18: Pathway Analysis of Differentially Expressed ILC Transcripts 
(A-C) IPA analysis of top predicted regulators based on transcripts whose differential expression 
(>2 fold) attained statistical significance when comparing (A) ILC3 to Th17, (B) iILC1 to Th1, 
and (C) ILC3 to iILC1. –log(p-values) are shown as gray lines and z-scores for the comparisons 
are depicted as bar graphs. (D) The highest scoring IPA network generated from transcripts 
differentially expressed in ILCs versus T helper cells, as in Figure 16B. Transcripts represented 
in red were upregulated by ILCs versus T helper cells at least two-fold in microarray data, and 
those in green were similarly downregulated. Darker colors indicate greater fold changes among 
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upregulated or downregulated transcripts. 
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CHAPTER 3 
 
Jak3 Deficiency Blocks ILC Development  
While Pharmacologic Inhibition Impairs Function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter were adapted from  
 
Robinette ML, Cella M, Telliez JB, Ulland TK, Barrow AD, Capuder K, Gilfillan S, Lin LL, 
Notarangelo LD, Colonna M. Jak3 deficiency blocks innate lymphoid cell development. Mucosal 
Immunol 11(1): 50-60 (2018). 
© 2018 Society for Mucosal Immunology  
 
Human ILC data were obtained by Marina Cella. All other work recreated here is that of the 
author of this dissertation.   
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3.1 Abstract 
Loss-of-function mutations in the tyrosine kinase JAK3 cause autosomal recessive (AR) 
severe combined immunodeficiency (SCID). Defects in this form of SCID are restricted to the 
immune system, which led to the development of the immunosuppressive JAK3 inhibitor 
tofacitinib.  We find that the B6.Cg-Nr1d1tm1Ven/LazJ mouse line purchased from Jackson 
Laboratories harbors a spontaneous mutation in Jak3 generating a SCID phenotype, with a 
particular inability to generate antigen-independent professional cytokine-producing innate 
lymphoid cells (ILCs). Mechanistically, loss of Jak3 causes a progressive depletion of restricted 
lymphoid progenitors in the bone marrow along their differentiation to mature ILCs. We further 
demonstrate that acute JAK3 inhibition by tofacitinib of human tonsillar ILCs impairs the ability 
of intraepithelial ILC1 (iILC1) to produce IFN-γ, without affecting ILC3 production of IL-22. 
However, it impaired the proliferation of both iILC1 and ILC3. Tofacitinib is currently approved 
for the treatment of moderate-to-severely active rheumatoid arthritis (RA) and is under clinical 
trial for several other immune-mediated conditions. Our data suggests that therapeutic inhibition 
of JAK3 may also impact ILCs and, to some extent, underlie clinical efficacy. 
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3.2 Introduction 
Primary immunodeficiencies (PIDs) are inborn errors that cause developmental and/or 
functional defects in the immune system (186). Most frequently rare and monogenic, PIDs 
present clinically with a broad array of phenotypes including but not limited to increased 
susceptibility to infection, autoimmunity, and cancer. One of the most deadly categories of PID 
is SCID, which typically presents early in childhood with failure to thrive and severe recurrent 
infections, and is universally fatal if untreated (187). SCID is invariably caused by severe 
developmental and/or functional defects of T lymphocytes, but may also present with variable 
defects of B and/or NK cells depending on the type of causative mutation(186, 188).  
The most common variant of SCID is X-linked (X-SCID) and is caused by inactivating 
mutations in IL2RG, which encodes the common gamma chain or γc (134, 188). Although the γc 
is shared between many cytokines, defects in lymphocyte generation are due to loss of IL-7 and 
IL-15 signaling, which regulate thymocyte and NK cell differentiation and survival, respectively 
(136). Therefore, γc mutations cause a severe defect of both T and NK lymphocytes. 
Furthermore, mice (but not humans) with Il2rg defects also present an additional defect in the 
development of B cells due to a species-difference in their requirement for IL-7 (136). In both 
human and mouse, the γc signals through the tyrosine kinase JAK3; therefore, inactivating 
mutations in JAK3 phenocopy X-SCID, except for their AR inheritance pattern (189, 190). 
Patients with either X-SCID or AR JAK3 SCID are cured by hematopoietic cell transplant 
(HCT) and lack deficits in other organ systems (187, 191). Based on the restricted immune 
defect in these SCID variants, the JAK inhibitor tofacitinib was developed to induce therapeutic 
immunosuppression, with the rationale that a more targeted approach may be clinically superior 
to calcineurin inhibitors and corticosteroids, which act on many different cell types and can have 
87	
substantial off-target effects (191).  Reminiscent of T cell immunodeficiency in SCID, tofactinib 
has been shown to inhibit CD4+ T cell polarization (192), and it is now an effective, approved 
treatment for moderate-to-severely active RA(193). 
ILCs are exquisitely interconnected with cytokines, depending on them for their 
development, activation, and function. In mice, the development of ILC2 and ILC3 are reported 
to require IL-7 like T cells, while the development of ILC1 requires IL-15 like NK cells (24, 38, 
135). Furthermore, the polarized cytokines that mouse ILCs produce are now thought to 
substantially contribute to a variety of homeostatic and disease processes, which have been 
extensively reviewed (26, 27, 194, 195). However, the developmental requirements for human 
ILCs, their contribution to homeostasis and disease, and their degree of regulation by 
immunosuppressive drugs are substantially less clear (196). Here, we identify a spontaneous 
mutation in Jak3 in the Jackson Nr1d1tm1Ven/LacZ mouse line causing a SCID phenotype with 
impaired lymphoid tissue development, and isolate the first Jak3 deficient line on the C56BL6/J 
background. We also identify a critical role for Jak3 in mouse ILC development and test the 
effect of acute pharmacologic JAK3 inhibition on human ILCs. 
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3.3 Materials and Methods 
 
Mice 
B6.Cg-Nr1d1tm1Ven/LazJ, B6;129S4-Jak3tm1Ljb/J, and C57BL6/J mice were purchased 
from the Jackson Laboratory. All mice were bred and maintained in a pathogen-free facility at 
Washington University. Age- and sex-matched animals were used in experiments when possible, 
and were analyzed between 4 and 16 weeks of age. The WUSM Animal Studies Committee 
approved all experiments. 
 
Antibodies and flow cytometry 
Anti-CD3ε (145-2C11), anti-CD19 (ebio1D3), anti-CD45 (30-F11), anti-CD45.1 (A20), 
anti-CD45.2 (104), anti-NK1.1 (PK136), anti-RORγt (AFKJS-9), anti-EOMES (Dan11mag), 
anti-CD8a (53-6.7), anti-CD4 (GK1.5), anti-KLRG1 (2F1), anti-CD62L (MEL-14), anti-CD11c 
(N418), anti-GR1 (RB6-8C5), anti-Ter-119 (TER-119), anti-B220 (RA3-6B2) anti-NKp46 
(29A1.4), anti-Ly6C (HK1.4), SAv Pe-Cy7, SAv APC-Fluor 780, and 123count eBeads were 
obtained from eBioscience. Anti-Ly6G (1A8), anti-CD127 (A7R39), anti-CD19 (6D5), anti-
CD11b (M1170), and anti-Siglec H (551) were obtained from BioLegend. Anti-CCR6 (140706), 
anti-CD45 (30-F11), anti-GATA3 (L50-823), anti-CD11b (M1/70), and SAV BV421 were 
obtained from BD Biosciences. Anti-pSTAT5 (C7185) was obtained from Cell Signaling. Anti-
Jak3 (D7B12) was obtained from Cell Signaling. LIVE/DEAD Fixable Aqua was from Life 
Technologies. Anti-NKp46 (CS96) was produced and biotinylated by the Colonna lab at WUSM 
(182). Fc receptors were blocked before staining with supernatant from hybridoma cells 
producing monoclonal antibody to CD32 (HB-197; ATCC). For intracellular transcription factor 
staining, the FOXP3 staining kit (eBioscience) was used. For intracellular cytokine staining, the 
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BD Cytofix/Cytoperm kit was used. For phosphoflow, cells were fixed using 2% 
paraformaldehyde (Electron Microscopy Sciences) for 10 minutes at 37º, washed three times 
with PBS, and lysed for 30 minutes on ice with 90% methanol before staining. Data were 
acquired on a BD FACSCanto II or BD FACSCalibur and analyzed with FlowJo software 
(Treestar).  
 
Cell isolation, culture, and cytokine measurements 
From mice, siLP lymphocytes were isolated by Collagenase 4 digestion after two EDTA 
washes to remove intraepithelial lymphocytes. Lymphocytes were enriched from digested cells 
by Percoll gradients. From human, cells were isolated and either expanded in culture or directly 
stimulated ex-vivo, as previously described (177, 197). Briefly, iILC1 and ILC3 were sorted from 
human tonsil and cultured in vitro with IL-2 or IL-7 supernatants until reaching sufficient 
numbers for experiments. Tofacitinib was added to cultured cells at the indicated concentration 
48-hours before stimulation, or ex-vivo at the time of stimulation.  Cells were stimulated for 7-8 
hours before analyzing protein by intracellular stain or CBA of supernatants. All cytokines were 
purchased from Peprotech. 
 
Sequencing and analysis 
Whole exome sequencing (WES) was performed by BGI Americas using an Agilent 
platform. Briefly, the genomic DNA sample was randomly fragmented into 200 to 250bp pieces, 
ligated to adapters, and purified by the Agencourt AMPure SPRI beads.  Fragments with insert 
size ~200bp were excised, amplified by ligation-mediated polymerase chain reaction (LM-PCR), 
purified, and hybridized to the SureSelect Biotinylated RNA Library (BAITS) for enrichment 
with streptavidin beads. Captured LM-PCR product was loaded on Illumina Hiseq4000 platform 
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for high-throughput sequencing. After sequencing, data were preprocessed, aligned to the 
C57BL6/J genome using Burrows-Wheeler Aligner (BWA) software, and SNP and InDel 
variants were called using the Genome Analysis Toolkit HaplotypeCaller (Broad Institute). 
Variants were hard-filtered to generate a high-confidence dataset, which were then annotated to 
identify protein-coding changes. 
 For Sanger sequencing, the region around the putative mutation in Jak3 was amplified by 
PCR using the following primers: Jak3 F: 5’- CACCCACTATACCCCGTGTC-3’ and Jak3 R: 
5’-TGAGCCTCCTGGAGACATTC-3’. PCR products were purified (Qiagen) and sequenced 
using an internal sequencing primer, 5’- GGACCCTTTGTGCAAAGGTGACC-3’ (GeneWiz). 
Data were visualized using ApE. 
 
Statistics 
Prism 6 (GraphPad Software) was used for all statistical analyses. All graphical data show mean 
± SEM.  
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3.4 Results 
AR phenotype in Nr1d1tm1Ven/LacZ line leads to impaired ILC development   
We recently reported that Nr1d1, which encodes the transcriptional repressor REV-
ERBα, is part of a core molecular signature that distinguishes ILC3 from other ILC subsets 
(182). To test if REV-ERBα is important for ILC3, we purchased Nr1d1tm1Ven/LacZ mice 
(lacking REV-ERBα expression) from Jackson Laboratories.  During the preliminary analysis of 
these mice, we noted a phenotype characterized by lack of lymphoid tissue development that 
emerged in the F1 from original Jackson breeders and that segregated independently from 
Nr1d1tm1Ven alleles, which we called Wolverine (WLVRN) (Figure 19A).  Grossly, mice with the 
WLVRN phenotype lacked PPs and peripheral lymph nodes as measured by inguinal lymph node 
presence or absence, and also demonstrated thymic aplasia compared to littermates (Figure 19B 
and data not shown). Pedigree analysis demonstrated an AR pattern of inheritance (Figure 19A). 
We tested this interpretation by backcrossing an Nr1d1+/+ mouse with the WLVRN phenotype to 
C57BL6/J and intercrossing the F1. Supporting the conclusion that the phenotype was AR, F1 
mice were phenotypically normal, while the WLVRN phenotype reemerged in the F2 (Figure 
19C). Collectively, these data suggested that the Jackson-derived Nr1d1tm1Ven/LacZ mouse line 
most likely carried a second mutation unrelated to Nr1d1. 
As LTi cells are critically important for lymphoid tissue development and are a fetal 
member of the ILC3 lineage (24), we assessed ILCs in Nr1d1+/+ WLVRN mice compared to 
unrelated WT controls. In adult mice, we found that NK cells, ILC1, ILC2, and ILC3 subsets 
excluding CCR6+ ILC3 were significantly reduced in frequency in the siLP of mice with the 
WLVRN phenotype. All ILCs were significantly reduced in total number, with each subset 
amounting to less than 1000 cells in WLVRN mice, a reduction of over 100-fold compared to WT 
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mice for all subsets except DN ILC3, which were reduced by 36-fold (Figure 20A-C). This 
phenotype was intrinsic to the immune system, as significantly fewer ILCs could be recovered 
from the siLP of irradiated CD45.1 mice that received CD45.2 WLVRN marrow compared to 
those that received CD45.2 WT marrow after 8 weeks of reconstitution (Figure 20D). Moreover, 
among the ILCs that could be recovered, there was significantly less CD45.2+ donor 
reconstitution by transplanted WLVRN marrow than by WT among all of the ILC subsets. In fact, 
most ILCs from recipients of WLVRN marrow remained CD45.1+ host-derived at 8 weeks, while 
in recipients of WT marrow, only radioresistant DN and CCR6+ ILC3 (125) subsets remained 
substantially CD45.1+ host-derived (Figure 20E). Thus, the putative mutation causing the 
WLVRN phenotype led to a cell-intrinsic block in ILC development, and confounded the 
interpretation of ILC biology in the Nr1d1 tm1Ven/LacZ mouse line. 
 
WLVRN phenotype impairs lymphoid and increases myeloid development 
 Given the immune-intrinsic deficiency in all ILC subsets, we next asked if the 
development of other lymphoid cells was similarly impaired in Nr1d1+/+ WLVRN mice. 
Evaluation of splenic lymphocytes demonstrated a dramatic reduction in both innate and 
adaptive cells (Figure 21A), with significantly reduced frequency of B cells, CD8+ T cells, and 
NK cells among CD45+ immune cells (Figure 21B). All lymphocytes were significantly reduced 
in total number (Figure 21C). Similar to siLP ILCs, the most dramatic decrease was found 
among splenic NK cells with an over 100-fold reduction in their total number between WT and 
WLVRN mice (341-fold), followed by B cells (150-fold), CD8+ T cells (91-fold) and CD4+ T 
cells (6-fold) (Figure 21C). Consistent with the relative preservation of CD4+ T cells by total 
number, these cells were not significantly reduced in frequency compared to WT mice (Figure 
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21B), and were the major population of lymphocytes found in mice with the WLVRN phenotype 
(Figure 21D). As CD4+ T cells appeared to be selectively expanded, we next asked if T cell 
subsets in WLVRN mice were activated or naïve (Figure 21D). The majority of T cells in both 
the CD4+ and CD8+ lineages from WLVRN mice were CD62L–CD44+ effector memory cells, 
which were significantly greater in frequency compared to WT mice (Figure 21E). We also 
found a significant and concomitant decrease in naïve CD62L+CD44– cells in both T cell subsets, 
and a significant decrease in CD62L+CD44+ central memory T cells among CD4+ T cells from 
WLVRN mice compared to WT. This phenotype was reminiscent of Il2rg–/– SCID mice, which 
have dramatically impaired lymphoid development and expansion of residual T cells(134, 188).  
Because myeloid development is intact in SCID mice, we next asked if myeloid 
development was normal in Nr1d1+/+ WLVRN mice. Indeed, development of pDC, monocytes, 
and neutrophils was intact (Figure 22A), with a significantly higher frequency and total number 
of monocytes and neutrophils in the spleen of WLVRN mice compared to WT controls (Figure 
22B-C). Lymphoid and myeloid phenotypes were intrinsic to the immune system, because bone 
marrow chimeras generated with CD45.2 WLVRN marrow or CD45.2 WT marrow into CD45.1 
recipient mice demonstrated a significant reduction in recovered B and NK cells in mice that 
received WLVRN marrow compared to those that received WT marrow (Figure 23A), and a 
significant increase in recovered monocytes with a trend for recovered neutrophils (Figure 23B). 
Moreover, among the cells that were recovered, splenic T, B, and NK cells from mice that 
received WLVRN marrow were predominantly host-derived after 8-weeks reconstitution 
compared to those that received WT marrow (Figure 23C), while splenic monocytes and 
neutrophils were almost entirely donor-derived from both WLVRN and WT donors (Figure 
23D). From these data we concluded that WLVRN mice have a SCID phenotype with selective 
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and profound inability to generate all lymphocytes. The developmental block in lymphocyte 
generation was greatest for ILCs, which may lack an intrinsic program to undergo significant and 
rapid clonal expansion. Given that this phenotype originated at Jackson, this observation is 
additionally notable because most studies of REV-ERBα deficient mice have thus far studied 
macrophages or non-immune populations and could potentially miss this confounding immune 
defect.  
 
Spontaneous loss-of-function mutation in Jak3 cause WLVRN phenotype 
To determine if there was a spontaneous mutation in the Nr1d1tm1Ven/LacZ line 
responsible for the WLVRN phenotype, we performed WES on genomic DNA banked from a 
male mouse with the WLVRN phenotype lacking Nr1d1tm1Ven alleles (Figure 19A). Analysis of 
sequencing results revealed 2423 SNPs and 571 insertions or deletions compared to the reference 
C57BL6/J genome, of which 126 SNPs and 136 insertions/deletions were homozygous 
(Appendix 2). Among these were 5 frameshift variants (Figure 24), which included Jak3. 
Published mouse studies from Jak3 deficient mice describe a phenotype similar to WLVRN mice; 
Jak3tm1Ljb/tm1Ljb mice have diminished lymphoid and increased myeloid development, with 
residual lymphocytes skewed to activated, oligoclonally expanded CD4+ T cells (198, 199). 
Furthermore, ILC development is known to be critically dependent upon γc (23, 24), which 
signals through Jak3 (136), although adult non-NK ILCs have never been evaluated in Jak3 
deficient mice or patients. Thus, we hypothesized that the WLVRN phenotype was caused by a 
Jak3 mutation.  
The mutation identified in Jak3 corresponds to the insertion of an additional cytosine 
residue 3’ to a stretch of five cytosines, at position 2067 of the coding mRNA, in exon 14 of the 
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gene (Figure 24).  This leads to a frameshift at position 689 within the pseudokinase domain of 
Jak3 and the introduction of a stop codon at position 702, thereby resulting in the expression of a 
truncated Jak3 molecule lacking the C-terminal kinase domain responsible for transmitting γc–
dependent signals (Figure 25A). PCR amplification around the predicted mutation in exon 14 
from genomic DNA of littermates discordant for the WLVRN phenotype in the original pedigree 
(Figure 19A), followed by Sanger sequencing, confirmed homozygosity for the c.2067insC 
mutation in phenotypically affected mice, whereas phenotypically normal littermates were either 
homozygous for the wild-type sequence or showed two traces diverging at position 2067 (Figure 
25B).  
We next assessed if Nr1d1+/+ WLVRN mice were unable to signal through γc cytokines. 
As predicted, splenic CD4+ T cells from WLVRN mice were unable to phosphorylate STAT5 in 
response to 15 minutes of IL-7 stimulation, while littermate CD4+ T cells could robustly do so 
(Figure 25C). This defect was not simply due to lack of the receptor expression, as CD4+ T cells 
from both WLVRN mice and littermates expressed the receptor for IL-7, CD127 (Figure 25D), 
albeit at lower levels in WLVRN mice. To test if Jak3 protein was present in WLVRN mice, we 
next performed an immunoblot, using an N-terminal anti-Jak3 antibody to bone marrow derived 
macrophage (BMDM) lysates generated from Sanger-sequenced Nr1d1+/+ littermates. In Jak3+/+, 
Jak32067insC/+, and unrelated WT mice, expression of the Jak3 protein was clearly detected, but it 
was absent in Jak32067insC/2067insC mice and Jak3tm1Ljb/tm1Ljb negative controls (Figure 25E). Thus, 
WLVRN mice failed to express full-length Jak3 with an intact C-terminus kinase domain. 
Although we did not detect a truncated protein in mice with Jak32067insC alleles, we hypothesize 
that the frameshifted variant may be unstable or improperly folded and therefore undergo 
degradation.  
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To determine if the Jak32067insC mutation caused the WLVRN phenotypic lack of siLP 
ILCs and loss of lymphoid tissue development, we first assessed littermates genotyped by Sanger 
sequencing. We found that there was no significant difference between WT and heterozygous 
mice, but significant decreases in all ILC subsets in homozygous mice (Figure 25F). 
Homozygous mice also lacked lymphoid tissue development (data not shown). This defect 
phenocopied littermates from intercrossed Jak3tm1Ljb/+ mice, which are on a mixed 129S4 and 
C57BL6/J background (Figure 25G and data not shown). Finally, to test directly if Jak3 
deficiency caused these WLVRN phenotypes, we intercrossed Jak3tm1Ljb/+ and Jak32067insC/+, and 
found that there was complementation between the two alleles, such that Jak32067insC/ tm1Ljb mice 
had reductions in ILCs and lacked lymphoid tissue development, though there was no difference 
between WT and either heterozygous allele (Figure 25H and data not shown). From these data, 
we conclude that the WLVRN phenotype is caused by a spontaneous loss-of-function mutation in 
Jak3, leading to the first C57BL6/J Jak3 deficient mouse line. We demonstrate for the first time 
that Jak3 is critically important for the development and/or maintenance of all ILCs. 
 
Jak3 deficiency progressively reduces restricted ILC-generating progenitors 
 Though the role of Jak3 in lymphoid development is well recognized, the stage at which 
it is required for ILC development is completely unknown. Therefore, we next tested the 
developmental requirements for Jak3 within progenitor populations in the bone marrow. ILCs 
develop from distinct bone marrow progenitors along a sequence of cells with progressively 
restricted fates (23, 24): Downstream of the common lymphoid progenitor (CLP) that generates 
all lymphoid cells, early innate lymphoid progenitors (EILPs)(53) and α-lymphoid precursors 
(αLP)(54) give rise to all ILCs, a common helper ILC precursor (CHILP) to ILCs excluding NK 
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cells (51), an ILC precursor (ILCP) to ILC1, ILC2, and ILC3 cells excluding the CCR6+ ILC3 
subset (55), and an ILC2 precursor (ILC2P) to ILC2 (51, 56). As EILPs and ILCPs require 
transcription factor reporter mice to analyze, we assessed CLPs, CHILPs, and ILC2Ps in 
Jak3tm1Ljb/+ and Jak3tm1Ljb/ tm1Ljb littermates. We found that all progenitors were reduced in Jak3-
deficient mice compared to sufficient littermates (Figure 26A), both as the frequency of lineage 
negative cells (Figure 26B) and the total number within one tibia (Figure 26C). Furthermore, 
the effect of Jak3 deficiency was greatest on the most restricted ILC2Ps, which were almost 
completely depleted, while CLP and CHILP were still to some extent intact (Figure 26A-C). We 
conclude that Jak3 deficiency reduces early lymphoid progenitors with an even greater effect as 
differentiation proceeds to mature ILCs.  
 
Tofacitinib diminishes human ILC proliferation and function 
Based on our finding that Jak3 was critically important for mouse ILCs and prior reports 
that NK cells are reduced in patients treated with the JAK inhibitor tofacitinib (200), we 
hypothesized that this inhibitor may also affect human ILCs. To test this, we either sorted iILC1 
and ILC3 from inflamed pediatric tonsil specimens and expanded them in vitro or tested ILC3 
directly ex-vivo, as previously described (177). We inhibited cells acutely with low (20 nmol) or 
high doses (100 nmol) of tofactinib, corresponding to a selective but partial inhibition of JAK3 at 
low dose and dual JAK3/JAK1 inhibition with minimal JAK2 inhibition at high dose(192). In 
response to stimulation with IL-12 and IL-15, significantly fewer expanded iILC1 produced IFN-
γ at low dose compared to control, an effect that was even greater at high dose (Figure 27A). 
The MFI of IFN-γ was also reduced in both conditions compared to control (Figure 27B). Thus, 
fewer iILC1 produced cytokine after acute JAK3/JAK1 inhibition, and they made less cytokine 
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per cell, resulting in a highly significant, dose-dependent decrease in IFN-γ protein in the 
supernatant (Figure 27C). In contrast, in response to IL-23 stimulation ex-vivo, ILC3 stimulated 
in the presence of tofacitinib produced IL-22 equally well compared to control; there was no 
significant difference in the percent of ILC3 that produced IL-22 or in the MFI of IL-22 (Figure 
27D-E). Similarly, we found no difference in IL-22 protein levels in the supernatant between 
expanded ILC3 stimulated in the presence of tofacitinib and control (Figure 27F), although 
expanded ILC3 also responded less to stimulation with IL-23 than primary cells as we have 
previously reported(177). We conclude that tofacitinib impairs cytokine production by iILC1 but 
not ILC3, at least in conventional stimulation conditions.   
We next tested whether tofacitinib affects ILC proliferation. We found that both 
expanded iILC1 (Figure 28 A-B) and ILC3 (Figure 28C-D) were substantially less proliferative 
in the presence of tofacitinib. Unlike the differential effect on cytokine production between types 
of ILCs, both iILC1 and ILC3 incorporated significantly less BrdU in a dose-dependent manner, 
and their proliferation almost completely blocked at high dose. Therefore, long-term 
administration of tofacitinib may reduce human ILC proliferation caused by a pro-proliferative 
inflammatory context. 
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3.5 Discussion 
 
Collectively, we demonstrate that the Nr1d1tm1Ven/LacZ line harbors a spontaneous loss-
of-function mutation in Jak3 that originated in Jackson Laboratories and is responsible for an AR 
SCID phenotype marked by loss of lymphoid tissue development and a lack of ILCs. Given that 
this mutation arose at Jackson and profoundly effects mice, these results may be particularly 
notable to investigators who have purchased this mouse line and can easily be tested through 
methods we describe. Isolated from Nr1d1 tm1Ven alleles, the Jak32067insC mutation is further the 
first Jak3-deficient mouse model of SCID on the C57BL6/J background. To our knowledge, this 
is also the first time Jak3 has been shown to be critical to the development of adult ILCs.  
How does loss of Jak3 block mouse ILC development? Through analysis of bone 
marrow, we show that Jak3 deficiency causes a progressive depletion restricted ILC progenitors 
as they differentiate toward mature ILCs. These data are reminiscent of the progressive depletion 
of other restricted lymphoid progenitors in IL-7 deficient mice from lymphoid-primed 
multipotent progenitor (LMPP), to multipotent Ly6D– CLP, to B-cell generating Ly6D+ 
CLP(201, 202). Interestingly, although mature ILC2 and ILC3 depend on IL-7R signaling, 
CHILP development has been reported to be intact in IL-7R deficient mice, while ILC2P 
differentiation is almost completely depleted (51). However, it is unclear how the author’s 
assessed these populations in the absence of CD127. Our data that CHILP are reduced in Jak3 
deficient mice suggests that an additional γc cytokine beyond IL-7 may support CHILP 
generation, though the generation of these cells is also to some extent γc independent. Thus, there 
is likely some redundancy in signals to generate and/or maintain early bone marrow ILC 
progenitors, while more restricted progenitors and mature ILCs become almost completely Jak3 
dependent. 
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In most human PID, ILCs have yet to be evaluated and may differ from mouse, similar to 
the divergent requirements for IL-7 in B cell development between species (136). However, ILC 
development is most likely impaired in patients with JAK3 mutations given the absence of 
lymphoid tissue in these patients (136) and the near absence of “Stage 3 NK cells” which include 
RORC+ ILC3 (39, 178) in the peripheral blood of IL7R-deficient patients (43), though this 
remains to be formally evaluated. If ILCs are JAK3- and IL-7-dependent in human, they may 
further contribute to the profound degree of immunodeficiency in SCID patients.  
Similar to the lack of information on human ILCs in SCID patients, the degree to which 
human ILCs are affected by immunosuppressive therapies remains mostly unknown. As ILCs are 
primarily a tissue-resident population in both human and mouse, we were unable to assess ILC 
function from patients treated with JAK3 inhibitors directly ex-vivo. However, we were able to 
test the role of acute-JAK3 inhibition in vitro on prevalent human tonsillar ILC1 and ILC3 
populations using tofacitinib; ILC2 are rare populations within the human tonsil and could not be 
tested (197). At the doses of tofacitinib we chose for our study, there is minimal impact of JAK2 
function (192), which along with TYK2 transduces both IL-12 and IL-23 signals (203). 
Consistent with this, we found no impact of tofacitinib on ILC3 production of IL-22 after 
stimulation with IL-23. Thus, the reduced production of IFN-γ by iILC1 we found is unlikely to 
be caused by direct blockade of IL-12 signaling. Downstream of JAK3, γc cytokine signaling is 
important for the growth and fitness of lymphocytes. For example, IL-15 is known to enhance 
NK cell and CD8+ T cell activation, including IFN-γ production, by increasing cellular 
proliferation and metabolic fitness (204, 205). As we also find reduced proliferation of expanded 
ILCs in the presence of tofacitinib, most likely, an overall bioenergetic impairment similarly 
contributes to the reduced IFN-g production by iILC1.  
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Interestingly, JAK3 inhibitors have thus far shown clinical efficacy in RA (193) and 
psoriasis (206), but have had surprisingly weak phase-two results in Chron’s disease trials (207). 
Our data that tofacitinib can repress antigen-independent iILC1 IFN-γ production but not ILC3 
production of IL-22 suggests that there may also be a differential effect on these cells in a 
therapeutic context. In the long term, reduced ILC proliferation combined with inhibited iILC1 
function may further contribute to the therapeutic efficacy of this drug, which warrants further 
investigation.  
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3.6 Figures 
 
 
 
FIGURE 19: Identification of the Wolverine Phenotype 
 
(A) Pedigree analysis of intercrossed heterozygous B6.Cg-Nr1d1tm1Ven/LazJ mice beginning with 
original breeding trio purchased from Jackson Laboratories. WLVRN probands emerge in F1. (B) 
Number of PPs in WLVRN mice compared to littermate controls. (C) Pedigree analysis of an 
Nr1d1+/+ WLVRN mouse backcrossed to C57BL6/J. (B) Data represent n=5 mice per group from 
3 independent experiments. ** p<.01, two-tailed Mann-Whitley test. 
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FIGURE 20: ILCs Fail to Develop in the Wolverine Mice  
 
(A-C) Evaluation of ILC populations from the siLP of Nr1d1+/+ WLVRN or unrelated WT 
control mice. (A) Gating strategy and representative flow plots. (B) Frequency and (C) total 
number of ILC subsets. (D) Frequency of recovered siLP ILCs from bone marrow chimeras and 
(E) the degree of chimerism per subset 8 weeks post-irradiation. Data represent (B-C) n=5 mice 
per group or (D-E) n=4-5 mice per group from 2-3 independent experiments. *p<.05, ** p<.01, 
two-tailed Mann-Whitley test. 
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FIGURE 21: Wolverine Mice Have Impaired Lymphocyte Generation 
 
(A-E) Spleen was isolated from Nr1d1+/+ WLVRN or unrelated WT control mice and lymphoid 
populations were assessed. (A) Gating strategy and representative flow plots for lymphocyte 
analysis. (B) Frequency and (C) total number of lymphocyte subsets. (D) Gating strategy, 
representative flow plots, and (E) quantification of T cell populations. (A-E) Data represent n= 5 
mice per group from 2-3 independent experiments. *p<.05, ** p<.01, two-tailed Mann-Whitley 
test. 
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FIGURE 22: Wolverine Mice Have Increased Myeloid Generation 
 
(A-C) Spleen was isolated from Nr1d1+/+ WLVRN or unrelated WT control mice and myeloid 
populations were assessed. (A) Gating strategy and representative flow plots for myeloid 
analysis. (B) Frequency and (C) total number of selected myeloid subsets. (A-C) Data represent 
n= 5 mice per group from 2-3 independent experiments. ** p<.01, two-tailed Mann-Whitley test. 
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FIGURE 23: Wolverine Lymphocyte Deficiency is Cell-Intrinsic 
 
Frequency of recovered (A) spleen lymphocytes and (B) spleen myeloid cells from bone marrow 
chimeras and the degree of chimerism per subset (C-D) 8 weeks post-irradiation. Data represent 
n= 5 mice per group from 2-3 independent experiments. *p<.05, ** p<.01, two-tailed Mann-
Whitley test. 
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FIGURE 24: Identification of Frameshift Mutations in the Nr1d1tm1Ven/LacZ	Mouse Line 
 
A male Nr1d1+/+ Wolverine mouse from the original pedigree (Figure 19A, Appendix 2) was 
sequenced by WES for complete coverage of the genome. In comparison to the C57BL6/J 
genome, variants detected by WES were called as SNPs or Insertions/Deletions (Indels). Among 
filtered homozygous variants, five frameshift variants were found, including Jak3. 
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FIGURE 25: Jak32067insC Causes the Wolverine Phenotype 
 
(A) Diagram of mouse Jak3 with location of predicted frameshift mutation and introduced stop 
codon based on WES. (B-H) Analysis of littermates discordant for the WLVRN phenotype, either 
from (B) original Nr1d1tm1Ven/LazJ pedigree or (C-H) isolated Nr1d1+/+ WLVRN line. (B) Sanger 
sequencing of Jak3 exon 14 from banked genomic DNA (1A).  Representative flow plots of (C) 
p-STAT5 from CD4+ T cells after 15 minutes of IL-7 stimulation or (D) CD127 expression from 
resting CD4+ T cell and CD19+ B cells. (E) Immunoblot for Jak3 from BMDMs. (F-H) Total 
number of ILCs in littermates from (F) Jak32067insC/+ intercross, (G) Jak3tm1Ljb/+ intercross, and 
(H) Jak32067insC/+ x Jak3tm1Ljb/+ intercross as gated in 1D, but without the use of NK1.1 for 
Jak3tm1Ljb mice which are on a mixed 129S4 and C57BL6/J background. Data represent (F) n=4 
(G) n=5 or (H) n= 6 mice per genotype and (C-D, F-G) n = 3, (E) n = 1, or (H) n = 4 
109	
independent experiments. *p<.05, **p<.01, ***p<.001, ****p<.0001 one-way ANOVA with 
Tukey’s multiple comparisons test.  
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FIGURE 26: Jak3 Deficiency Progressively Reduces Restricted Lymphoid Progenitors 
(A-C) Analysis of lymphoid progenitors from the tibia of Jak3tm1Ljb/+ and sex-matched 
Jak3tm1Ljb/tm1Ljb littermates. (A) Representative flow plots of bone marrow progenitors among 
lineage (CD3e, CD4, CD8a, CD11b, CD11c, CD19, NK1.1, GR1, Ter-119, B220) negative cells. 
CLP: CD127+CD135+ CLP; CHILP: CD127+CD135–a4b7+ST2– CHILP; and ILC2P: 
CD127+CD135–a4b7+ST2+ ILC2P. (B) Frequency of progenitors among lineage negative cells. 
(C) Total number of progenitors in one tibia. ** p<.01, two-tailed Mann-Whitley test. 
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FIGURE 27: JAK3	Inhibition	Impairs	Human	ILC	Cytokine	Production	
(A-C) Effect of 48-hour tofacitinib culture on expanded human tonsillar iILC1 IFN-g production 
in vitro. Data show (A) percentage of IFN-γ+ cells and (B) IFN-g mean fluorescent intensity 
(MFI) by flow cytometry, and (C) representative IFN-s protein in supernatant of Donor 3 by 
CBA. (D) Percentage of IL-22+ ILC3 cells and (E) MFI of IL-22 after IL-23 stimulation ex-vivo 
in the presence of the indicated dose of tofacitinib. (F) Representative IL-22 protein in 
supernatant of expanded human tonsillar ILC3 after 48-hours of tofacitinib. Data represent (A-B, 
D-E) n = 3 or (C, F) n = 2 donors. #p<.05, paired t-test. ***p<.001, ****p<.0001, one-way 
ANOVA with Tukey’s multiple comparison test. 
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FIGURE 28: JAK3	Inhibition	Impairs	Human	ILC	Cytokine	Production	
(A-D) Effect of 48-hour tofacitinib culture on BrdU incorporation in expanded (A-B) iILC1 and 
(C-D) ILC3. Data show (A,C) representative flow plots and (B,D) quantification.  Data represent 
n = 2 donors. *p<.05, **p<.01, ***p<.001, ****p<.0001, one-way ANOVA with Tukey’s 
multiple comparison test. 
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CHAPTER 4 
 
IL-15 Sustains IL-7R-Independent ILC2 and ILC3 Development 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter were adapted from  
 
Robinette ML, Bando JK, Song W, Ulland TK, Gilfillan S, Colonna M. IL-15 sustains IL-7R-
independent ILC2 and ILC3 development. Nat Commun 8, 14601 doi:10.1038/ncomms14601 
(2017). 
© The Authors 2017 
 
All work recreated here is that of the author of this dissertation. 
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4.1 Abstract 
 
The signals that maintain tissue-resident innate lymphoid cells (ILCs) in different 
microenvironments are incompletely understood. Here, we systematically characterize the extent 
to which ILCs require IL-7R in mucosal tissues. We demonstrate that IL-7R is not strictly 
required for the development of any ILC subset, as residual ILC2 and ILC3 cells persist in the 
siLP of adult IL-7R deficient mice. ILC2s predominantly expressed an ST2–KLRG1+ phenotype, 
but were not inflammatory ILC2. CCR6+ ILC3, which expressed higher Bcl-2 than other ILC3 
further enhanced by loss of IL-7R, became the most abundant ILC. All ILC subsets were 
functionally competent in vitro, and were sufficient to provide enhanced protection during 
infection with C. rodentium in vivo. IL-15 compensated for IL-7R deficiency, as residual ILCs 
were depleted in mice lacking both molecules. Collectively, these data demonstrate that siLP 
ILCs are not completely IL-7R dependent, but can partially persist through IL-15.  
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4.2 Introduction 
In mice, ILC development requires Jak3 (Figures 19-20, 25).  This protein tyrosine 
kinase associates with the γc and mediates the downstream intracellular signaling events from 
cytokines that engage it as co-receptor (140). While all lymphocytes depend on Jak3 and γc for 
their normal development and are only generated in trace numbers in the absence of either 
molecule (Figures 19-25), the γc family cytokines that sustain cellular development and 
maintenance differ between lymphocyte classes. Within ILCs, ILC1 and NK cells require IL-15 
(21, 204, 208-211), while ILC2 and ILC3 are thought to require IL-7.  
There is a consensus in the field that ILC2 and ILC3 require IL-7 for their differentiation 
and/or survival, as these classes of cells are greatly reduced in number in IL-7 or IL-7Rα 
deficient mice (21, 212). Furthermore, these defects appear to be greater in IL-7Rα deficient 
mice, which transduces signal for both IL-7 and TSLP (21, 212). However, as the ILC field has 
rapidly expanded, findings have been piecemeal, and therefore the requirement for IL-7R by the 
primary ILC subsets defined by lineage studies have not systematically been tested across the 
mucosal surfaces where ILC2 and ILC3 principally reside. It is therefore unknown if certain 
microenvironments differentially require IL-7 to support ILC homeostasis, and if so, the identity 
of the compensatory survival signal. Moreover, the function of residual cells remains 
controversial for ILC3 and unknown for ILC2, the latter of which have never been reported in 
substantial number in mice lacking IL-7 signals. Given that ILC2 and ILC3 have been widely 
cited to be IL-7-dependent, these questions are particularly important, as IL-7 and IL-7rα 
deficient mice are now used as experimental controls and to establish lineage relationships of 
new ILC subsets.  
Here, we systematically test the frequency, number, phenotype, and function of ILC2 and 
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NKp46+, DN, and CCR6+ ILC3 subsets compared to NK cells and ILC1 in IL-7Rα deficient 
mice, which should have the most severe defect in ILC generation. We demonstrate a selective 
preservation of substantial numbers of partially functional ILC2 and ILC3s, particularly CCR6+ 
ILC3, in the siLP. CCR6+ ILC3 express higher levels of Bcl-2 than other ILC3, which is 
surprisingly increased further by IL-7R deficiency. Finally, we show that IL-15 partially 
compensates for IL-7 in the siLP, as IL-7R/IL-15 double knockout mice almost entirely lose ILC 
development.  
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4.3 Materials and Methods 
Mice 
Il15–/–, Rag1–/–, and C57BL6/J mice were purchased from the Jackson Laboratory. Rag2–/– Il2rg–/– 
mice were purchased from Taconic. Il7ra–/– mice were a gift from Dr. Ken Murphy. All mice 
were bred and maintained in a pathogen-free facility at Washington University. Age- and sex-
matched animals were analyzed between 6 and 12 weeks of age. The WUSM Animal Studies 
Committee approved all experiments. 
 
Antibodies and flow cytometry 
Anti-CD3ε (145-2C11), anti-CD19 (ebio1D3), anti-CD45 (30-F11), anti-NK1.1 (PK136), anti-
RORγt (AFKJS-9), anti-EOMES (Dan11mag), anti-KLRG1 (2F1), anti-ST2 (RMST2-2), anti-
Bcl-2 (10C4), anti-Ki67 (SolA15), SAV Pe-Cy7, and 123count eBeads were obtained from 
eBioscience. Anti-CCR6 (140706), anti-GATA3 (L50-823), and SAV BV421 were obtained 
from BD Biosciences. LIVE/DEAD Fixable Aqua was from Life Technologies. Anti-NKp46 
(CS96) was produced and biotinylated by the Colonna lab at WUSM(182). Fc receptors were 
blocked before staining with supernatant from hybridoma cells producing monoclonal antibody 
to CD32 (HB-197; ATCC). For intracellular transcription factor staining, the FOXP3 staining kit 
(eBioscience) was used. For intracellular cytokine staining, the BD Cytofix/Cytoperm kit was 
used. Data were acquired on a BD FACSCanto II and analyzed with FlowJo software (Treestar).  	
Cell cultures 
siLP immune cells were isolated using Collagenase 4 (Sigma) digestion and Percoll (GE 
Healthcare) gradient enrichment, then stimulated using recombinant cytokines or 
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PMA/ionomycin for 3 hours, followed by 3 additional hours in the presence of Golgi Plug (BD). 
All cytokines (Peprotech, R&D) were used at 10 ng/mL. 
 
Citrobacter rodentium infection  
Cohoused experimental mice were fasted for 4 hours, then gavaged with 2x109 CFU C. 
rodentium in 100 µL PBS. Weight loss was measured at the same time daily and normalized to 
the mass recorded on the day of infection.  
 
Microarray analysis 
ILC3 subsets were sorted from the siLP of three pooled WT donors. Cells were gated on CD3–
CD19– CD45lo Thy1+ ILC3s, then subdivided into three subsets using CCR6 and NKp46 
(resulting in CCR6+, NKp46+, and DN ILC3). RNA was isolated using the RNeasy Micro Kit 
(Qiagen). The Genome Technology Access Center (GTAC) at Washington University amplified 
RNA and hybridized the product to Affymetrix Mouse Gene 1.0 ST arrays. Analysis was carried 
out as previously described, using the Multiplot Studio function of GenePattern(182).  
 
Statistics 
Prism 6 (GraphPad Software) was used for all statistical analyses except for microarray analysis, 
which was performed in the Multiplot Studio function of GenePattern. All graphical data show 
mean ± SEM. 
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4.4 Results 
siLP sustains residual ILCs in Il7ra–/– mice 
To test the functional role of IL-7R in ILCs, we first systematically assessed the 
frequency and total number of these cells in Il7ra–/– mice, which lack IL-7R expression, using an 
intracellular TF staining approach (Figure 29A). As ILC2 and ILC3s are found in greatest 
number and diversity at mucosal surfaces, particularly in the gastrointestinal tract(23, 182, 213), 
we focused on these sites. In the siLP of Il7ra–/– mice, we clearly detected all ILC subsets 
(Figure 29B). NK cells, ILC1, and CCR6+ ILC3 were significantly increased in frequency 
among CD45+ cells in the lymphocyte gate compared to WT control (Figure 29B). Meanwhile, 
ILC2 and NKp46+ ILC3 were significantly reduced in frequency by 1.9-fold and 2.2-fold, 
respectively. The frequency of DN ILC3 subset was unchanged between genotypes (Figure 
29B). Consistent with previous reports (43, 51, 56, 138, 214), the total numbers of all siLP ILC 
subsets except NK cells and ILC1 were reduced (Figure 29C) due to a reduced numbers of 
lymphocytes in these mice (data not shown). Despite their overall significant reduction from WT 
mice, we noted that residual siLP Il7ra–/– ILC2 we were still present at total numbers equal to or 
greater than that of other ILCP-derived cells (Figure 29C). Furthermore, CHILP-derived CCR6+ 
ILC3 became the most abundant ILC3 subset in the Il7ra–/– mice (Figure 29C), in line with their 
significantly increased frequency along with NK cells and ILC1 (Figure 29B).  
We next turned our attention to two other mucosal surfaces, colon and lung. In WT mice, 
NK cells, ILC1, and ILC2 are major colonic populations, while ILC3s account for only a small 
fraction of ILCs (Figure 30A-C). Similar to the siLP, in this organ we found a significant 
increased frequency of NK cells and ILC1, and a significantly decreased frequency of ILC2 by 
11.9-fold in Il7ra–/– mice compared to control. There was no difference in the frequency between 
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minor siLP ILC3 subsets (Figure 30B). All ILCs were reduced in total number in the colon, with 
the greatest difference between ILC2 from WT and Il7ra–/– mice, which became more similar in 
number to rare colonic ILC3 subsets (Figure 30C). Similarly, in the lung, IL7R deficiency 
reduced the frequency of ILC2 by 4.5-fold (Figure 30D-E), resulting in a total number of cells 
even less than in the colon (Figure 30F). Thus, persistence of substantial numbers of residual 
ILCs other than NK cells and ILC1 was predominantly a feature of the siLP.  
 
Partially functionally ST2– ILC2 are not inflammatory ILC2 
ILC2 are frequently identified among lineage negative cells by cell-surface markers 
rather than an intracellular TF staining approach, which typically includes the markers KLRG1 
and ST2. As appreciable numbers of ILC2 have never been reported in Il7–/– or Il7ra–/– mice (56, 
105, 152, 214-216), we wondered if siLP ILC2 from Il7ra–/– mice had an altered cell-surface 
phenotype that may lead to a failure to recognize these cells. We found that ST2+ ILC2 were 
significantly reduced in frequency among KLRG1+ cells (Figure 31A). Although the majority of 
ILC2 expressed KLRG1 in the siLP of both WT and Il7ra–/– mice (Figure 31B), only a minority 
of cells expressed ST2, even in WT mice (Figure 31A-B). This phenotype was reminiscent of 
IL-25-induced mouse ST2–KLRG1+ “inflammatory ILC2” (iILC2), which have been reported to 
persist in Il7ra–/– mice and express intermediate levels of RORγt compared to siLP ILC3 (217). 
To test if ST2– KLRG1+ siLP ILC2 from WT or Il7ra–/– mice were iILC2, we measured their 
expression of RORγt compared to positive control CCR6+ ILC3 and negative control 
KLRG1+ST2+ ILC2. We found that there was no difference in RORγt expression between ST2+ 
and ST2– cells in either WT or Il7ra–/– mice, which were both negative for RORγt compared to 
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CCR6+ ILC3 (Figure 31B). We conclude that siLP ILC2 include both ST2+ and ST2– subsets, 
which are skewed to ST2– cells in the absence of IL-7R signaling.  
The function of residual ILC2 in Il7ra–/– mice has not been tested. ILC2 constitutively 
produce IL-5, which along with IL-13, is increased by stimulation with cytokines including 
TSLP, the danger signal IL-33, and tuft-cell produced IL-25 (101-103, 218). However, Il7ra–/– 
ILC2s were unlikely to respond TSLP and IL-33, given the absence or near absence of the 
respective receptors for these cytokines, IL-7R and ST2. Therefore, we tested ILC2 function by 
culturing them with medium, PMA + ionomycin, IL-25 alone, or IL-25 + IL-33 + TSLP, and 
comparing the frequency of ST2+ and ST2– cells that produced IL-5 and IL-13 from both Il7ra–/– 
mice and WT mice (Figure 32A-D). PMA and ionomycin generated the strongest cytokine 
production from all ILC2s (Figure 21A-D). The ILC2 subset that produced cytokines with the 
greatest frequency across all conditions tested was WT ST2+ ILC2, while Il7ra–/– ST2+ ILC2 and 
WT ST2– ILC2 were indistinguishable (Figure 32A-D). Furthermore, only WT ST2+ ILC2 were 
able to substantially produce IL-13 (Figure 32C-D). The major Il7ra–/– population, ST2– ILC2, 
produced IL-5 and IL-13 at the lowest frequency (Figure 32A-D). As a greater frequency of 
ST2+ ILC2 produced IL-5 and IL-13 compared to ST2– ILC2 from both WT and Il7ra–/– mice 
even when IL-33 was not included in the stimulation, we conclude that conditioning of these 
cells occurs in vivo. We also conclude that Il7ra–/– ILC2s are less conditioned than WT ILC2s, 
by a factor equivalent to the expression of ST2.  
 
Il7ra–/– ILC3s produce IL-22 and partially protect against C. rodentium  
 We next turned our attention to the most abundant ILC class in the siLP of Il7ra–/– and 
WT mice, ILC3 (182) (Figure 29A). It has been controversial whether ILC3 in Il7ra –/– mice are 
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functional, and only the production of IL-22 from NKp46+ ILCs or bulk ILC3 has been tested in 
vitro(138, 214). To test the function of DN, NKp46+, and CCR6+ ILC3s, we first cultured cells 
with IL-23 and IL-1β in vitro, and measured IL-22 and IL-17a production. We found that there 
was no significant difference in IL-22 production among any of the ILC3 subsets in Il7ra–/– and 
WT mice (Figure 33A-D). In comparison, a significantly reduced amount of DN and CCR6+ 
ILC3 produced IL-17a (Figure 33C-D). NKp46+ ILC3 in WT mice produce little IL-17a (42), 
and there was no significant difference between Il7ra –/– mice and WT (Figure 33C-D).  
ILC3-produced IL-22 is a critical factor to promote survival and weight maintenance of 
mice at early time points during infection with the attaching-and-effacing mouse pathogen C. 
rodentium, acting on the gastrointestinal epithelium to induce the production of antimicrobials 
(120). Because IL-22 production was equally intact in Il7ra–/– ILC3s in vitro (Figure 33A-B) 
unlike any tested function of Il7ra–/– ILC2s (Figure 32A-D), we next wondered if these cells 
were competent in vivo to protect mice from C. rodentium. To perform this experiment, we first 
generated Rag1–/–Il7ra–/– mice, as Il7ra–/– mice unlike Rag mice develop some T cells(219), that 
may compete with ILCs for trophic factors(220) and therefore may limit their activation and/or 
homeostatic proliferation in vivo. We then infected cohoused Rag1–/–, Rag1–/–Il7ra–/–, and Rag2–
/–Il2rg–/– with a lethal dose of C. rodentium and measured weight loss and survival (Figure 34A-
B). Beginning at day 4 post-infection through day 6, ILC3-lacking Rag2–/–Il2rg–/– lost 
significantly more weight more quickly than either Rag1–/–Il7ra–/– or Rag1–/–, while there was 
never a difference between weight loss in Rag1–/–Il7ra–/– and Rag1–/– mice (Figure 34A).  As 
expected, this corresponded a highly significant difference in survival between ILC3-sufficient 
Rag1–/– and ILC3-deficient Rag2–/–Il2rg–/– mice (Figure 34B). Meanwhile, Rag1–/–Il7ra–/– 
trended torward intermediate survival, consistent with the reduced number of ILC3, but equal IL-
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22-competence, in the absence of IL-7R (Figure 34B). Thus, IL7R-independent ILCs are 
functional in vivo to partially protect mice from C. rodentium. 
  
CCR6+ ILC3s express higher Bcl-2, enhanced by IL-7R deficiency 
Among all ILCs in the siLP of Il7ra–/– mice, the CCR6+ ILC3 subset is the most abundant 
(Figure 29A-C). Despite the established differences in ontogeny between CCR6+ ILC3 and 
ILCP-derived DN and NKp46+ ILC3 subsets, the extent to these subsets are transcriptionally 
unique or overlapping is unknown. To answer this question and to determine if there were any 
unique factors expressed by CCR6+ ILC3 that could explain their relative preservation in Il7ra–/– 
mice, we performed microarray analysis on ILC3s isolated from WT mice. Comparisons 
between ILC3 subsets revealed that the CCR6+ ILC3 had the greatest number of “uniquely” 
expressed transcripts (n=54), defined as transcripts significantly upregulated at least 2-fold 
compared to other ILC3 subsets. The second greatest number of transcripts were shared by DN + 
NKp46+ ILC3 (n=35) (Figure 35A and Appendix 1G). Thus, ILC3 transcriptional profiles align 
with ontogeny. Because Il7ra–/– mice have increased frequency of CCR6+ ILC3 and decreased 
frequency of NKp46+ ILC3 but unchanged frequency of DN ILC3 (Figure 29B), we next 
directly compared CCR6+ ILC3 to NKp46+ ILC3. With this approach, we found that CCR6+ 
ILC3 expressed Bcl2 at higher levels than NKp46+ ILC3 (1.965-fold, p = 0.011) (Figure 35B), 
which was not true for DN ILC3 versus NKp46+ ILC3 (1.071-fold, p = 0.811) (data not shown).  
We next tested if Bcl-2 expression was different at the protein level in ILC3s from WT 
and Il7ra–/–mice (Figure 36A). Validating our array data, we found that CCR6+ ILC3 in WT 
mice had higher expression of Bcl-2, while NKp46+ ILC and DN ILC3 were identical (Figure 
36A). Surprisingly, in Il7ra–/– mice, the MFI of Bcl-2 increased in both DN ILC3 and CCR6+ 
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ILC3 compared to NKp46+ ILC3, such that NKp46+ ILC3 had lowest expression of Bcl-2, 
followed by intermediate expression by DN ILC3, and high expression by CCR6+ ILC3 (Figure 
36A). Moreover, Bcl-2 expression was significantly higher in both Il7ra–/– DN ILC3 and CCR6+ 
ILC3 compared to WT control, but not in any other siLP ILCs (Figure 36B). As γc cytokines 
regulate both proliferation and survival(140, 221), we next asked if there were also any changes 
to the proliferative capacity of CCR6+ ILC3, as measured by percentage of cells expressing Ki67 
(Figure 36C). Unlike Bcl-2 expression, the percentage of Ki67+ cells did not increase in CCR6+ 
ILC3, but was increased in the other ILCs with increased frequency in Il7ra–/– mice, IL-7-
independent ILC1 and NK cells (Figure 36C).  Both CCR6+ ILC3 and DN ILC3 were weakly 
proliferative in WT and Il7ra–/– mice, consistent with the long half-life(42) and 
radioresistance(125) previously reported for ILC3s. Thus, IL-7R-deficiency paradoxically 
increases anti-apoptotic machinery in CCR6+ ILC3 and, to a lesser extent, DN ILC3. 
 
IL-15 partially compensates for IL-7 in siLP ILC development 
Given the continued presence of all ILC subsets in the siLP of Il7ra–/– mice but 
dependence of ILCs on γc signaling, we next asked if another γc cytokine had a redundant 
function to sustain the development of these cells in the absence of IL-7 signaling. As IL-15 
supports the development of NK cells(208, 209) and ILC1(21) and signals through JAK1 and 
JAK3 like IL-7(140), we hypothesized that this cytokine may compensate. To test this 
hypothesis, we generated Il7ra–/–Il15–/– double-knock out mice, and assessed the frequency and 
total number of ILCs in the siLP of these mice compared to WT and Il7ra–/– mice using the prior 
intracellular TF strategy (Figures 29A, 37A-C). While we reproduced our data in a comparison 
of Il7ra–/– and WT mice, every ILC subset from Il7ra–/–Il15–/– mice was highly significantly 
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reduced in both frequency and total number compared to WT mice (Figure 37A-C). Moreover, 
there were also significant reductions in the frequency and total number of all ILC subsets 
between Il7ra–/–Il15–/– mice compared to Il7ra–/– mice, with the exception of the CCR6+ ILC3 
frequency, which did not reach statistical significance due to highly variability in Il7ra–/– mice in 
these experiments (Figure 37A-C). While there were still some ILCs generated in these mice, 
the total numbers of cells generated were very low and the most abundant population of cells 
remained CCR6+ ILC3s, which were dramatically reduced. Indeed, these data are reminiscent of 
the total numbers of ILCs generated in Jak3 deficient mice that are unable to signal through the 
γc (Figure 20A-E). We conclude that IL-15 partially compensates for IL-7 in the development 
and/or maintenance of siLP ILCs in the absence of IL-7R.  
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4.5 Discussion  
The signals that phenotypcally condition and maintain tissue-resident ILCs are emerging. 
The extent to which each ILC subset relies on IL-7R in different microenvironments remains 
unclear. Here, we systematically assessed the role of IL-7R in adult ILCs, and demonstrated for 
the first time that substantial numbers of functionally capable ILC2s and ILC3s persist in the 
siLP of Il7ra–/– mice. These residual cells were sustained by IL-15, because they were depleted 
when IL-15 was also deleted. 
 Although ILC2s persisted in the greatest frequency and number in the siLP of Il7ra–/– 
mice compared to other commonly studied ILC2-harboring organs colon and lung, their 
phenotype and functions were changed. We find that the siLP includes both ST2+KLRG1+ and 
ST2–KLRG1– ILC2 subsets in WT mice, but that IL-7R deficient ILC2s were further skewed to 
the ST2–KLRG1+ phenotype. Because ILC2 are very rare in non-siLP organs, the persistence of 
IL-25 induced ST2–KLRG1+ iILC2 in Il7ra–/– lung has been used to argue that these cells have 
different developmental origins from other ILC2(217). However, our data suggest that Il7ra–/– 
mice can support ST2– ILC2s regardless of inflammation. It is unclear if lack of ST2 expression 
is caused directly by a cell-intrinsic requirement of IL-7R signaling for ST2 or by secondary 
changes to the environment induced by IL-7R deficiency, which may also be interrelated. For 
example, investigators have recently shown that epithelial tuft cells are dramatically reduced in 
Il7ra–/– mice(103). These cells produce IL-25, inducing ILC2 to produce IL-13, which then feeds 
back on epithelial stem cells to increase tuft cell generation(101-103). In a comprehensive 
analysis of function by ST2+ and ST2– cells from WT and Il7ra–/– mice, we found that only WT 
ST2+KLRG1+ substantially produced IL-13, and that WT ST2–KLRG1+ ILC2 as well as all IL-
7R deficient ILC2s were functionally impaired compared to these cells. Therefore, there is a 
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break in the tuft cell cycle in IL-7R deficient mice that most likely affects both ILC2 and the 
siLP microenvironment. Beyond tuft cells, T cells are also substantially reduced in IL-7R 
deficient mice (140, 219). This could further negatively impact ILC2, as IL-2 has been shown to 
increase ILC2 proliferation and function (222, 223). Whether these factors also regulate ILC2 
expression of ST2 beyond their function remains unclear. 
 The role of IL-7R in ILC3 function has been somewhat controversial. An early report 
demonstrated that Il7–/– NKp46+ ILC3 were unable to generate IL-22 (138), while a recent report 
showed that bulk Il7–/– ILC3 were able to produce significantly more IL-22 after stimulation with 
IL-23 in vitro (214). To assess both IL-17 and IL-22 production, we stimulated cells with IL-1β 
and IL-23, and found that all subsets of ILC3 were equally capable to produce IL-22, but had 
moderately impaired ability to produce IL-17a. As our results for IL-22 were intermediate 
between earlier reports, perhaps reflecting differences in stimulation conditions, we also tested 
the function of these cells in vivo for the first time by generating Rag1–/– Il7ra–/– mice and 
challenging them with C. rodentium. Il7ra–/–Rag1–/– had an intermediate phenotype between 
Rag1–/– and Rag2–/–Il2rg–/–, most likely reflecting intact ILC3 production of IL-22 from reduced 
numbers of cells. Compared to adult ILC3 function, there is a well-established role for IL-7R in 
fetal LTi lymphotoxin expression (224-226). Consistent with this, we did not detect any PPs in 
IL-7R deficient mice (data not shown). Collectively, we conclude that IL-7R deficient ILC3s are 
at least partially functional, both in vitro and in vivo. 
 Among all ILCs in adult Il7ra–/– mice, CCR6+ ILC3 were the most abundant subset. In 
WT mice, fetal-derived CCR6+ LTi persist postnatally, but are outnumbered after week two by 
ILCP-derived subsets (42, 45). In adult mice, the bone marrow can also generate new CCR6+ 
LTi-like ILC3 (51). Here, we assessed ILCs exclusively in adult Il7ra–/– mice, but we are unable 
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to determine if these cells are adult-generated CCR6+ LTi-like ILC3, persistent fetal-generated 
LTi, or a combination of both subsets, given the overlapping cell-surface phenotypes of these 
populations. Similar to our results in adult mice, CCR6+ LTi are known to be intact in fetal Il7ra–
/–mice, and therefore do not depend on this cytokine receptor for their survival (162). Yet, IL-7 
does increase LTi survival, because IL-7 overexpressing transgenic mice have supernumerary 
PPs caused by increased LTi survival (227); TSLP can cause a similar effect on an IL-7 deficient 
background(228). In T cells, IL-7 increases survival by inducing machinery that blocks 
mitochondrial apoptosis pathways, predominantly through STAT5-mediated expression of Bcl-2 
and Mcl-1 (140, 221). In our study, we found by microarray analysis that WT adult CCR6+ ILC3 
expressed higher levels of Bcl-2 than other ILC3 subsets, although we detected no difference in 
Mcl-1 expression (data not shown). We confirmed higher expression of Bcl-2 by protein in WT 
CCR6+ ILC3 and also found that, paradoxically, Bcl-2 was further increased by the absence of 
IL-7R in CCR6+ ILC3 as well as DN ILC3 subsets, but not in other ILCs. Moreover, these 
changes to Bcl-2 expression correlated with changes in the relative frequency of ILC2 and ILC3 
subsets in Il7ra–/– mice. Thus, CCR6+ ILC3 are a particularly robust subset in steady state, that 
are most likely better able to engage compensatory pro-survival pathways in the absence of IL-
7R. 
 What signals compensate for IL-7 and facilitate the relative preservation of ILC2 and 
ILC3s in the siLP of Il7ra–/– mice? We hypothesized that the γc cytokine IL-15 may be the 
compensatory signal, as this cytokine maintains NK cells, ILC1, and other intestinal lymphocyte 
populations (229), provides compensatory signals to other innate lymphocyte subsets in the 
absence of IL-7 (230), and like IL-7, acts through STAT5 to induce prosurvival Bcl-2 (140, 221). 
As predicted, we found that mice lacking both IL-7R and IL-15 generated significantly fewer 
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ILCs than IL-7R deficient mice, such that almost all ILCs were depleted in the siLP. Given that 
IL-7R is a critical cell-surface marker for ILC progenitors that is essentially missing in our 
experiments, we were unable to determine if IL-15 sustained restricted progenitors, supported 
differentiated ILCs, or had both functions. From published literature, it is known that WT CHILP 
do not express CD122 (51), which is required to transduce IL-15 signals; however, this may be 
different in IL-7R deficient mice, which we could not test. Although we were unable to establish 
the precise mechanism by which IL-15 sustains ILCs, we show for the first time that this 
cytokine supports ILC2 and ILC3 in vivo in the absence of IL-7R.  
It is unclear the extent to which IL-15 physiologically impacts ILC2 and ILC3s. Besides 
unchanged ILC2 and ILC3 in IL-15 deficient mice, IL-15 overexpressing transgenic mice or 
Cish–/– mice with increased IL-15 signaling do not have changed numbers of siLP NKp46+ ILC3 
(138) or lung ILC2 (231), respectively, suggesting at least in steady state, IL-15 has a limited 
trophic roles these populations. For ILC3, IL-15 can sustain both human (177) and mouse (43) 
cells in vitro, though it increases their plasticity to IFN-γ producing ILC1-like cells. Furthermore, 
IL-15 is substantially produced in the siLP, and unlike IL-7, is increased during epithelial 
damage (229, 232). Therefore, in an inflammatory context when IL-7 trophic signals are 
limiting, IL-15 may provide signals to ILCs. 
In the modern paradigm that NK cells mirror CD8+ T cells, while ILCs parallel CD4+ T 
cells, it is worthwhile to consider the γc requirements of T cells. All naïve T cells predominantly 
utilize T cell receptor (TCR) signaling and IL-7 for their survival (140, 221, 233). Meanwhile, 
similar to TCR-lacking ILCs, memory T cells are TCR-independent and instead use γc cytokines 
for survival (221, 234). Like NK cells, memory CD8+ T cells use more IL-15, while like ILCs, 
memory CD4+ T cells use more IL-7 (221). However, both CD8+ and CD4+ memory T cells use 
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a combination of IL-7 and IL-15 for long-term survival (140, 234). Reminiscent of the published 
literature for ILC2 and ILC3, memory CD4+ T cells were originally considered to be IL-15 
independent, because unlike the deficiency of memory CD8+ T cells in mice lacking IL-15, 
memory CD4+ T cells are normal in these mice. Now, it is recognized that memory CD4+ T cells 
require both IL-15 and IL-7 for optimal fitness and long term survival in WT, but not 
lymphopenic, mice (221, 235, 236). Collectively, these data, combined with our data from IL-7R 
deficient mice, hint at a similar physiologic function of IL-15 in ILCs, which remains to be more 
comprehensively interrogated.  
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4.6 Figures 
 
 
 
FIGURE 29: Il7ra–/– Mice Have Residual ILCs in siLP, Skewed to CCR6+ ILC3 
(A-C) siLP lymphocytes were isolated from Il7ra–/– or WT control mice and indicated ILC 
subsets assessed. (A) Electronic gating strategy and representative flow plots of siLP. (B) 
Frequency and (C) total number of ILC subsets from siLP. (A-C) Data represent n=6 mice per 
genotype from 3 independent experiments. *p<.05** p<.01, two-tailed Mann-Whitley test. 
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FIGURE 30: ILC2s are Not Substantially Preserved in Colon or Lung  
 
(A-C) colon LP and (D-F) lung lymphocytes were isolated from Il7ra–/– or WT control mice and 
indicated ILC subsets assessed. (A) Electronic gating strategy and representative flow plots of 
colon LP. (B) Frequency and (C) total number of ILC subsets from colon LP. (D) Representative 
flow plots of lung. (E) Frequency and (F) total number of ILC subsets from lung. (A-D) Data 
represent n=4 mice per genotype from 2 independent experiments. *p<.05** p<.01, two-tailed 
Mann-Whitley test. 
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FIGURE 31: Residual Il7ra–/– ILC2 are Predominantly ST2– 
 
(A) Quantification of ST2+ cells among KLRG1+GATA3+ ILC2 in the siLP of Il7ra–/– or WT 
control mice. (B) Representative flow plots of siLP ILC2 phenotype and analysis of RORγt 
expression by ST2+ and ST2– subsets compared to CCR6+ ILC3, from Il7ra–/– or WT control 
mice. Data represent (A) n=8 mice per genotype from 4 independent experiments or (B) n=4 
mice per genotype from 2 independent experiments. ###p<.001, two-tailed Mann-Whitley test. 
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FIGURE 32: ST2+ ILC2 Produce More Cytokines After Stimulation  
 
(A) Representative flow plots of IL-5 production by ST2+ and ST2– ILC2 cells at rest or after 
stimulation with PMA/ionomycin, from Il7ra–/– or WT control mice. (B) Quantification of IL-5 
production by ST2+ and ST2– ILC2 cells at rest or after stimulation with PMA/ionomycin, IL-25, 
or IL-25 + IL-33 + TSLP, from Il7ra–/– or WT control mice. (C) Representative flow plots and 
(D) quantification of IL-13 production as in C-D. (A-D) Data represent n=4 mice per genotype 
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from 2 independent experiments. **p<.01, ***p<.001, ****p<.0001, one-way ANOVA with 
Tukey’s test for multiple comparisons.  
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FIGURE 33: Il7ra–/– ILC3s Produce IL-22 Normally 
 
(A) Representative flow plots and (B) quantification of IL-22 production from NKp46+, DN, and 
CCR6+ ILC3 subsets after stimulation with IL1β and IL-23. ILC3 were electronically gated on 
CD3–CD19– CD45lo Thy1+ and subdivided by NKp46 and CCR6. (C) Representative flow plots 
and (D) quantification of IL-17a production from ILC3 subsets, as in A. (A-D) Data represent n 
= 6 mice per genotype from 3 independent experiments *p<.05, two-tailed Mann-Whitley test. 
##p<.01, one-way ANOVA.  
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FIGURE 34:  Il7ra–/– ILC3s Partially Protect Mice from C. rodentium Infection 
 
(A) Weight loss and (B) survival of Rag1–/–, Rag1–/–Il7ra–/–, Rag2–/–Il2rg–/– mice after infection 
with 2*109 CFU C. rodentium. (A-B) Data represent n = 7 mice per genotype from 2 
independent experiments. . ^p<.0167, ^^^p<.0003, Gehan-Breslow-Wilcoxon test with 
Bonferroni correction for multiple comparisons. 
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FIGURE 35:  CCR6+ ILC3 are Transcriptionally Distinct  
 
(A) Plot comparing the fold-change of CCR6+ ILC3 and DN ILC3 to the fold-change of DN 
ILC3 and NKp46+ ILC3 depicts transcripts differentially expressed among ILC3 subsets. (B) 
Volcano plot comparing CCR6+ ILC3 to NKp46+ ILC3. (A-B) Colored circles represent 
transcripts expressed ≥ 2-fold with p-value ≤.05 in comparisons matching the color code 
above the plot. (A-B) Data represent 3 pooled mice each genotype from 2 independent 
experiments.
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FIGURE 36: CCR6+ ILC3 Highly Express Bcl-2, Enhanced by Lack of IL-7R 
 
(A) Representative histograms of Bcl-2 protein expression measured by flow cytometry among 
ILC3 subsets in WT and Il7ra–/– mice. (B) Mean fluorescent intensity (MFI) of Bcl-2 and (C) 
percentage of Ki67+ cells among indicated siLP ILC subsets in WT and Il7ra–/– mice, measured 
by flow cytometry. (A-C) Data represent n = 5 mice per genotype from 2 independent 
experiments. *p<.05, two-tailed Mann-Whitley test. 
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FIGURE 37: Il7ra–/–Il15–/– Mice Generate Significantly Fewer ILCs than Il7ra–/– Mice  
 
(A) Representative flow plots of siLP ILCs, as gated in 1A. (B) Frequency and (C) total number 
of indicated ILC subsets from the siLP. Data represent (A-C) n = 5 mice per genotype from 2 
independent experiments. *p<.05, **p<.01, ***p<.001, ****p<.0001, one-way ANOVA with 
Tukey’s test for multiple comparisons.  
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CHAPTER 5 
 
Concluding Remarks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Portions of this chapter were adapted from  
 
Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J 
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5.1 Brief Summary of Findings 
In the past several years, ILCs have emerged as innate populations that express conserved 
modules of immunity, previously thought to be restricted to the adaptive immune lineage. Given 
the similarity of some ILCs to previously recognized subsets, namely ILC1 to NK cells and ILC3 
to LTi, it was unclear the extent to which these cells were similar or different from their 
predecessors. The natural question for any newly discovered class of cells followed: What do 
they do?  
We collaborated with the ImmGen consortium to profile the transcriptomes of mouse 
ILC1, ILC2, ILC3, and NK cells, including several reported subsets of cells within these classes. 
With this approach, we found that each class of cells was transcriptionally distinct, and identified 
new genes that were uniquely expressed by each subset as well as those shared between multiple 
subsets. However, we also found that some subsets of cells were not distinct, namely CD4+ and 
CD4– ILC3, and RORγthiNKp46+ and RORγtloNKp46+ ILC3. Other investigators have 
subsequently reproduced these data (237). In more recent work, we have expanded these data to 
characterize the transcriptional profiles of what are now recognized to be the major ILC3 
subsets, CCR6+, DN, and NKp46+ ILC3.  
The distinction between NK cells and ILC1 has been and continues to be controversial. 
By comparing ILC1 and NK cells from many tissues, we found 1- that these cells were 
transcriptionally distinct, unlike some ILC3 subsets, and 2- the “ILC1 signature” was also 
predominantly shared by other ILCs, which we called the “core ILC signature.” As we originally 
suggested, recent data supports the notion that this core signature is likely a signature of tissue 
residency rather than lineage (79, 238). 
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Over time, phenotypic, developmental, and functional similarities with effector T cells 
suggested that these cells represent innate immune versions of CD8+ cytotoxic T cells, and Th1, 
Th2, and Th17 in the CD4+ helper T cell lineage. However, it remained unclear the extent to 
which ILCs and T cells had unique or overlapping functions, particularly in human. As in mouse, 
a comprehensive analysis of ILC functional capacity was also lacking. 
We again utilized a microarray technique to compare human tonsillar iILC1, ILC3, Th1, 
Th17, and blood NK cell transcriptomes and performed similar analyses as in mouse. Beyond the 
molecules identified for the first time in these analyses, our major findings are as follows. First, 
ex-vivo, human tonsillar ILCs appeared to be more polarized than the T helper cell counterparts. 
Second, while ILCs and T helper cells in the same module of immunity had overlapping 
functions, these differences were outnumbered by lineage factors such as signaling molecules. 
Third, iILC1 and blood NK cells were transcriptionally distinct. 
We wanted to interrogate the function of a newly identified putative regulator of Module 
3, REV-ERBα, but a spontaneous Jak3 mutation in this line refocused our attention to the role of 
γc cytokines in ILCs. Through comprehensive analyses of Jak32076insC/2076insC mice, we 
demonstrate that Jak3 is a critical factor for the development of all ILCs, to an even greater 
extent than T and B cells.  Furthermore, we found that JAK3 blockade by the FDA-approved 
drug tofacitinib reduced human iILC1 and ILC3 proliferation as well as iILC1 function.  
The core cytokines responsible for lymphocyte generation, IL-7 and IL-15, signal 
through Jak3 so we next focused on these molecules assessed. Departing from dogma, we found 
that IL-7Rα was not completely required for ILC2 and ILC3 differentiation. Furthermore, ILC2 
and ILC3 from Il7ra–/– were partially functional in vitro, and ILC3 were partially function in 
vivo. Residual cells were sustained by IL-15, because Il7ra–/–Il15–/– phenocopied Jak3 deficient 
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mice. In the bone marrow, Jak3 deficiency progressively depleted restricted lymphoid 
progenitors. Although we could not perform similar experiments in Il7ra–/–Il15–/– mice due to 
lack of lineage-defining IL-7R, the ILCP has recently been shown to express CD122. Thus, IL-
15 likely maintains ILC progenitors, but may also function in the periphery to sustain developed 
cells from Il7ra–/– mice. 
 
5.2 Modular Immunity Revisited  
 The identification of ILCs was a surprise in part because an entire lineage of cells was 
missed for many years, but also because it suggested that modules of immunity conventionally 
thought to belong to the adaptive paradigm could also be expressed by innate immunity (213). 
Although ILCs are a relatively small population of cells compared to adaptive lymphocytes, in 
certain microenviroments such as the mouse siLP, they appear to play major homeostatic roles 
through cross talk with the epithelium and constitutive production of cytokines (26, 42, 101-103, 
105, 154). Amazingly, these cytokines include the exact same factors that were only recently 
considered to be specialized products of the adaptive immune compartment.  Furthermore, the 
transcriptional networks respectively engaged during Th1, Th2, and Th17 differentiation now 
appear to almost completely overlap with the TFs required for ILC1, ILC2, and ILC3 
development. 
In retrospect, the observation that innate lymphocytes and adaptive lymphocytes can 
express overlapping core modules is not unexpected. It is well known that differential expression 
of TFs guides cellular circuitry and effector program, which are frequently redundant between 
different lineages of cells. A good example of this is T-bet expression by CD8+ and CD4+ T 
cells, which is able to induce similar cytokine-producing effector programs between these cell 
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types. Yet, CD8+ T cells are clearly distinct from CD4+ T cells based on their respective 
activation pathways by MHCI and MHCII. Furthermore, as CD8+ and CD4+ T each engage 
divergent TFs during development and maintenance in the periphery, these cells also have 
distinct functions. For ILCs, engagement of master TFs necessary for T helper cell polarization 
similarly explains the convergent function of these cells in a single module. Notably, these 
master TFs often directly activate module-defining effector cytokines. Like the developmental 
differences between CD8 and CD4 T cells, ILC expression of lineage-defining TFs such as the 
master-ILC regulator Id2 are also likely to result in distinct functions for ILCs. 
Given that the factors that polarize naïve CD4+ T cells to these different effector fates are 
now textbook material, one may ask, how can ILCs develop without appearing to engage similar 
signals? This question recalls the bias of history; we think of immune modules as “adaptive” 
because they were first discovered and are best studied in conventional T cells. Mechanistically, 
as ILCs develop, they may acquire modular pathways de novo, whereas T cells require STAT-
activation to generate chromatin landscapes from naïve cells. Is it possible, then, that ILCs 
represent the purest analysis of immune modules, reminiscent of their constitutive production of 
modular cytokines in steady-state?  
Recently, data from our lab and the O’Shea lab compared ILCs and CD4+ T cells for the 
first time using an epigenetic approach, and generated data that supports this view (88, 197). 
These data demonstrated that ex-vivo, human ILC3 had the most unique regulatory architecture, 
followed by less in Th17, and the least, in comparable amounts, between Th1 and ILC1. In 
mouse, ILC2 similarly retained significantly more unique ATAC+ regulatory elements than Th2 
after in vivo activation by the helminth N. brasiliensis. Furthermore, the majority of de novo Th2 
acquired elements were shared with ILC2, while only about one quarter were unique to Th2 (88). 
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Thus, at least for ILC2 and ILC3 populations, naïve T cell polarization in vivo appears to cause 
in the acquisition of some but not all ILC effector programs. Although it is possible that lineage 
factors also contribute to the unique mouse ILC2 regulome, for human, ILC3 and ILC1 shared 
factors were not counted, suggesting differences are not simply indicative of lineage.  It is 
unclear why ILC1 do not follow the same pattern of unique regulatory diversity in human. One 
possibility is that simple counting of unique regulatory elements may dilute true ILC1 signal due 
to the recognized and continually emerging plasticity of ILC3 and ILC2 to ILC1-like cells (176, 
177, 239). Given the similarity of ILCs to memory T cells, in the future, it will be interesting to 
test if ILC effector programs have an even more graded acquisition from naïve, to effector, to 
effector memory cells. 
 
5.3 ILCs and γc Cytokines  
 While the requirement for γc in lymphoid development is well known, here, we show that 
ILCs are even more dependent on γc signaling through Jak3 than adaptive immune lymphocytes. 
Consistent with the literature, we show that ILC2 and ILC3 predominantly rely on IL-7 while 
ILC1 and NK cells rely on IL-15. However, IL-15 can also sustain residual ILC2 and ILC3 
generation and/or maintenance in the periphery, and in the absence of IL-7R and IL-15, ILC 
development drops to absolute numbers comparable to Jak3 deficient mice. Like other cytokines 
in immune modules, these data are reminiscent of the T cell literature, where effector memory 
CD4+ T cells primarily rely on IL-7 and effector memory CD8+ T cells primarily rely on IL-15, 
but both cells engage both cytokines for optimal maintenance and survival (221). 
 Why are ILCs more dependent on Jak3 than other lymphocytes? One possibility is that 
adaptive immune cells have a programmed propensity to undergo clonal expansion. Indeed, 
147	
CDR3 sequencing of residual CD4+ T cells in Jak3 deficient mice has previously shown that 
cells are oligoclonally expanded in the periphery, but also have impaired effector functions (199, 
240). In the absence of ILCs at mucosal surfaces, there is likely to be substantial antigenic 
burden in these mice (241). Supporting this view, a similar process appears to occur for NK cells 
that recognize cognate antigens, as MCMV infection rescues Ly49H+ NK cell development in 
Il15–/–, Il15ra–/–, and Rag2 Il2rg–/– mice (242). This process is likely to be clonal as it 
preferentially supports Ly49H+ cell expansion, which recognizes the MCMV glycoprotein m157, 
and is also dependent on m157 and IL-12 (242, 243). Interestingly, MCMV infection can engage 
the same pathway to rescue Ly49H+ cells in NK cell-deficient Nfil3–/– mice, though in this case, 
NK cells that developed were still IL-15 dependent (244). Collectively, these data suggest that 
clonal expansion, probably mediated by Jak1, can rescue γc developmental requirements, though 
this is a rather artificial condition and cells are most likely to be conditioned to rely on non-
physiologic signals. As we show the Ly49 receptor expression is a marker of NK cell lineage, it 
remains unclear if other ILCs also have the capacity to undergo clonal expansion in steady state 
or the absence of γc.  
 The reliance of memory T cells and ILCs on γc cytokines raises the intriguing possibility 
that in physiologic conditions, γc signals are a required component of modular immunity. This 
model would also explain the profound reliance of ILCs on Jak3. In the periphery, naïve T cells 
persist using a combination of IL-7R and tonic TCR signaling (221, 234). However, IL-7 is 
produced in limited quantities and cells compete for the use of this growth signal (232). Thus, 
CD4+ T cells are required to upregulate IL-7R to transition from effector to effector memory 
cells, and no long utilize TCR signaling for their maintenance (221, 234), similar to the 
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constitutive expression of IL-7R by ILC2 and ILC3. Likewise, CD8+ T cells upregulate IL-15rβ  
during this transition (221), a factor that is also constitutively produced by NK cells and ILC1.  
While there is already substantial evidence to support this idea for IL-15, data are more 
limited for IL-7R. In Cytotoxicity and Module 1, T-bet and Eomes directly induce the 
transcription of Il15rb (72). IL-15 binding to CD122 then enhances both cytotoxicity and IFN-γ 
production (245, 246). In Module 2, cells appear to be mutually regulated by TSLP, a γc-family-
like cytokine that also shares the IL-7R as a co-receptor. Yet, ILC2s are normal in the absence of 
TSLP (212). Finally, in Module 3, IL-7 appears to stabilize RORγt expression, at least in ILC3, 
and preserve cell identity through a currently unknown mechanism (43, 177). However, our data 
suggests that IL-7-signaling is not required for IL-22 production. In the future, conditional 
deletion of IL-7R will be helpful to clarify the role of IL-7 and TSLP in Modules 2 and 3.  
 
5.4 Innate and Adaptive Immunity in Lymphocytes Revisited 
 Over the years, three theoretical immunological paradigms have characterized the way 
that we consider immunity, which continue to be relevant today (1). In 1949, Burnet originally 
proposed the Self-Nonself model, which correctly predicted core features of adaptive immunity 
such as TCR/BCR signaling, clonal expansion, and developmental deletion of autoreactive cells. 
With the observation that adjuvant activation of innate immunity was a critical feature for 
adaptive immune function, Janeway next proposed the Infectious-Nonself model. This model 
appreciates the role for antigen presenting cells and PRRs in the immune response. Finally, 
Matzinger proposed the Danger model, which emphasized the role of tissues and their stress 
signals in the generation of immunity (1).  
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 How do these models impact our understanding of ILCs? Although these are frameworks 
that describe the function of the entire immune system, it appears that lymphocytes create a 
spectrum across these different models, ranging from naïve MHC-restricted T lymphocytes best 
represented by Self-Nonself model, pattern-recognizing ILLs best represented by Infectious-
Nonself, and cytokine-sensing ILCs best represented by the Danger model. As naïve T cells 
become activated and polarize to effector then effector memory programs, they become more 
similar to ILCs. 
 Can ILCs perform all the functions of T cells? Thus far, there appear to be two fates that 
ILCs lack. First, as immediately functional cells, ILCs lack the capacity for naivety, leading one 
group to propose that the naïve state is the defining feature of adaptive immune cells, rather than 
any particular effector function (3). Second, to date, no ILL or ILC subset has been discovered to 
express the master regulatory TF FOXP3, which drives Treg development. IL-2 is an important 
driver of Treg development, homeostasis, and function through the high affinity receptor 
composed of CD25, CD122, and γc (247); yet, many ILCs express high levels of CD25. In the 
future, it will be interesting to determine if FOXP3 expression is inconsistent with ILL and ILC 
lineage, and if so, the mechanism by which this occurs.  
  
5.5 Future Directions 
The biggest challenge facing ILC biologists is the lack of mouse models selectively 
deficient for specific ILC lineages that do not also impact T cells. Our data transcriptionally 
profiling mouse ILCs generated with the ImmGen Consortium should be helpful to this end. To 
further improve this resource, we are currently sorting liver ILC1 and siLP subsets ILC2, CCR6+ 
ILC3, DN ILC3, and NKp46+ ILC3 subsets for RNAseq and ATACseq with ImmGen. Methods 
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for these sorts were improved from original sorts by the transition to WT mice instead of knock-
in RORgteGFP/+ reporter mice, which may have had haploinsufficiency for some transcripts due to 
lower levels of RORγt. In addition, we added negative markers CD5 and TCR-β to address 
questions in the field regarding possible minor T cell contamination. As these cells will be 
processed in parallel to most other ImmGen immune cells, fine analysis of transcriptomes and 
regulatory elements may be even more helpful in identifying novel factors helpful for the 
generation of new reagents. 
 Originally, we wanted to study the role of REV-ERBα in ILC3, a goal that was foiled by 
a spontaneous Jak3 mutation originating at Jackson Laboratories. Before we discovered the 
cause of the Wolverine phenotype, we began backcrossing these mice. Now, after 5 generations 
of backcrossing, Sanger sequencing of breeders confirms that all Jak32067insC alleles have been 
eliminated. Since finding REV-ERBα in the core ILC3 signature, we also noted its emergence as 
one of the few transcripts in our analysis shared between human ILC3 and TH17. Recently, 
another group demonstrated that this molecule is also expressed by IL-17-producing NKT cells, 
or NKT17 (248). Thus, widespread expression of REV-ERBα in Module 3 across species 
reinvigorates our interest in this molecule. 
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Appendix 1B 
 
ILC2 & LTi-
like genes ≥2-
fold vs ILC3 & 
ILC1 
ILC3 genes≥2-
fold vs ILC1, 
ILC2, & LTi-
like 
ILC2 & ILC1 
genes ≥2-fold 
vs ILC3 & 
LTi-like 
ILC3 & LTi-
like ≥2-fold vs 
ILC1 & ILC2 
ILC1 genes ≥ 
2-fold vs ILC2, 
ILC3, & LTi-
like 
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Il17rb Upp1 Bmp7 Il22 Ccl3 
Pdcd1 Eps8l3 Inpp4b Chad Il12rb2 
Depdc6 Il1r2 Atp8a2 Igfbp7 Ccl5 
Npnt A830080D01Rik Il10ra Rorc Klrd1 
H2-Oa F2rl2 Ets2 Il1r1 Gzma 
Ret Capg Dennd5a Dmrta1 Klrc2 
Cd81 Fah Igsf5 Eps8l3 Gzmb 
Cysltr1 Dusp4 Sytl2 Pram1 Ccl4 
Arg1 Gda Gm10008 Ly86 Ccr5 
Ifngr2 Nmbr Cd3g Tacstd2 Plek 
Vipr2 Ccne2 Adora2a Mapk10 Sulf2 
1110002B05Rik Gjb2 Acp5 Cxcr5 Entpd1 
Tspan32 Ryk Aim1 Kcnk1 Itgax 
Rps29 Tmtc2 Myc Rasl11a Ms4a4b 
Pgcp Dpep2 Sytl3 Serinc2 Gpr55 
BC005685 B3galt2 Gm4956 Xkrx Il21r 
 
  Ly6c1 Tns4 Gramd3 
 
  Prkcq Scpep1 Dennd4a 
 
  
 
Ablim3 Prf1 
 
  
 
Ly6g5b Irg1 
 
  
 
Prelid2 Tigit 
 
  
 
Large 2010002N04Rik 
 
  
 
Asphd2 Cd2 
 
  
 
Tnf Sytl2 
 
  
 
Gpr157 Mmp9 
 
  
 
Fnbp1l Ugcg 
 
  
 
Zfp57 Klra6 
 
  
 
Stom Klra9 
 
  
 
Tns3 Cst7 
 
  
 
Cd93 Klre1 
 
  
 
Rhobtb1 Cpne7 
 
  
 
Lipo1 Cd28 
 
  
 
Nr1d1 Klra10 
 
  
 
Ncoa7 LOC100503878 
 
  
 
Tnfrsf21 1700025G04Rik 
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Thy1 Gm11435 
 
  
 
Apobec1 Sh2d2a 
 
  
 
St3gal3 Klrb1a 
 
  
 
Lrrc49 Pmepa1 
 
  
 
Smox Klra3 
 
  
 
Ucp3 Chsy1 
 
  
 
S100a1 Samd3 
 
  
 
Cdh20 Sepn1 
 
  
 
Tifa Gas7 
 
  
 
Sepp1 Ncf1 
 
  
 
Frrs1 Hopx 
 
  
 
Smyd2 Cdh1 
 
  
 
Il17re Mctp2 
 
  
 
Eps8 Sult2b1 
 
  
 
Glt25d2 Bcl2l11 
 
  
 
Lingo4 Gpr18 
 
  
 
S1pr3 Trat1 
 
  
 
Gpr183 Gpr174 
 
  
 
Rgnef Icam1 
 
  
 
Igf1r Jub 
 
  
 
Nrgn Pik3r5 
 
  
 
Dlg5 Adamts14 
 
  
 
Cryaa Zdhhc15 
 
  
 
Hs6st2 Padi2 
 
  
 
Coro2b Gpc1 
 
  
 
  Sema6d 
 
  
 
  Satb1 
 
  
 
  Itm2a 
 
  
 
  Kdm2b 
 
  
 
  Lyst 
 
  
 
  Pion 
 
  
 
  Glp1r 
 
  
 
  Lrrc8d 
 
  
 
  Niacr1 
 
  
 
  Eomes 
 
  
 
  Sell 
 
  
 
  Baiap3 
 
  
 
  Gm71 
 
  
 
  Baiap2 
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LTi-like genes 
≥2-fold vs 
ILC1, ILC2, & 
ILC3 
ILC1&ILC3 ≥ 
2-fold vs ILC2 
& LTi-like 
ILC2 genes ≥ 
2-fold vs ILC1, 
ILC3, & LTi-
like 
Cxcr5 Klrc1 Ccr8 
Il1r1 Ccl3 Ccr4 
Stom Il12rb2 Il5 
Ptges Ccl5 Klrg1 
Cntn1 Klrd1 Il17rb 
Nrp1 Klri2 Hs3st1 
Vipr2 Fasl Il1rl1 
Hmgn3 Klrc2 Il13 
Ctsh Xcl1 Slc7a8 
Ccr6 Gzmb Cd27 
Apobec1 Ccl4 Neb 
Cd2ap Ccr5 Rxrg 
Gm626 Plek Calca 
Mapk10 Ncr1 Il6 
P2ry1 Sulf2 Il4 
Gucy1a3 Entpd1 Ptpn13 
Igfbp4 Gzmc Pdcd1 
Lingo4 Ms4a4b Depdc6 
Dll1 Gpr55 Npnt 
Tifa Klrb1c H2-Oa 
Ptger2 Ifng Hes1 
Sdc4 Nkg7 Lpcat2 
Hs6st2 Itga1 Il9r 
Igf1r Slc6a20a Pparg 
Cx3cl1 2010002N04Rik Tph1 
Il17re Litaf Stxbp6 
BC018473 Serpinb9 Cybb 
Gria3 Mmp9 Bmp7 
Galm Bcl2a1c Inpp4b 
Npl Cdk14 Ccl1 
Sdc2 Bcl2a1a Bmp2 
4930506M07Rik Tbx21 Ar 
Atrnl1 Bcl2a1d Mc5r 
Zfp599 Bcl2a1b Atp8a2 
Ppap2b Cst7 Ppp2r3a 
Snord14c B3galt5 Kcnn4 
Slc6a13 Arrdc3 Dgat2 
Olfr1342 Ms4a6c Nmur1 
171	
Cacna1g Serpinb6b Kcnq5 
Dnajc6 Cables1 Rab27b 
Ermp1 LOC100503878 Rad51l1 
Rnase6 Sntb1 Lrrc52 
Olfr1259 Enpp1 Alox5 
2310061C15Rik Klrb1a Ptgir 
Pde6d Ctsw Zc3h12c 
Hnrpll Chsy1 Art2a-ps 
Pdgfrb Slc16a10 Tgm2 
Ddc Ctla4 Il10ra 
1600012F09Rik Nedd9 Acer2 
Napepld Pglyrp1 Hba-a1 
Eef2k H60b 4930412O13Rik 
Tuba8 Mctp2 Gata3 
Adk Plcxd2 Chdh 
Fam184b Slc16a6 A630001O12Rik 
0610009B22Rik Tyrobp Nck2 
Gm4979 Plk3 Bzw2 
Tox2 Cd200r2 Naip5 
Hells Lck Mras 
Slc41a3 Btbd11 AB124611 
7330403C04Rik Icam1 Hba-a2 
Khdrbs3 4930503L19Rik Tspan13 
Batf3 Trf Areg 
Alg14 Klrk1 Ebi3 
Msrb3 Orai1 Klf5 
Flrt2 Pltp Lrrc33 
Ttyh2 Slc28a2 Plaur 
Sdc1 Ephx1 Adam19 
Ltb B4galt5 Irf4 
Dsg2 Nab1 Eepd1 
Tmem60 Lgals1 Snora16a 
Cited4 Irf8 Pdlim1 
Ldhb Prdm2 Fam55d 
Slc6a7 L1cam Nckap5 
Actr6 Got1 Tanc2 
Acat1 Sgtb Serpine1 
H2-Aa Tnfrsf1a Fbxl21 
Abca3 Tlcd1 Ube2e2 
Srr Me2 Rnf128 
Irgm1 Ccr2 Ipmk 
Hk3 Tmem2 Car13 
Dnajb1 Pag1 Med12l 
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Golph3l Tmem194b D330045A20Rik 
Htra2 Fryl Pard3 
Zfp386 Ehd1 Chd7 
Parvb Ust Pde7b 
Tm9sf2 Crot Pcsk1 
Fermt2 Rgs9 Map4k3 
Plb1 5430411C19Rik Lgmn 
Cdc14a Tiprl Taf1d 
Abhd15 Dbf4 Rps19 
Dennd3 Klrb1f Cacna1d 
Med21 Cblb Spcs3 
Tmem70 Stx11 St6galnac5 
Rhob Arap2 Rplp1 
Gm5148 Irf7 Nfkb1 
Fancl Ptprj Galnt3 
Gm10802 Sntb2 Cxcl2 
Pmpcb Fam46c Naip6 
Gdpd5 Acvr2a Snora3 
Dscam Ppp1r3b Lphn2 
Tmem229b Pik3r1 Dhx40 
D17H6S56E-5 Il2rb Stab2 
P2rx1 Runx2 Plk2 
Apoa1 Lgals3 Glb1 
Eid1 Gabarapl1 Gcfc1 
Lsm10 Ttc39b Ptpn9 
Zfp738 Thap6 Rab4a 
Tmem126b Cd200r4 Nfix 
Abca1 LOC100504914 Bambi 
  Rhoc Ube2l6 
  Cd244 Nav2 
  Tpm4 Acbd7 
  Timp2 Snord8 
  Fam49a Fam71f2 
  Mettl4 Apbb2 
  Gm9766 Mboat1 
  Cd4 3110043O21Rik 
  Atp6v0d2 Arl5c 
  Lysmd3 Runx1t1 
  Rai14 Hlf 
  Srgap3 Csf2 
  Pgm2l1 Emp3 
  
 
Homer2 
  
 
Cyp51 
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Spry1 
  
 
Grin2d 
  
 
5730469M10Rik 
  
 
Cyp2d22 
  
 
Foxp3 
  
 
Unc5b 
  
 
Nsg2 
  
 
Specc1 
  
 
Dusp10 
  
 
4932438H23Rik 
  
 
0610010O12Rik 
  
 
Krt80 
  
 
Klf4 
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Appendix 1C 
Up RORgtlo/ 
RORgthi    
Up CD4–/ 
RORgthi ILC3 
  
Up RORgthi 
ILC3/ CD4–     
  FC P 
 
FC P   FC P 
Ccl5 8.745 0.000 Cd81 11.630 0.000 Ccl3 52.924 0.000 
Klrd1 3.353 0.003 Hmgn3 9.872 0.000 Klri2 28.253 0.000 
Klrc2 3.021 0.015 Gm626 9.641 0.000 Il12rb2 28.158 0.000 
Ccr5 2.382 0.010 Vipr2 8.830 0.001 Ncr1 22.476 0.000 
Klrc1 2.313 0.012 Ptges 8.349 0.000 Slc6a20a 20.817 0.000 
Ccl4 2.297 0.007 Nrp1 8.330 0.000 Fasl 19.300 0.000 
Gzma 2.209 0.026 Ret 6.934 0.000 Klrc1 18.891 0.000 
Ms4a4b 2.188 0.009 Gucy1a3 6.585 0.001 Xcl1 16.799 0.000 
Gm10008 2.112 0.036 Snord14c 6.245 0.008 Gzmc 11.528 0.000 
Entpd1 2.079 0.012 Snord14c 6.245 0.008 Klrb1c 10.572 0.000 
Itgax 2.018 0.026 Ccr6 6.120 0.000 Ifng 10.553 0.000 
   
P2ry1 5.965 0.000 Nkg7 9.964 0.000 
   
Cxcr5 5.920 0.000 Sulf2 9.961 0.000 
Up RORgthi/ 
RORgtlo    Gria3 4.826 0.000 Bcl2a1c 8.213 0.000 
  FC P Ptger2 4.683 0.001 Litaf 8.085 0.000 
Cxcr5 2.560 0.027 Stom 4.671 0.000 Ifitm2 8.010 0.001 
Vegfa 2.091 0.015 Arg1 4.575 0.002 Bcl2a1a 7.923 0.000 
Cxcr4 2.040 0.012 Dll1 4.556 0.005 Nr4a2 7.554 0.001 
   
Cntn1 4.462 0.000 Dennd4a 7.452 0.002 
   
Cacna1g 4.442 0.009 Gzmb 7.430 0.002 
   
Igfbp4 4.238 0.001 Bcl2a1d 7.420 0.000 
   
Ccr8 4.194 0.000 Bcl2a1b 7.289 0.000 
   
Ltb 4.177 0.001 Itga1 7.186 0.000 
   
1110002B05Rik 4.135 0.002 Cdk14 7.055 0.000 
   
Mir142 3.853 0.005 Ms4a6c 6.835 0.003 
   
Lingo4 3.683 0.002 Serpinb9 6.754 0.001 
   
Pdgfrb 3.667 0.001 Il1r2 6.644 0.000 
   
Dnajb1 3.641 0.004 Ifitm2 6.585 0.001 
   
Cited4 3.614 0.017 Errfi1 6.579 0.005 
   
Sdc4 3.610 0.008 Nr4a3 6.552 0.002 
   
Olfr1259 3.605 0.005 Gpr55 6.529 0.001 
   
H2-Oa 3.537 0.000 Plek 6.522 0.001 
   
Sdc2 3.467 0.010 Prdm1 6.293 0.000 
   
Galm 3.381 0.002 Ms4a6b 6.249 0.000 
   
BC018473 3.349 0.009 Tbx21 6.228 0.000 
   
Tspan32 3.319 0.000 Sgtb 6.108 0.000 
   
Ppap2b 3.253 0.023 Klrd1 5.871 0.000 
   
Atrnl1 3.250 0.000 Serpinb6b 5.499 0.000 
   
Adk 3.232 0.001 Entpd1 5.489 0.001 
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Zfp599 3.231 0.000 Ctla4 5.417 0.000 
   
Npnt 3.229 0.001 Ccl4 5.245 0.000 
   
7330403C04Rik 3.194 0.002 Socs2 5.203 0.000 
   
Ramp1 3.170 0.001 Arrdc3 4.989 0.000 
   
Igf1r 3.159 0.011 Sntb1 4.905 0.000 
   
Tifa 3.156 0.000 H60b 4.895 0.016 
   
Hells 3.066 0.002 Pltp 4.854 0.001 
   
Cdkn1b 3.057 0.003 Prf1 4.853 0.000 
   
Gm15772 3.048 0.005 Malt1 4.793 0.000 
   
Pdcd1 3.039 0.000 4930503L19Rik 4.762 0.000 
   
Slc6a7 2.978 0.025 Ptger4 4.761 0.001 
   
Actr6 2.966 0.006 Usmg5 4.722 0.000 
   
Slfn3 2.930 0.008 Plk3 4.671 0.007 
   
S100a4 2.878 0.012 Klrc2 4.634 0.000 
   
Ctsh 2.870 0.022 Nmbr 4.616 0.001 
   
Apobec1 2.869 0.002 Lgals1 4.582 0.000 
   
Slc6a13 2.841 0.000 Slc16a10 4.559 0.008 
   
Flrt2 2.805 0.001 Slc16a6 4.518 0.001 
   
Ddc 2.797 0.000 Gp49a 4.508 0.004 
   
1600012F09Rik 2.791 0.001 Abcb1a 4.419 0.002 
   
Gm10136 2.775 0.004 Areg 4.403 0.001 
   
Usp6nl 2.757 0.001 Rnf125 4.388 0.001 
   
Rnase6 2.748 0.005 Ctsw 4.364 0.001 
   
Dnajc6 2.739 0.002 Ppp1r3b 4.355 0.000 
   
0610009B22Rik 2.732 0.006 Mxd1 4.237 0.006 
   
Msrb3 2.724 0.001 Nab1 4.188 0.000 
   
D17H6S56E-5 2.655 0.002 Klrb1f 4.186 0.001 
   
Hist1h2bb 2.644 0.004 Ccr5 4.147 0.004 
   
Olfr1342 2.641 0.004 2010002N04Rik 4.049 0.000 
   
Fermt2 2.635 0.006 Rnf128 4.036 0.000 
   
Dsg2 2.631 0.000 Enpp1 4.000 0.003 
   
Rps29 2.622 0.010 Rel 3.960 0.000 
   
Lif 2.621 0.007 5430411C19Rik 3.897 0.016 
   
Rpl24 2.620 0.003 Cst7 3.884 0.004 
   
Dennd3 2.619 0.000 Cd4 3.841 0.022 
   
Cd2ap 2.619 0.012 Nedd9 3.824 0.000 
   
Alg14 2.605 0.014 B3galt5 3.785 0.013 
   
Dscam 2.603 0.025 Pglyrp1 3.689 0.000 
   
Malat1 2.582 0.018 Ccne2 3.653 0.004 
   
Srp14 2.574 0.049 Coq10b 3.575 0.001 
   
Rps27l 2.573 0.037 Atp6v0d2 3.560 0.003 
   
Tox2 2.570 0.000 Ell2 3.555 0.004 
   
Plb1 2.568 0.009 Cables1 3.526 0.014 
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Med21 2.564 0.000 Ahrr 3.494 0.000 
   
Abca3 2.516 0.004 Cdkn1a 3.482 0.004 
   
Snord82 2.512 0.004 Ikzf3 3.464 0.000 
   
Rpl5 2.506 0.010 Icos 3.464 0.000 
   
Hist1h2ak 2.503 0.002 Gm10008 3.458 0.013 
   
Tuba8 2.499 0.002 Trp53inp2 3.420 0.004 
   
Usp18 2.489 0.004 Plcxd2 3.414 0.006 
   
Zfp386 2.485 0.001 AI848100 3.369 0.003 
   
Snrpe 2.482 0.007 Cxcl2 3.368 0.012 
   
Cdc14a 2.478 0.000 L1cam 3.359 0.000 
   
Rpl26 2.475 0.009 Gda 3.352 0.001 
   
Hk3 2.461 0.005 F2rl2 3.345 0.006 
   
Dok1 2.457 0.027 Ugcg 3.336 0.004 
   
Batf3 2.453 0.000 Eps8l3 3.290 0.004 
   
Rps23 2.449 0.035 Gm4956 3.277 0.000 
   
Ifngr2 2.440 0.008 Jmy 3.260 0.012 
   
Eid1 2.435 0.010 Zbtb10 3.247 0.005 
   
4930506M07Rik 2.428 0.009 Lck 3.240 0.000 
   
Fam184b 2.416 0.002 Cpne7 3.237 0.012 
   
Golph3l 2.416 0.001 Il4ra 3.234 0.007 
   
Arhgap15 2.415 0.003 Gabarapl1 3.224 0.000 
   
Tm9sf2 2.412 0.001 Tuba4a 3.223 0.001 
   
Napepld 2.399 0.036 Orai1 3.200 0.001 
   
H2-Aa 2.398 0.026 Fam46a 3.193 0.008 
   
Slc25a4 2.395 0.007 Lin54 3.193 0.000 
   
Cysltr1 2.392 0.002 Lilrb4 3.193 0.008 
   
Tra2a 2.389 0.040 Abi3bp 3.160 0.002 
   
Gm4979 2.387 0.009 Tnfrsf18 3.153 0.001 
   
Depdc6 2.382 0.001 Fam46c 3.139 0.004 
   
Il1r1 2.376 0.010 Fosl2 3.111 0.023 
   
Rps12 2.372 0.039 Irf8 3.100 0.000 
   
Cnr2 2.370 0.003 Bpnt1 3.099 0.006 
   
Ythdc2 2.357 0.015 Tmtc2 3.078 0.000 
   
Skp1a 2.351 0.002 Ccl5 3.071 0.007 
   
Hist1h1a 2.348 0.005 Gpr65 3.061 0.004 
   
Stab1 2.348 0.001 Rgs9 3.057 0.002 
   
Tnfrsf11a 2.346 0.000 Timp2 3.021 0.001 
   
Npl 2.343 0.000 Abcb1b 2.990 0.006 
   
Rhob 2.339 0.004 Ttc39b 2.987 0.000 
   
Tmem70 2.334 0.008 Tigit 2.983 0.005 
   
Pfdn5 2.330 0.036 Myc 2.981 0.010 
   
Zfp608 2.325 0.004 Ephx1 2.974 0.002 
   
Hnrpll 2.323 0.010 Me2 2.958 0.001 
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Rps28 2.311 0.026 Avil 2.921 0.004 
   
Pde6d 2.298 0.004 Gstm5 2.897 0.004 
   
Htra2 2.277 0.007 Tyrobp 2.894 0.000 
   
Hist1h2bg 2.273 0.000 Gjb2 2.886 0.001 
   
Abca1 2.267 0.001 Sh2d2a 2.886 0.001 
   
Parvb 2.264 0.016 B4galt5 2.866 0.000 
   
Eya1 2.262 0.011 Grb7 2.862 0.011 
   
Slc30a4 2.262 0.014 Klrk1 2.827 0.002 
   
Irgm1 2.259 0.000 D16Ertd472e 2.804 0.000 
   
Cx3cl1 2.257 0.017 Hmgcr 2.790 0.001 
   
Rap1gap2 2.248 0.003 Klk8 2.779 0.003 
   
Rps27a 2.243 0.048 Gprc5a 2.771 0.003 
   
Pmpcb 2.242 0.000 Capg 2.765 0.003 
   
Gm5167 2.242 0.043 Irf7 2.761 0.027 
   
Hist1h2bk 2.227 0.000 Upp1 2.754 0.006 
   
Ier2 2.226 0.002 Stard4 2.739 0.004 
   
Acat1 2.222 0.043 Gch1 2.736 0.014 
   
Hist1h2bf 2.221 0.000 Arl15 2.735 0.011 
   
Tmem229b 2.215 0.028 Got1 2.731 0.015 
   
Nebl 2.208 0.007 Gabpb1 2.731 0.003 
   
AI467606 2.208 0.002 Tnfrsf1a 2.730 0.001 
   
Tfam 2.206 0.008 Tlcd1 2.729 0.004 
   
Rpl23a 2.199 0.032 Adora2a 2.727 0.002 
   
Eef2k 2.196 0.017 Dppa2 2.724 0.002 
   
Hint1 2.193 0.034 Dbf4 2.716 0.002 
   
Rnu2 2.191 0.006 Lysmd3 2.716 0.002 
   
Hist1h2bl 2.187 0.000 Lamc1 2.710 0.002 
   
Rps8 2.185 0.010 Lgals3 2.709 0.008 
   
Fam185a 2.184 0.005 Mmp9 2.702 0.032 
   
Hs6st2 2.182 0.013 Pik3ap1 2.697 0.001 
   
2310061C15Rik 2.180 0.002 Osgin2 2.686 0.007 
   
Hist1h2bn 2.179 0.000 Dot1l 2.673 0.020 
   
Rps24 2.177 0.013 Rai14 2.669 0.002 
   
Sdc1 2.171 0.028 Lef1 2.665 0.001 
   
Hist1h2bm 2.171 0.000 Gzma 2.657 0.011 
   
Mrfap1 2.164 0.007 A830080D01Rik 2.653 0.004 
   
Pgcp 2.158 0.006 Chd7 2.647 0.003 
   
Gdpd5 2.157 0.031 Arap2 2.634 0.000 
   
Ttyh2 2.156 0.014 LOC100503878 2.634 0.015 
   
Tmem206 2.155 0.000 4732471D19Rik 2.618 0.017 
   
Plb1 2.155 0.010 Arl5b 2.607 0.002 
   
Cited2 2.147 0.010 Riok1 2.605 0.004 
   
Lsm10 2.147 0.012 Pik3r1 2.601 0.000 
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Il17rb 2.147 0.002 Trf 2.596 0.002 
   
Zfp738 2.144 0.007 Usp38 2.585 0.006 
   
Dkk3 2.142 0.008 Stx11 2.579 0.004 
   
Hist1h2bj 2.140 0.000 Crem 2.566 0.000 
   
Srr 2.140 0.010 Fryl 2.563 0.000 
   
Apoa1 2.139 0.010 Eprs 2.562 0.008 
   
Slc41a3 2.137 0.006 Kdm6b 2.559 0.011 
   
Hspe1 2.130 0.019 Slc43a3 2.535 0.003 
   
0610012G03Rik 2.124 0.032 Ndrg1 2.532 0.002 
   
Gm5148 2.118 0.001 Spty2d1 2.525 0.004 
   
Gm9897 2.114 0.015 Pqlc3 2.516 0.003 
   
Tmem126b 2.107 0.009 Irak3 2.515 0.000 
   
Gm10374 2.107 0.003 Cd200r2 2.504 0.003 
   
BC005685 2.106 0.047 Tnfrsf10b 2.464 0.002 
   
Gm10802 2.104 0.012 Vps37b 2.462 0.009 
   
Klhdc2 2.103 0.000 Rabgef1 2.460 0.001 
   
Chchd1 2.101 0.002 Tiprl 2.458 0.000 
   
Clec2d 2.097 0.040 Ust 2.456 0.010 
   
Mars2 2.097 0.003 Rbpms2 2.452 0.047 
   
Khdrbs3 2.095 0.000 Btbd11 2.438 0.007 
   
Rps27 2.088 0.031 Glcci1 2.436 0.029 
   
Tmem60 2.087 0.018 Csf2 2.435 0.005 
   
Rpl31 2.087 0.005 Osbpl3 2.421 0.003 
   
Fancl 2.086 0.001 Traf4 2.417 0.009 
   
Hmox2 2.080 0.003 Chsy1 2.390 0.010 
   
Gm11277 2.069 0.000 Irg1 2.384 0.003 
   
Pde2a 2.067 0.002 Rhoc 2.382 0.001 
   
Mapk10 2.065 0.030 Tmem194b 2.375 0.015 
   
Arhgef11 2.057 0.001 Pgm2l1 2.368 0.005 
   
Vdac3 2.057 0.005 Tatdn2 2.363 0.012 
   
Hist1h2be 2.051 0.000 Tnfrsf1b 2.358 0.021 
   
Mterf 2.049 0.017 Tnfrsf9 2.349 0.018 
   
N6amt2 2.046 0.020 Slc3a2 2.347 0.007 
   
Derl2 2.045 0.005 Mical2 2.334 0.003 
   
Apobec3 2.044 0.004 Mettl4 2.315 0.009 
   
Rpl27a 2.034 0.027 6330407A03Rik 2.313 0.021 
   
Ldhb 2.034 0.002 Ets2 2.312 0.034 
   
Klhl7 2.032 0.004 Ccr2 2.305 0.017 
   
Cep97 2.028 0.006 Samsn1 2.304 0.000 
   
Abhd15 2.024 0.003 Cblb 2.301 0.001 
   
2900092E17Rik 2.023 0.015 Ppm1j 2.297 0.009 
   
LOC100503669 2.013 0.034 Sntb2 2.293 0.001 
   
Il17re 2.011 0.020 Pitpnc1 2.268 0.001 
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P2rx1 2.009 0.002 Tnfsf10 2.262 0.005 
   
Ermp1 2.001 0.001 Igsf5 2.259 0.001 
    
 
 
Hccs 2.257 0.002 
      
Acvr2a 2.255 0.019 
      
Ptprj 2.254 0.009 
      
Plscr1 2.250 0.008 
      
Tbc1d2b 2.249 0.008 
      
Slc28a2 2.245 0.003 
      
B3galt2 2.244 0.012 
      
Cyp51 2.241 0.014 
      
Nr3c1 2.238 0.000 
      
Runx2 2.230 0.014 
      
Cd244 2.229 0.002 
      
Rnf19a 2.223 0.015 
      
Thap6 2.213 0.001 
      
Obfc2a 2.212 0.002 
      
Pcyt1a 2.209 0.024 
      
Itgav 2.202 0.018 
      
P2ry10 2.202 0.001 
      
Ptpn3 2.201 0.002 
      
Slc7a5 2.193 0.000 
      
Cxcr3 2.193 0.008 
      
Ltv1 2.183 0.005 
      
Nlrc5 2.181 0.003 
      
Nfe2l2 2.172 0.001 
      
Srrd 2.168 0.004 
      
Kcnab2 2.166 0.003 
      
Cd72 2.165 0.005 
      
Gm9766 2.163 0.009 
      
Il2rb 2.162 0.001 
      
Prdm2 2.159 0.007 
      
Rhog 2.159 0.010 
      
Taf4b 2.154 0.023 
      
LOC100504914 2.150 0.000 
      
Fam49a 2.149 0.001 
      
Nfil3 2.146 0.011 
      
Ywhah 2.145 0.002 
      
Arsb 2.137 0.029 
      
Dusp5 2.136 0.024 
      
Itpkb 2.135 0.024 
      
Rnft1 2.135 0.002 
      
Slc41a1 2.133 0.010 
      
D8Ertd82e 2.128 0.007 
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Fah 2.114 0.015 
      
Dpep2 2.113 0.010 
      
Hbs1l 2.110 0.002 
      
Tiparp 2.109 0.000 
      
Mllt4 2.109 0.001 
      
Crot 2.109 0.003 
      
Sfn 2.098 0.008 
      
Reep5 2.096 0.000 
      
Plcg1 2.089 0.007 
      
Tgif1 2.088 0.028 
      
Cd200r4 2.087 0.000 
      
Dusp4 2.086 0.026 
      
Sqle 2.085 0.002 
      
Mctp2 2.085 0.006 
      
Tmem149 2.085 0.003 
      
Tmem97 2.085 0.019 
      
Cytip 2.083 0.006 
      
St3gal6 2.079 0.011 
      
Itga2 2.076 0.031 
      
Srgap3 2.073 0.001 
      
Opa3 2.067 0.028 
      
Atp2b4 2.064 0.017 
      
Tfrc 2.058 0.015 
      
Hey1 2.056 0.003 
      
Hif1a 2.056 0.004 
      
Hopx 2.055 0.000 
      
Dpp4 2.055 0.009 
      
7-Mar 2.048 0.001 
      
Gna13 2.040 0.013 
      
Pag1 2.039 0.012 
      
Csda 2.035 0.001 
      
Tubb2b 2.033 0.046 
      
Tpm4 2.032 0.013 
      
Ldlr 2.029 0.003 
      
Tmem2 2.022 0.019 
      
Pole4 2.017 0.001 
      
Icam1 2.010 0.015 
      
Olfml3 2.008 0.003 
      
Olfr1148 2.004 0.036 
      
Zranb1 2.003 0.010 
      
Ryk 2.001 0.006 
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Appendix 1D 
 
Liver: 
ILC1/NK FC 
Liver: 
NK/ILC1 FC 
Spleen: 
ILC1/NK FC 
Spleen: 
NK/ILC1 FC 
Cxcr6 32.12 Sell 76.55 Il7r 44.23 Klrg1 11.53 
Cd3g 27.40 Eomes 23.06 Tcrg-V3 39.25 Serpinb9b 8.95 
Cd200r1 24.85 Klra1 17.05 Tcrg-V2 30.98 Gzmb 7.52 
Itga1 24.43 Cmah 16.90 Tcrg-C 19.85 Cma1 6.64 
LOC100503878 20.37 Klrg1 16.88 Tmem176b 15.12 Cyp17a1 6.49 
Gzmc 16.02 As3mt 15.97 Cd3e 10.86 Gzma 5.89 
Tcrg-C 14.09 Car5b 15.57 Gpr183 10.59 Entpd1 5.88 
Tnfsf10 13.36 Serpinb9b 15.09 Cxcr6 10.57 Cmklr1 5.60 
Mmp9 13.35 S1pr5 11.82 Tmem176a 10.54 Khdc1a 5.11 
Inpp4b 12.41 Itgam 11.53 Il2ra 9.19 Itgam 5.04 
Tmem176b 11.47 Sh2d1a 11.13 Cd3g 8.53 2010012O05Rik 4.98 
Tcrg-V3 11.01 Ly6c1 10.96 Atp6v0d2 8.07 Mcam 4.85 
Tcrg-V2 10.17 Kcnip3 10.41 Inpp4b 7.34 Gpx8 4.68 
Atp8a2 9.83 Zeb2 10.31 Cd74 6.85 As3mt 4.38 
Cd200r2 9.74 Cma1 9.25 H2-Aa 6.73 Car5b 4.30 
Asb2 7.90 Ly6c2 8.90 Gp49a 5.54 Cym 4.28 
Rln3 7.54 A430084P05Rik 8.78 Tnfsf10 5.46 Zeb2 4.04 
Acpp 6.75 Cym 8.52 Acpp 5.45 Cdc20b 3.98 
Adam19 6.46 Cmklr1 8.46 Cd200r1 5.38 St5 3.94 
Socs2 6.15 2010012O05Rik 8.33 Gpr114 5.31 Klra3 3.68 
Tmem176a 5.99 AB124611 7.81 Dtx1 5.29 A430084P05Rik 3.60 
Pdzd2 5.80 Elovl7 7.59 Dscam 5.24 Gm10522 3.44 
Sema6d 5.74 Pdlim1 7.57 Trat1 5.21 Rac3 3.27 
Gpr114 5.66 Cxcr4 7.42 Ahr 5.20 Klra9 3.24 
P2rx7 5.54 Rap1gap2 7.38 Socs2 5.09 Snora16a 3.19 
Il21r 5.46 Fcgr2b 7.15 LOC100503878 5.07 Gzmk 3.15 
Podnl1 5.26 Prr5l 7.13 Bmp7 4.58 Nrarp 3.08 
Gp49a 5.23 Klra6 6.97 Dapl1 4.57 Klhl30 3.05 
Il7r 5.00 Cd55 6.49 Lilrb4 4.53 Klra10 3.04 
Sntb1 4.90 Emb 6.38 Itga1 4.47 Klra1 3.02 
2900026A02Rik 4.77 S1pr1 6.19 Ikzf2 4.47 Prf1 2.79 
Ifitm2 4.57 D1Ertd622e 6.06 Aqp9 4.39 Styk1 2.78 
Lphn1 4.57 Nrarp 5.54 Gpr15 4.04 Hist1h2bg 2.76 
Gpr97 4.56 Angpt1 5.49 Slco3a1 4.01 Hist1h2bb 2.75 
Tnfsf8 4.47 Snora16a 5.30 H2-Ab1 3.89 Irf8 2.61 
Klk8 4.43 Itga4 5.24 St6galnac3 3.86 Cdk14 2.57 
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Pip5k1b 4.39 Lpin1 5.19 Tnf 3.83 Prdm1 2.50 
Zmat4 4.34 Slamf6 5.05 Fam124b 3.83 Prr5l 2.45 
St6galnac3 4.30 Klf2 5.00 Gramd3 3.75 Lair1 2.45 
BC005685 4.16 Gm10522 4.98 Asb2 3.70 S100a1 2.45 
Lilrb4 4.15 Anxa1 4.92 Lyst 3.67 Sord 2.44 
Osgin1 4.12 Itga2 4.85 Camk4 3.63 Klre1 2.34 
Lpar6 4.09 Gpx8 4.72 Itgb3 3.59 Hist1h1c 2.26 
Tspan31 4.03 Khdc1a 4.69 Rora 3.44 Acpl2 2.23 
Rbpj 3.95 Aff3 4.56 Kit 3.40 Rnu1b1 2.17 
Aqp9 3.95 St5 4.43 Gpr97 3.36 Snora44 2.16 
Ckb 3.85 Eltd1 4.40 Ltb 3.36 Fcgr2b 2.16 
Cd160 3.76 Sgk1 4.40 Tnfsf8 3.34 Hist1h4c 2.13 
Ly6g5b 3.57 Klf12 4.31 Sidt1 3.33 Stk32c 2.13 
Cd38 3.50 Eya1 4.31 Cd226 3.32 Lat2 2.11 
Cd226 3.44 Dhrs3 4.27 Podnl1 3.14 Cd55 2.10 
Camk4 3.41 B3gnt5 4.23 Tmem154 3.02 Tigit 2.06 
Actn1 3.34 Pde2a 4.23 Dpp4 2.99 4930431A04Rik 2.06 
A130014H13Rik 3.33 Gramd3 4.21 Sema6d 2.98 Eomes 2.06 
Rnf128 3.32 H2afz 4.09 Cd3d 2.97 Rasgef1a 2.04 
Cxcr3 3.28 Flna 3.99 Psd2 2.92 Pycard 2.02 
Gcnt2 3.27 Plxnc1 3.96 Gm9766 2.90 Rnu3b1 2.02 
Ahr 3.26 Atp1b3 3.92 Ckb 2.89 
  Glrx 3.23 Il18r1 3.89 Ahcyl2 2.89 
  Tasp1 3.21 Cyp17a1 3.83 Lpar6 2.88 
  Rgs1 3.19 1700025G04Rik 3.72 Cdon 2.85 
  Tubb6 3.08 Irf8 3.60 Cd160 2.76 
  Ptprj 3.06 Rasa3 3.59 Serpina3f 2.75 
  Rcbtb2 3.03 Mcam 3.58 Lpxn 2.73 
  Hic1 3.03 Dnajb4 3.57 Slfn1 2.72 
  Bmp7 3.02 P2ry14 3.56 Dzip1 2.71 
  Tmem154 3.02 Mef2c 3.46 Tspan31 2.71 
  Aim2 3.01 4831426I19Rik 3.45 Emb 2.70 
  4930503L19Rik 2.99 Stmn1 3.36 Tnfrsf25 2.70 
  Abi3 2.98 Sord 3.26 Cd28 2.69 
  Gimap7 2.96 Vcl 3.18 Il20ra 2.67 
  Cish 2.94 Nuak2 3.17 Gpr52 2.65 
  Trf 2.93 Slc9a7 3.15 Chst15 2.62 
  Lag3 2.93 Myb 3.15 Cldnd1 2.61 
  Gdpd5 2.86 Taf1d 3.12 Rab11fip1 2.57 
  Phxr4 2.82 Ctla2b 3.10 Dmrta1 2.57 
  Stau2 2.82 Hexb 3.08 Pip5k1b 2.52 
  Gdf11 2.80 Racgap1 3.04 Klk8 2.52 
  Gm4956 2.79 Gramd4 3.02 Parp8 2.49 
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S100a4 2.74 Fbxl2 3.01 Gpr55 2.41 
  Lpxn 2.71 Stard10 3.00 Treml2 2.40 
  Tox 2.69 Cx3cr1 3.00 Phxr4 2.39 
  Abcb9 2.68 Ctss 3.00 Tnfrsf21 2.36 
  Fam125b 2.68 Cdc20b 2.96 Fam46c 2.34 
  Trip4 2.68 Fam69a 2.95 Tgtp1 2.33 
  41890.0000 2.67 Rap2b 2.93 Nebl 2.33 
  Itgad 2.67 Itm2a 2.91 Cxcr3 2.33 
  Abca3 2.65 Abcg2 2.90 A130014H13Rik 2.31 
  Appl2 2.64 Cdc14b 2.88 Atp8a2 2.30 
  Vav3 2.63 Pogk 2.86 N4bp2 2.30 
  Dusp6 2.63 Acpl2 2.84 BC021614 2.29 
  AW555464 2.63 Klra3 2.82 Il6st 2.26 
  Gm10008 2.62 Tcf7 2.72 Cd274 2.26 
  Apol7e 2.61 Nr4a1 2.69 Slc27a6 2.25 
  Gbp9 2.61 Prf1 2.68 Klrb1b 2.24 
  Adam8 2.60 Rps27l 2.66 Egln3 2.24 
  Cdh1 2.59 Sypl 2.65 Fchsd2 2.24 
  Slc16a10 2.59 Serpinb9 2.65 Vipr1 2.24 
  Clnk 2.58 Klhdc2 2.65 Aim2 2.22 
  Apol7b 2.57 Pfkp 2.65 Tcrb-J 2.21 
  Nlrc5 2.56 Ccr2 2.61 Cd22 2.20 
  Cd7 2.56 Snrpe 2.60 Icos 2.20 
  Parp12 2.55 Ier2 2.59 Gm7075 2.20 
  Dll1 2.53 Tm6sf2 2.57 Gdpd5 2.18 
  Dtx1 2.52 Ndufa4 2.56 Lysmd2 2.16 
  LOC641050 2.52 Man2a1 2.56 Gm6273 2.16 
  B3galt5 2.50 Hist1h1b 2.55 2900026A02Rik 2.16 
  Pitpnm2 2.49 Cd2 2.55 Amica1 2.15 
  Ipcef1 2.45 Phf11 2.54 E030037K03Rik 2.15 
  Plcg1 2.45 Gns 2.52 Xcl1 2.15 
  Abr 2.45 Kcnab2 2.51 St6gal1 2.15 
  Tnf 2.44 Klf3 2.51 Ipcef1 2.14 
  Cysltr2 2.44 Med21 2.49 Gna15 2.14 
  1700009P17Rik 2.44 Plek 2.48 Dgka 2.12 
  Chn2 2.43 Dnahc8 2.48 Gpr132 2.12 
  H1f0 2.42 Rps12 2.47 Parp12 2.09 
  Gpr52 2.42 Rasgrp2 2.46 Tiam2 2.08 
  Edaradd 2.41 Hist1h2bg 2.44 Pdk1 2.07 
  Tgfbr1 2.40 Crtam 2.44 Jak2 2.06 
  Jak2 2.40 Il18rap 2.43 Rbpj 2.06 
  Mpa2l 2.40 A430078G23Rik 2.43 H2-Ob 2.06 
  Slain2 2.39 Klhl6 2.42 Armc7 2.05 
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Nedd9 2.38 Hist1h1a 2.42 Wwp1 2.04 
  Foxo3 2.38 Gm10063 2.41 Nsg2 2.01 
  Atxn1 2.37 Sidt1 2.36 Tgtp1 2.01 
  Fam101b 2.36 Atp1a1 2.36 Rnf144a 2.01 
  Large 2.36 Lair1 2.33     
  Susd2 2.35 Ndufb6 2.32     
  Tmem149 2.32 Tspo 2.29     
  Mfsd10 2.32 Ugt1a9 2.28     
  Il2ra 2.32 Gnptab 2.28     
  LOC100504914 2.32 Fert2 2.27     
  Gbp8 2.32 Fry 2.26     
  Rabgap1l 2.31 Arl4c 2.26     
  Chad 2.28 Satb1 2.26     
  Gm7265 2.25 Hist1h2ak 2.25     
  Dkkl1 2.25 Hist1h3e 2.25     
  Tspan14 2.25 Hist1h3i 2.24     
  Sh3bp2 2.24 Ccl9 2.23     
  St14 2.23 Rps18 2.23     
  Myo6 2.21 Plscr4 2.23     
  Ptpn3 2.20 Gm5167 2.21     
  AB041803 2.20 Btf3l4 2.21     
  Susd3 2.20 Hist1h4c 2.21     
  Pde7a 2.19 Hist1h3c 2.21     
  Pygl 2.19 Cd9 2.20     
  Fam134b 2.17 Lgals1 2.19     
  Fgl2 2.16 Hist1h3b 2.19     
  Sik1 2.15 Hist1h3d 2.19     
  Il4ra 2.14 Scpep1 2.19     
  Slc27a6 2.13 Memo1 2.19     
  Inpp4a 2.12 Hist1h3a 2.18     
  Chst15 2.12 Sgk3 2.18     
  Il12rb1 2.11 Hist1h3h 2.18     
  Gbp4 2.10 Hist1h3g 2.17     
  Cdc42ep1 2.10 Nt5c3 2.16     
  Dtx3 2.10 Lef1 2.15     
  Gpnmb 2.10 Hint1 2.13     
  Tgtp1 2.09 Gpr137b-ps 2.13     
  Crot 2.08 Ier5 2.12     
  Cd200r4 2.08 Nt5c 2.12     
  Igsf5 2.08 A930038C07Rik 2.12     
  Qpct 2.07 S1pr4 2.12     
  Zbtb38 2.07 Rpl31 2.11     
  Gimap3 2.06 Rpl36a 2.11     
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Abcg3 2.05 Rps28 2.11     
  Pltp 2.05 Glud1 2.10     
  Lrp5 2.05 Cox4i1 2.09     
  P2rx4 2.04 Gm15772 2.09     
  Cdon 2.03 Hist2h3b 2.09     
  Acsbg1 2.02 Arl6ip5 2.07     
  Serpina3f 2.02 Rpl24 2.07     
  Bcl2a1a 2.01 Hist2h3c1 2.07     
  Pdcd1lg2 2.01 Gm10136 2.06     
  Xcl1 2.00 Gzmk 2.05     
      Rps19 2.04     
      Rnf125 2.04     
      Dmrta1 2.04     
      2010107E04Rik 2.03     
      Add3 2.03     
      Klhl30 2.03     
      Hist1h2an 2.03     
      Itgb1 2.02     
      Hist2h2aa1 2.02     
      Rps23 2.01     
      Tspan13 2.01     
      Rpl26 2.01     
      Hist2h2ab 2.01     
      Arl5c 2.00     
      Rps14 2.00     
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siLP: 
ILC1/NK FC 
siLP: 
NK/ILC1 FC 
ILC1: Liver/    
spleen FC 
ILC1: 
Spleen/liver FC 
Eomes 11.13 Serpinb1a 9.17 Gzmb 17.79 Sell 70.38 
Klra9 10.44 Il23r 8.97 Gzmc 17.29 Cmah 16.80 
Klra10 10.33 Plekhg1 8.52 Entpd1 14.31 Emb 16.06 
Sell 8.82 Rorc 8.13 Mmp9 11.26 S1pr1 14.19 
Klra3 8.53 Abi3bp 7.47 Hba-a1 10.31 Eomes 13.74 
Klra1 6.42 Gstm5 6.58 Hba-a2 9.86 Ly6c1 12.88 
Serpinb9b 5.71 Upp1 5.93 Hbb-b2 9.48 Klra6 12.46 
Car5b 5.37 Tmem176a 5.53 Cd200r2 6.98 Slamf6 12.34 
Klra6 5.33 Prelid2 5.07 Hbb-b1 6.47 Gramd3 11.80 
Eya1 4.52 Il22 4.81 Itga1 5.38 Pdlim1 11.07 
A430084P05Rik 4.19 Rbpms2 4.71 Pdzd2 5.07 Ly6c2 10.25 
Myb 4.12 Plxdc2 4.46 LOC100503878 4.66 Sidt1 10.18 
Vegfa 4.11 Tmem176b 4.41 Adam19 4.62 Cxcr4 9.80 
Klrg1 3.95 Tcrg-V3 4.32 Atp8a2 4.60 Aff3 9.12 
Sema4a 3.85 Slc6a20a 4.25 Gzma 4.50 Kcnip3 9.01 
AB124611 3.71 Il7r 4.20 Cxcr6 4.42 Plxnc1 7.90 
Itgam 3.66 Irak3 4.15 Zmat4 4.37 Atp6v0d2 7.59 
Sh2d1a 3.37 Npas2 4.10 Cd200r1 4.33 AB124611 7.45 
Itga4 3.35 Large 3.92 Fgl2 4.33 Klra1 7.16 
Kcnip3 3.30 Tmem64 3.90 Ifitm2 3.85 Il18r1 6.47 
Styk1 3.29 Kcnk1 3.81 Rln3 3.81 Tcf7 6.35 
Ccr7 3.23 Gpr183 3.77 Osgin1 3.75 Eltd1 6.26 
Khdc1a 3.10 Psd2 3.77 Tigit 3.51 Cd3e 6.16 
Sgk1 3.02 Tcrg-V2 3.73 Cd3g 3.34 Cd28 6.13 
Rgs16 2.95 Lmo4 3.70 Il21r 3.28 Dmrta1 6.11 
Atp8b4 2.90 Sgtb 3.54 Stau2 3.14 Kit 6.09 
Ly6c1 2.88 Tmem154 3.44 Stk32c 3.03 Sh2d1a 5.93 
Klf12 2.83 Plcb4 3.33 Pygl 3.01 Itga4 5.71 
Plxnc1 2.78 Oasl2 3.29 Ptgs1 2.87 Gpr183 5.42 
Itga2 2.75 Adam12 3.20 Cish 2.82 Sgk1 5.42 
Ly6c2 2.73 Ckb 3.10 P2rx7 2.69 Angpt1 4.88 
Irf8 2.73 Podnl1 3.01 Cd200r4 2.67 Cd55 4.84 
Crtam 2.71 Mmp9 2.98 Susd3 2.65 Il7r 4.76 
Anxa1 2.71 Atp6v0d2 2.96 Ly6g5b 2.62 H2-Aa 4.75 
Ccbl2 2.63 Tnfrsf25 2.91 Igsf5 2.60 Pde2a 4.56 
Myc 2.61 Cxcr6 2.84 Dusp6 2.59 Elovl7 4.54 
Ctla2b 2.59 Chad 2.83 Abcb9 2.56 Ehd3 4.52 
Rap1gap2 2.58 Capg 2.83 Gimap7 2.53 1700025G04Rik 4.45 
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Slamf6 2.57 Nr1d1 2.78 Tnfsf10 2.53 Itga2 4.34 
Ppargc1a 2.46 Rnase4 2.78 LOC641050 2.47 Slco3a1 4.23 
Gzma 2.46 Trat1 2.75 Plcg1 2.46 Klf2 4.22 
Cmklr1 2.46 Slc27a6 2.73 Abi3 2.44 Klf3 4.21 
Cd247 2.43 8-Sep 2.72 Styk1 2.41 Dapl1 4.14 
Gpr174 2.42 Pde5a 2.72 Jup 2.39 Dscam 4.06 
Lphn2 2.39 Epas1 2.67 S100a6 2.39 B3gnt5 4.06 
Chd7 2.38 Ahcyl2 2.66 Asb2 2.39 Rap1gap2 3.89 
Cd83 2.37 Eps8l3 2.63 Gm4956 2.38 Rasa3 3.82 
Zeb2 2.34 Fam184b 2.63 Itgad 2.33 Atp1b3 3.73 
Tfam 2.34 Cdk14 2.63 Klra9 2.32 Fcgr2b 3.72 
Setbp1 2.29 Icos 2.60 Gdf11 2.26 As3mt 3.68 
Klre1 2.29 Dmrta1 2.54 Sepn1 2.23 Dennd2d 3.65 
Rab27b 2.29 Cyp4f16 2.51 Lphn1 2.22 D1Ertd622e 3.62 
Aff3 2.26 Rab11fip1 2.51 Lphn1 2.20 Man2a1 3.59 
Ugt1a9 2.25 Fam124b 2.51 Cdh1 2.19 Car5b 3.50 
Ccl9 2.24 Cdon 2.49 BC005685 2.19 Car2 3.48 
Aim1 2.23 Maf 2.44 2900026A02Rik 2.19 Cd74 3.43 
Adap1 2.21 Ryk 2.41 Gp49a 2.17 Wwp1 3.41 
Slc41a2 2.16 Gm10008 2.38 Nedd9 2.16 Kbtbd11 3.37 
Tmem163 2.15 Lysmd2 2.38 Sh3bp2 2.14 Cd22 3.34 
S100a6 2.13 1300014I06Rik 2.37 AW555464 2.13 Zeb2 3.31 
Tmcc3 2.13 H1f0 2.34 Sntb1 2.13 Mef2c 3.29 
Itgax 2.11 Gpr97 2.33 Hip1 2.12 Prr5l 3.25 
Gnptab 2.09 Susd2 2.30 Fam19a3 2.12 Slc9a7 3.23 
Gramd3 2.08 Ifitm2 2.29 Slc16a10 2.09 Flna 3.23 
P2ry14 2.06 Zfp462 2.28 Sema6d 2.09 Dhrs3 3.14 
Gramd4 2.04 Ly6g5b 2.28 Slc16a6 2.06 Tgfb3 3.13 
Sykb 2.01 Adam8 2.27 Optn 2.06 Eya1 3.13 
Cym 2.01 Sgms1 2.26 Dennd5a 2.05 H2-Ab1 3.11 
    Il1rl2 2.25 Lilrb4 2.04 Klhl6 3.10 
    Tasp1 2.25 St14 2.03 Crtam 3.09 
    Odc1 2.24 4930485B16Rik 2.03 Ctss 3.04 
    Socs2 2.24 B3galt5 2.02 Scpep1 3.00 
    Fam82a1 2.22 Cables1 2.02 Lef1 2.99 
    Dkkl1 2.22     S1pr5 2.99 
    Lztfl1 2.21     Gpr15 2.97 
    Gpr114 2.21     Lpin1 2.97 
    Fah 2.20     F630048H11Rik 2.93 
    Atp8a2 2.18     A430084P05Rik 2.92 
    Rln3 2.16     Cldnd1 2.91 
    Pde7b 2.16     Tnfrsf26 2.90 
    Ltb 2.15     Klf12 2.90 
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    Slc16a10 2.13     Frrs1 2.89 
    Serinc2 2.13     Ar 2.85 
    Snora44 2.12     Stard10 2.83 
    Cd4 2.12     Egln3 2.83 
    Rasl11a 2.11     Ssh2 2.81 
    Ero1l 2.10     Rasgrp2 2.81 
    Slc35f2 2.09     Il6st 2.79 
    Hoxa5 2.09     Ano10 2.78 
    Gpr157 2.09     Rcbtb1 2.78 
    Itgb3 2.09     Sike1 2.77 
    Hoxa6 2.09     D130062J21Rik 2.76 
    Ctla4 2.08     Dpp4 2.76 
    Il2ra 2.08     Cd3d 2.75 
    Rora 2.08     Fgf13 2.75 
    Fbxl21 2.06     Bzw2 2.73 
    Lipo1 2.06     Rhoq 2.72 
    Cpne7 2.05     Iqgap2 2.70 
    Gm2a 2.05     Gramd4 2.69 
    Rhod 2.04     Ttc28 2.68 
    St6galnac3 2.04     Cd2 2.63 
    Sla 2.04     Adamts6 2.62 
    Cd93 2.03     Phf11 2.62 
    Gpr55 2.03     Anxa1 2.59 
    Xlr4c 2.02     Slc14a1 2.57 
    Tmem156 2.02     Il18rap 2.54 
    
 
     Arl4c 2.53 
    
  
    Clcn3 2.53 
    
  
    Cym 2.51 
    
  
    Arhgap26 2.50 
    
  
    H2-Ob 2.49 
    
  
    Tagap 2.48 
    
  
    Satb1 2.47 
    
  
    Arhgef18 2.47 
    
  
    Dtx1 2.47 
    
  
    Bach2 2.46 
    
  
    Vipr1 2.45 
    
  
    Tnfrsf22 2.44 
    
  
    Rnf125 2.42 
    
  
    Gm2a 2.41 
    
  
    Pogk 2.39 
    
  
    Add3 2.39 
    
  
    Fam69a 2.38 
    
  
    Itgam 2.35 
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    Dgka 2.35 
    
  
    A430078G23Rik 2.34 
    
  
    Zfp36 2.33 
    
  
    Dnahc8 2.33 
    
  
    Hes1 2.32 
    
  
    Man1c1 2.30 
    
  
    Treml2 2.30 
    
  
    Pik3r5 2.29 
    
  
    Cobll1 2.28 
    
  
    Raph1 2.28 
    
  
    Trat1 2.27 
    
  
    Uhrf1bp1l 2.27 
    
  
    Arap2 2.26 
    
  
    Fam65b 2.24 
    
  
    Rnf144a 2.23 
    
  
    Etv6 2.22 
    
  
    Bin2 2.22 
    
  
    Rnf138 2.21 
    
  
    Kcnab2 2.20 
    
  
    Sigmar1 2.19 
    
  
    Atp11b 2.19 
    
  
    Klhdc2 2.17 
    
  
    Cdc25b 2.17 
    
  
    Foxo1 2.17 
    
  
    Runx2 2.16 
    
  
    Cdk6 2.16 
    
  
    Gprin3 2.16 
    
  
    Ikzf2 2.16 
    
  
    Thtpa 2.15 
    
  
    H2afz 2.15 
    
  
    Nsg2 2.14 
    
  
    Atp8b4 2.14 
    
  
    Fam124b 2.14 
    
  
    Ccdc52 2.14 
    
  
    Cdc14b 2.13 
    
  
    St3gal1 2.12 
    
  
    Vcl 2.11 
    
  
    Fbxl2 2.11 
    
  
    Zc3h12d 2.10 
    
  
    Rps6ka5 2.09 
    
  
    Nrarp 2.09 
    
  
    P2ry14 2.09 
    
  
    Gnptab 2.08 
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    Rap2b 2.08 
    
  
    Myb 2.08 
    
  
    Pfkp 2.08 
    
  
    Sgk3 2.07 
    
  
    Xylt1 2.06 
    
  
    St6gal1 2.05 
    
  
    Arl2bp 2.04 
    
  
    Rnf157 2.04 
    
  
    Ctla2b 2.03 
    
  
    Psd2 2.03 
    
  
    Pola1 2.03 
    
  
    Top2a 2.03 
    
  
    Elmo1 2.03 
    
  
    Amd1 2.03 
    
  
    Nck2 2.02 
    
  
    Eml3 2.02 
    
  
    H2-Oa 2.02 
    
  
    Atp1a1 2.02 
    
  
    Il17ra 2.01 
    
  
    Mfsd6 2.01 
    
  
    Ifi44 2.01 
    
  
    Atp10a 2.01 
    
  
    Tmem141 2.01 
    
  
    Coro7 2.00 
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Appendix 1E 
 
Liver and 
spleen: ILC1/ 
NK 
FC: 
Liver 
ILC1/ 
liver 
NK 
FC: 
Spleen 
ILC1/ 
spleen 
NK 
Liver and 
spleen:NK/ILC1 
FC: 
Liver 
NK/ 
liver 
ILC1 
FC: 
Spleen 
NK/ 
spleen 
ILC1 
Cxcr6 32.12 10.57 Eomes 23.06 2.06 
Cd3g 27.40 8.53 Klra1 17.05 3.02 
Cd200r1 24.85 5.38 Klrg1 16.88 11.53 
Itga1 24.43 4.47 As3mt 15.97 4.38 
LOC100503878 20.37 5.07 Car5b 15.57 4.30 
Tcrg-C 14.09 19.85 Serpinb9b 15.09 8.95 
Tnfsf10 13.36 5.46 Itgam 11.53 5.04 
Inpp4b 12.41 7.34 Zeb2 10.31 4.04 
Tmem176b 11.47 15.12 Cma1 9.25 6.64 
Tcrg-V3 11.01 39.25 A430084P05Rik 8.78 3.60 
Tcrg-V2 10.17 30.98 Cym 8.52 4.28 
Atp8a2 9.83 2.30 Cmklr1 8.46 5.60 
Asb2 7.90 3.70 2010012O05Rik 8.33 4.98 
Acpp 6.75 5.45 Fcgr2b 7.15 2.16 
Socs2 6.15 5.09 Prr5l 7.13 2.45 
Tmem176a 5.99 10.54 Cd55 6.49 2.10 
Sema6d 5.74 2.98 Nrarp 5.54 3.08 
Gpr114 5.66 5.31 Snora16a 5.30 3.19 
Podnl1 5.26 3.14 Gm10522 4.98 3.44 
Gp49a 5.23 5.54 Gpx8 4.72 4.68 
Il7r 5.00 44.23 Khdc1a 4.69 5.11 
2900026A02Rik 4.77 2.16 St5 4.43 3.94 
Gpr97 4.56 3.36 Cyp17a1 3.83 6.49 
Tnfsf8 4.47 3.34 Irf8 3.60 2.61 
Klk8 4.43 2.52 Mcam 3.58 4.85 
Pip5k1b 4.39 2.52 Sord 3.26 2.44 
St6galnac3 4.30 3.86 Klra9 3.02 3.04 
Lilrb4 4.15 4.53 Cdc20b 2.96 3.98 
Lpar6 4.09 2.88 Acpl2 2.84 2.23 
Tspan31 4.03 2.71 Klra3 2.82 3.68 
Rbpj 3.95 2.06 Prf1 2.68 2.79 
Aqp9 3.95 4.39 Klra10 2.61 3.24 
Ckb 3.85 2.89 Hist1h2bg 2.44 2.76 
Cd160 3.76 2.76 Lair1 2.33 2.45 
Cd226 3.44 3.32 Hist1h4c 2.21 2.13 
Camk4 3.41 3.63 Gzmk 2.05 3.15 
A130014H13Rik 3.33 2.31 Klhl30 2.03 3.05 
Cxcr3 3.28 2.33 
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Ahr 3.26 5.20 
   Bmp7 3.02 4.58 
   Tmem154 3.02 3.02 
   Aim2 3.01 2.22 
   Gdpd5 2.86 2.18 
   Phxr4 2.82 2.39 
   Lpxn 2.71 2.73 
   Parp12 2.55 2.09 
   Dtx1 2.52 5.29 
   Ipcef1 2.45 2.14 
   Tnf 2.44 3.83 
   Gpr52 2.42 2.65 
   Jak2 2.40 2.06 
   Il2ra 2.32 9.19 
   Slc27a6 2.13 2.25 
   Chst15 2.12 2.62 
   Tgtp1 2.09 2.33 
   Cdon 2.03 2.85 
   Serpina3f 2.02 2.75 
   Xcl1 2.00 2.15 
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Appendix 1F 
 
Mean probeset values in ILC gene signature 
Gene SP NK LIV NK SI NK 
IEL 
ILC1 
SP 
ILC1 
LIV 
ILC1 SI ILC1 
SI 
NKp46+ 
RORγthi 
ILC3 
SI 
NKp46+ 
RORγtlo 
ILC3 
SI CD4– 
NKp46– 
ILC3 
SI CD4+ 
NKp46– 
ILC3 
ILC2.SI 
Tcrg-V3 80.9 192.1 1367.5 3427.9 3142.5 2316.6 5664.1 8519.5 10562.3 9176.1 8543.1 9844.6 
Tcrg-V2 93.0 166.0 1246.9 2846.7 2773.3 1786.8 4427.3 6400.4 8186.7 7247.2 6767.5 7881.4 
Il7r 131.3 257.8 1271.0 1200.6 5731.7 1209.2 5118.5 6208.5 6224.0 6859.2 7663.0 3330.3 
Tmem176b 113.9 163.6 1048.4 1334.3 1710.3 1865.8 4420.7 6332.0 6811.4 6574.4 6360.8 3314.8 
Il2ra 69.6 249.4 1374.2 378.0 638.2 561.3 2871.4 3806.9 4678.4 5085.6 5159.9 4921.5 
Cxcr6 49.3 72.7 1169.6 1345.4 518.6 2289.8 3274.9 4382.4 3636.4 2545.0 2245.2 2550.6 
Socs2 163.1 238.7 1802.9 949.5 808.5 1365.4 4026.3 3905.2 2456.5 474.8 375.1 2947.8 
Ckb 239.3 304.6 494.3 811.5 689.5 1171.1 1605.4 2853.3 2764.0 3120.2 2939.8 508.2 
Gpr114 278.8 275.9 976.5 1267.8 1486.9 1540.0 2160.0 2436.0 1999.4 2147.3 2517.0 252.8 
Tmem176a 48.8 68.6 224.1 250.9 515.3 408.4 1232.5 2342.7 2434.6 2962.2 2980.7 1294.0 
Podnl1 108.5 109.8 332.0 444.5 341.3 575.7 993.2 1323.5 997.7 1153.0 1409.7 379.4 
Gpr97 79.3 112.7 240.7 214.7 254.5 514.2 559.9 959.0 948.3 1237.8 1229.5 90.1 
St6galnac3 77.3 82.7 329.7 338.4 301.1 356.6 673.1 758.2 741.4 601.8 650.1 547.8 
Tmem154 104.5 117.6 177.5 314.9 313.7 360.9 610.6 840.1 855.9 499.4 378.2 356.9 
Cdon 94.9 103.2 165.1 210.3 271.1 209.8 410.9 606.5 583.8 530.4 551.4 369.9 
Atp8a2 77.2 83.2 134.8 134.1 179.8 816.7 293.9 200.6 110.3 74.6 74.6 838.8 
Slc27a6 86.2 76.4 141.2 145.8 194.1 166.3 395.8 487.4 359.5 197.7 158.9 124.8 
 
Mean probeset values in NK gene signature 
Gene SP NK LIV NK SI NK 
IEL 
ILC1 
SP 
ILC1 
LIV 
ILC1 SI ILC1 
SI 
NKp46+ 
RORγthi 
ILC3 
SI 
NKp46+ 
RORγtlo 
ILC3 
SI CD4– 
NKp46– 
ILC3 
SI CD4+ 
NKp46– 
ILC3 
ILC2.SI 
Klra3 5071.1 5070.7 2924.2 1498.5 1407.7 1834.3 344.5 75.4 74.5 57.1 99.6 95.7 
Klra10 4425.3 4166.7 2440.6 1247.3 1449.0 1477.3 237.1 30.9 22.8 32.5 25.0 33.1 
Klra9 4064.0 4108.6 2173.8 1105.0 1253.8 1667.8 208.8 29.4 25.4 23.6 24.5 26.8 
Irf8 1802.9 2641.7 4655.0 1270.0 691.7 723.3 1689.9 1250.3 1403.6 452.5 346.0 186.0 
Eomes 3242.6 2658.2 2093.1 685.7 1572.0 116.1 187.8 66.2 63.7 64.4 61.0 63.2 
Klrg1 1603.1 1911.4 457.9 173.3 143.2 114.2 116.3 91.8 79.5 71.4 66.7 3739.4 
A430084P05Rik 1549.6 1362.0 261.3 168.7 444.6 150.9 63.1 51.5 56.8 48.0 71.7 58.7 
Itgam 1251.3 1221.3 365.7 192.2 248.4 103.5 99.0 57.1 50.3 45.0 43.0 53.0 
Cym 1352.1 1134.3 219.4 215.6 313.1 124.7 109.0 104.9 121.7 95.0 105.9 108.1 
Serpinb9b 867.0 1064.3 566.8 142.9 95.6 70.9 98.3 70.2 75.9 56.0 51.0 66.0 
Klra1 989.5 782.4 358.1 195.0 328.7 45.9 55.4 27.2 30.2 26.9 30.6 27.7 
Car5b 711.7 755.1 263.1 101.0 163.7 45.5 48.4 49.8 41.2 40.1 36.4 46.1 
Cmklr1 722.5 688.5 175.7 138.6 123.9 74.9 71.0 68.5 82.9 65.6 78.2 81.6 
Zeb2 774.7 595.1 175.4 125.1 183.5 55.3 73.9 46.9 57.1 57.3 56.9 99.1 
Khdc1a 288.8 247.4 136.8 53.5 56.5 52.2 44.1 47.5 48.8 42.0 58.5 57.5 	
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Appendix 1G 
 
CCR6+ ILC3 
genes  
FC: 
DN/  
NKp46 
FC: 
CCR6/DN 
NKp46+ 
ILC3 
genes 
FC: 
NKp46/DN 
FC: 
CCR6/DN 
DN 
ILC3 
genes 
FC: 
DN/  
NKp46 
FC: 
DN/  
CCR6 
 S100g 0.71 13.37  Slc6a20a 9.20 0.53  Il17rb 4.48 2.49 
 Dmbt1 1.10 11.62  Nmbr 8.99 0.74  Chchd5 3.08 2.24 
 Ccdc88a 1.27 10.22  Klri2 7.37 1.45  Hes1 2.95 2.49 
 Plb1 1.02 9.16  Slamf7 6.30 0.70 Znrf3 2.52 2.10 
 H2-Ab1 0.98 9.11  Xcl1 6.12 0.50  Arl5c 2.23 2.45 
 Cd4 1.26 8.95  Klrb1c 5.01 1.04  Zcchc18 2.02 2.10 
 Parvb 1.26 8.39  Klrb1f 4.69 1.24       
 Gm10802 0.98 8.11  Sulf2 4.03 0.90       
 Alcam 0.90 7.49 Cd244 3.84 0.80       
 Dscam 1.07 7.09  Tbx21 3.47 0.49       
 Maged1 1.03 7.08  Gda 3.42 0.20       
 Fut4 0.92 5.53  Pydc3 3.06 0.39       
 Olfm4 1.05 5.42  Klrb1a 3.00 1.40       
 Mef2c 1.18 5.14  Cdk14 2.81 0.35       
 BC018473 0.92 5.03  Abi3bp 2.33 0.96       
 Zc3h12c 1.70 5.01  Dusp2 2.32 0.73       
 Fermt2 1.68 4.97  Ccr9 2.32 0.15       
 H2-Eb1 1.03 4.97  Tmem37 2.24 0.70       
 Wfdc18 1.27 4.85  Myc 2.10 1.00       
 Serpine2 1.30 4.64 
   
      
 Bmp2 3.98 4.34 
   
      
 Il6st 1.37 4.04 
   
      
 Mmp23 0.58 3.95 
   
      
 Cacna1g 1.73 3.93 
   
      
 Mapk10 1.23 3.90 
   
      
 Ly86 4.09 3.72 
   
      
 Cd81 6.45 3.18 
   
      
 Nrp1 3.97 3.11 
   
      
 Marcks 1.06 3.10 
   
      
 Dennd3 1.27 2.98 
   
      
 Tmem206 0.92 2.80 
   
      
 Rfx3 0.98 2.80 
   
      
 Il17f 1.80 2.79 
   
      
 Fam189a1 1.04 2.76 
   
      
 Ctsl 1.34 2.74 
   
      
 Cx3cl1 2.71 2.72 
   
      
 Camsap2 0.82 2.67 
   
      
 Dnajc13 0.81 2.64 
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 Pacsin1 1.47 2.59 
   
      
 Hmgn3 3.40 2.53 
   
      
 Fam109b 1.04 2.48 
   
      
 Mfsd7b 1.09 2.33 
   
      
 Tm9sf2 1.52 2.27 
   
      
 Bst2 1.44 2.25 
   
      
 Pkp4 1.57 2.20 
   
      
 Tox2 1.62 2.20 
   
      
 Maml3 1.22 2.16 
   
      
 Sypl 1.04 2.14 
   
      
 Myof 1.33 2.13 
   
      
 Ern1 1.21 2.10 
   
      
 D430042O09Rik 1.11 2.09 
   
      
 Nxpe3 1.30 2.05 
   
      
 Col4a3bp 1.08 2.04 
   
      
 
NKp46+& DN 
ILC3 genes  
FC: 
DN/NKp46 
FC: 
DN/  
CCR6 
DN & CCR6+ 
ILC3 genes  
FC: 
DN/  
NKp46 
FC: 
CCR6/DN 
 Ifng 0.59 15.90  Cd3e 16.81 0.38 
 Ctsw 0.58 9.82  Cd3d 16.50 0.34 
 Nkg7 0.41 6.89  Il17a 10.89 0.66 
 Ccr9 0.43 6.87  Cd40lg 7.70 0.69 
 Cxcr3 0.72 6.38  Gria3 4.56 0.90 
 Il2 0.38 4.95  Ret 4.30 1.32 
 Gda 0.29 4.93  Ly86 4.09 3.72 
 Eps8l3 0.72 4.10  Bmp2 3.98 4.34 
 Csf2 1.26 4.01  Nrp1 3.97 3.11 
 Serpinb9 0.83 3.62  Npnt 3.92 1.80 
 Dppa2 1.11 3.46  Npl 3.64 0.90 
 Ryk 1.14 3.21  Hmgn3 3.40 2.53 
 Abcg3 0.88 3.06  Cntn1 3.28 1.98 
 Cdk14 0.36 2.89  Itk 3.18 1.58 
 Pcp4 1.06 2.68  Dll1 3.02 1.35 
 Nt5e 0.84 2.63  Khdrbs3 3.02 1.82 
 Socs2 0.83 2.53  Ramp3 2.51 0.86 
 Ikzf3 0.71 2.52  4930506M07Rik 2.33 1.01 
 1810011H11Rik 0.68 2.50  Pdcd1 2.11 1.95 
 Skap1 0.87 2.46  Sdc4 2.03 1.19 
 Itih5 0.92 2.46 
    Ccnd2 0.90 2.44 
    Cd226 0.87 2.43 
    Glcci1 0.60 2.41 
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 4930503L19Rik 0.56 2.35 
    Lef1 0.80 2.21 
    Gimap3 0.95 2.15 
    Slc27a6 0.65 2.11 
    Lgals1 0.57 2.11 
    Dusp6 0.96 2.07 
    Adrb2 0.94 2.06 
    Tbx21 0.29 2.06 
    Xcl1 0.16 2.02 
    Fam63b 0.92 2.02 
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APPENDIX 2:  
 
Wolverine Whole Exome Sequencing Results 
 
Func Gene Impact Chr Start End Ref Obs Type 
intron_variant Myo1b MODIFIER chr1 51769127 51769127 ATG A Ins/Del 
intron_variant Sf3b1 MODIFIER chr1 54997297 54997297 C CT Ins/Del 
intron_variant Stradb MODIFIER chr1 58976803 58976803 T TC Ins/Del 
intron_variant Arpc2 MODIFIER chr1 74263676 74263676 TG T Ins/Del 
intron_variant Usp37 MODIFIER chr1 74527476 74527476 TG T Ins/Del 
intron_variant Abcb6 MODIFIER chr1 75177538 75177538 TC T Ins/Del 
intron_variant Col4a3 MODIFIER chr1 82652298 82652298 CG C Ins/Del 
intron_variant Neu2 MODIFIER chr1 87584360 87584360 GC G Ins/Del 
intron_variant Nckap5 MODIFIER chr1 126695547 126695547 A AG Ins/Del 
intron_variant Pik3c2b MODIFIER chr1 133101463 133101463 TC T Ins/Del 
upstream_gene_variant Rgs1 MODIFIER chr1 144249104 144249104 AG A Ins/Del 
intron_variant Soat1 MODIFIER chr1 156442595 156442595 C CT Ins/Del 
intron_variant Nme7 MODIFIER chr1 164404735 164404735 TA T Ins/Del 
intron_variant Ppox MODIFIER chr1 171279111 171279111 A AG Ins/Del 
intron_variant Usp21 MODIFIER chr1 171283149 171283149 CN C Ins/Del 
intron_variant Phyh MODIFIER chr2 4925576 4925576 C CT Ins/Del 
5_prime_UTR_variant Rnd3 MODIFIER chr2 51148926 51148926 AAT A Ins/Del 
intron_variant Cytip MODIFIER chr2 58151609 58151609 GA G Ins/Del 
intron_variant Chd6 MODIFIER chr2 161041481 161041481 G GGTGT Ins/Del 
intron_variant Fam194a MODIFIER chr3 58623315 58623315 TC T Ins/Del 
intron_variant Sema6c MODIFIER chr3 95164541 95164541 TG T Ins/Del 
intron_variant Ecm1 MODIFIER chr3 95734539 95734539 TG T Ins/Del 
intron_variant Psip1 MODIFIER chr4 83473125 83473125 G GA Ins/Del 
intergenic_region   MODIFIER chr4 155044246 155044246 T TG Ins/Del 
intron_variant Sema3a MODIFIER chr5 13570054 13570054 A AT Ins/Del 
downstream_gene_variant Fbxl13 MODIFIER chr5 21483837 21483837 AG A Ins/Del 
splice_acceptor_variant Otop1 HIGH chr5 38300289 38300289 TG T Ins/Del 
intron_variant Wdfy3 MODIFIER chr5 101861256 101861256 CATA C Ins/Del 
intron_variant Oas2 MODIFIER chr5 120748505 120748505 AC A Ins/Del 
intron_variant Oas1f MODIFIER chr5 120847610 120847610 TG T Ins/Del 
intron_variant Oas1f MODIFIER chr5 120847649 120847649 TG T Ins/Del 
frameshift_variant Tctn2 HIGH chr5 124624334 124624334 T TAC Ins/Del 
intron_variant Atp6v0a2 MODIFIER chr5 124645074 124645074 T TG Ins/Del 
intron_variant Atp6v0a2 MODIFIER chr5 124645103 124645103 A AT Ins/Del 
intron_variant 14-Sep MODIFIER chr5 129697981 129697981 G GC Ins/Del 
intron_variant Cct6a MODIFIER chr5 129844725 129844725 G GT Ins/Del 
frameshift_variant Auts2 HIGH chr5 131476702 131476702 A AG Ins/Del 
intron_variant Plekha8 MODIFIER chr6 54615154 54615154 C CG Ins/Del 
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splice_acceptor_variant Sftpb HIGH chr6 72309802 72309802 TG T Ins/Del 
intron_variant Rtkn MODIFIER chr6 83148036 83148036 TC T Ins/Del 
intron_variant Dcp1b MODIFIER chr6 119206419 119206419 G GT Ins/Del 
intron_variant Dcp1b MODIFIER chr6 119206422 119206422 C CT Ins/Del 
5_prime_UTR_variant Kcna1 MODIFIER chr6 126643443 126643443 GC G Ins/Del 
intergenic_region   MODIFIER chr6 132439200 132439200 AG A Ins/Del 
intergenic_region   MODIFIER chr6 132439213 132439213 TC T Ins/Del 
intergenic_region   MODIFIER chr7 3181354 3181354 CA C Ins/Del 
intron_variant Ppp1r12c MODIFIER chr7 4486240 4486240 TG T Ins/Del 
intergenic_region   MODIFIER chr7 12468450 12468450 TC T Ins/Del 
splice_acceptor_variant 6330408A02Rik HIGH chr7 13260898 13260898 AG A Ins/Del 
intron_variant Lig1 MODIFIER chr7 13291662 13291662 GC G Ins/Del 
intron_variant Lig1 MODIFIER chr7 13296117 13296117 AG A Ins/Del 
splice_acceptor_variant Lig1 HIGH chr7 13305924 13305924 GC G Ins/Del 
intron_variant Pla2g4c MODIFIER chr7 13344570 13344570 TG T Ins/Del 
intron_variant Kcnn4 MODIFIER chr7 24379066 24379066 TGG T Ins/Del 
splice_region_variant Cadm4 LOW chr7 24499668 24499668 AC A Ins/Del 
splice_acceptor_variant 1600014C10Rik HIGH chr7 38194783 38194783 GC G Ins/Del 
intron_variant Anpep MODIFIER chr7 79839109 79839109 AC A Ins/Del 
intron_variant Idh2 MODIFIER chr7 80098332 80098332 CCCAGGG C Ins/Del 
intron_variant Dmbt1 MODIFIER chr7 131043851 131043851 GC G Ins/Del 
splice_acceptor_variant Kndc1 HIGH chr7 139923776 139923776 TC T Ins/Del 
upstream_gene_variant Olfr541 MODIFIER chr7 140704104 140704104 TA T Ins/Del 
intron_variant Col4a1 MODIFIER chr8 11242996 11242996 GA G Ins/Del 
non_coding_exon_variant Gm5607 MODIFIER chr8 12429967 12429967 CG C Ins/Del 
intron_variant Alg11 MODIFIER chr8 22067732 22067732 GC G Ins/Del 
intron_variant Whsc1l1 MODIFIER chr8 25706729 25706729 AT A Ins/Del 
intron_variant Fat1 MODIFIER chr8 45037549 45037549 TG T Ins/Del 
intron_variant Fat1 MODIFIER chr8 45038158 45038158 CAA C Ins/Del 
intron_variant Galnt7 MODIFIER chr8 57652801 57652801 A AC Ins/Del 
intron_variant Pde4c MODIFIER chr8 70746259 70746259 AG A Ins/Del 
intron_variant Pde4c MODIFIER chr8 70746680 70746680 GC G Ins/Del 
intron_variant Rab3a MODIFIER chr8 70755731 70755731 CT C Ins/Del 
splice_acceptor_variant Ifi30 HIGH chr8 70764763 70764763 TG T Ins/Del 
intron_variant Mast3 MODIFIER chr8 70780501 70780501 GT G Ins/Del 
frameshift_variant Jak3 HIGH chr8 71684243 71684243 G GC Ins/Del 
intron_variant Fam32a MODIFIER chr8 72222014 72222014 TG T Ins/Del 
5_prime_UTR_variant Lonp2 MODIFIER chr8 86624176 86624176 CA C Ins/Del 
intron_variant Usb1 MODIFIER chr8 95345228 95345228 TG T Ins/Del 
intron_variant Bean1 MODIFIER chr8 104181598 104181598 CA C Ins/Del 
intron_variant Bean1 MODIFIER chr8 104181845 104181845 AC A Ins/Del 
frameshift_variant Bean1 HIGH chr8 104182033 104182033 TC T Ins/Del 
intron_variant Bean1 MODIFIER chr8 104182136 104182136 TC T Ins/Del 
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3_prime_UTR_variant Adad2 MODIFIER chr8 119616788 119616788 A AG Ins/Del 
frameshift_variant+stop_lost Mmp1a HIGH chr9 7465083 7465083 T TG Ins/Del 
intron_variant Man2c1 MODIFIER chr9 57139814 57139814 TG T Ins/Del 
intron_variant Herc1 MODIFIER chr9 66434053 66434053 C CT Ins/Del 
upstream_gene_variant Arpp19 MODIFIER chr9 75037583 75037583 A AC Ins/Del 
intron_variant Syncrip MODIFIER chr9 88476694 88476694 C CA Ins/Del 
intergenic_region   MODIFIER chr9 88801599 88801599 C CT Ins/Del 
intron_variant Wdr48 MODIFIER chr9 119924341 119924341 G GCT Ins/Del 
downstream_gene_variant Rtdr1 MODIFIER chr10 74957363 74957363 TG T Ins/Del 
intron_variant Cry1 MODIFIER chr10 85143577 85143577 G GC Ins/Del 
intron_variant Nup107 MODIFIER chr10 117777505 117777505 T TA Ins/Del 
intron_variant Sfi1 MODIFIER chr11 3186208 3186208 G GA Ins/Del 
intron_variant Sfi1 MODIFIER chr11 3187441 3187441 GA G Ins/Del 
intron_variant Sfi1 MODIFIER chr11 3188666 3188666 ATTTT A Ins/Del 
intron_variant Sfi1 MODIFIER chr11 3188885 3188885 T TC Ins/Del 
intron_variant Sfi1 MODIFIER chr11 3189169 3189169 TG T Ins/Del 
intron_variant Sfi1 MODIFIER chr11 3189173 3189173 TG T Ins/Del 
intron_variant Tns3 MODIFIER chr11 8549176 8549176 C CG Ins/Del 
upstream_gene_variant N4bp3 MODIFIER chr11 51651118 51651118 C CG Ins/Del 
intron_variant Rad50 MODIFIER chr11 53692558 53692558 T TA Ins/Del 
intron_variant Mink1 MODIFIER chr11 70603106 70603106 TG T Ins/Del 
intron_variant Smg6 MODIFIER chr11 74993946 74993946 T TA Ins/Del 
intron_variant Syne2 MODIFIER chr12 76052469 76052469 T TC Ins/Del 
5_prime_UTR_variant Tmem196 MODIFIER chr12 119946286 119946286 GC G Ins/Del 
intron_variant Tnfsf11 MODIFIER chr14 78284529 78284529 A AATAT Ins/Del 
intron_variant Nalcn MODIFIER chr14 123299324 123299324 AG A Ins/Del 
splice_region_variant Oxct1 LOW chr15 4053869 4053869 GA G Ins/Del 
intron_variant Ranbp3l MODIFIER chr15 9001834 9001834 AC A Ins/Del 
splice_acceptor_variant Nadk2 HIGH chr15 9100143 9100143 TG T Ins/Del 
downstream_gene_variant Mroh1 MODIFIER chr15 76454629 76454629 GA G Ins/Del 
intron_variant Bop1 MODIFIER chr15 76455625 76455625 TG T Ins/Del 
intron_variant Dennd6b MODIFIER chr15 89185964 89185964 AC A Ins/Del 
downstream_gene_variant 2310008H04Rik MODIFIER chr16 15888888 15888888 A AC Ins/Del 
intron_variant Arvcf MODIFIER chr16 18399449 18399449 TG T Ins/Del 
intron_variant Arvcf MODIFIER chr16 18399462 18399462 GA G Ins/Del 
intron_variant Eif4a2 MODIFIER chr16 23110740 23110740 C CT Ins/Del 
intron_variant Mylk MODIFIER chr16 35000027 35000027 GC G Ins/Del 
intron_variant Rwdd2b MODIFIER chr16 87437174 87437174 ACT A Ins/Del 
non_coding_exon_variant Gm10509 MODIFIER chr17 21690587 21690587 AT A Ins/Del 
downstream_gene_variant Gm10509 MODIFIER chr17 21692360 21692360 AT A Ins/Del 
intron_variant Itpr3 MODIFIER chr17 27087482 27087482 GA G Ins/Del 
splice_acceptor_variant Trerf1 HIGH chr17 47353916 47353916 AC A Ins/Del 
intron_variant Pja2 MODIFIER chr17 64283569 64283569 CCAGT C Ins/Del 
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splice_region_variant Memo1 LOW chr17 74202367 74202367 TA T Ins/Del 
intron_variant Socs5 MODIFIER chr17 87133603 87133603 G GT Ins/Del 
intron_variant AW554918 MODIFIER chr18 25175252 25175252 TAC T Ins/Del 
intron_variant Nedd4l MODIFIER chr18 65198606 65198606 G GT Ins/Del 
intron_variant Pla2g16 MODIFIER chr19 7574608 7574608 T TG Ins/Del 
intron_variant Exoc6 MODIFIER chr19 37570364 37570364 GT G Ins/Del 
intron_variant Exoc6 MODIFIER chr19 37571652 37571652 A AG Ins/Del 
intron_variant Exoc6 MODIFIER chr19 37571660 37571660 TG T Ins/Del 
intron_variant Tectb MODIFIER chr19 55192663 55192663 TC T Ins/Del 
intron_variant Lancl3 MODIFIER chrX 9251129 9251129 T TA Ins/Del 
intergenic_region   MODIFIER chrUn 5280 5280 TA T Ins/Del 
intergenic_region   MODIFIER chrUn 5292 5292 CT C Ins/Del 
intron_variant Txndc9 MODIFIER chr1 37990570 37990570 A G SNP 
upstream_gene_variant Rfx8 MODIFIER chr1 39721029 39721029 T C SNP 
intron_variant Ppp1r12b MODIFIER chr1 134773266 134773266 C A SNP 
intergenic_region   MODIFIER chr1 142125135 142125135 A G SNP 
intergenic_region   MODIFIER chr1 142125179 142125179 C G SNP 
intron_variant Apoa2 MODIFIER chr1 171225530 171225530 C A SNP 
intron_variant Apoa2 MODIFIER chr1 171225552 171225552 C A SNP 
downstream_gene_variant Klhdc9 MODIFIER chr1 171358093 171358093 C T SNP 
intron_variant Cr2 MODIFIER chr1 195166209 195166209 A C SNP 
missense_variant Dhtkd1 MODERATE chr2 5921824 5921824 C T SNP 
intron_variant Gpr107 MODIFIER chr2 31168260 31168260 T C SNP 
intron_variant Tars2 MODIFIER chr3 95746478 95746478 C T SNP 
intron_variant Tars2 MODIFIER chr3 95746524 95746524 G C SNP 
intron_variant Rap1a MODIFIER chr3 105739279 105739279 C T SNP 
intron_variant Adh6a MODIFIER chr3 138323265 138323265 C A SNP 
intron_variant Sh3glb1 MODIFIER chr3 144697357 144697357 G T SNP 
intron_variant Ttll7 MODIFIER chr3 146903981 146903981 G C SNP 
intron_variant Pigk MODIFIER chr3 152717335 152717335 A C SNP 
intron_variant Fsd1l MODIFIER chr4 53694441 53694441 G A SNP 
intron_variant Alad MODIFIER chr4 62511457 62511457 A C SNP 
5_prime_UTR_variant Prkaa2 MODIFIER chr4 105109812 105109812 G C SNP 
intron_variant Mroh7 MODIFIER chr4 106714038 106714038 T A SNP 
intron_variant Zmym6 MODIFIER chr4 127102080 127102080 T C SNP 
synonymous_variant Gm13084 LOW chr4 143811683 143811683 A G SNP 
intron_variant Mmel1 MODIFIER chr4 154887547 154887547 T C SNP 
missense_variant Akap9 MODERATE chr5 4064639 4064639 G C SNP 
missense_variant Sema3a MODERATE chr5 13570208 13570208 A G SNP 
missense_variant Otop1 MODERATE chr5 38300085 38300085 G C SNP 
intron_variant A930011G23Rik MODIFIER chr5 99684990 99684990 G A SNP 
intron_variant Cct6a MODIFIER chr5 129794702 129794702 G T SNP 
intron_variant Rbm28 MODIFIER chr6 29125589 29125589 C T SNP 
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intron_variant Dgki MODIFIER chr6 36934547 36934547 T G SNP 
intron_variant Thnsl2 MODIFIER chr6 71134415 71134415 A C SNP 
intron_variant Thnsl2 MODIFIER chr6 71134423 71134423 T C SNP 
intergenic_region   MODIFIER chr6 71300368 71300368 A G SNP 
intron_variant Sftpb MODIFIER chr6 72305981 72305981 G C SNP 
downstream_gene_variant Rtkn MODIFIER chr6 83153684 83153684 C G SNP 
intron_variant Fbxo41 MODIFIER chr6 85480320 85480320 A G SNP 
missense_variant Hebp1 MODERATE chr6 135152963 135152963 C G SNP 
intron_variant Rgs10 MODIFIER chr7 128389117 128389117 G A SNP 
missense_variant Dmbt1 MODERATE chr7 131065072 131065072 C A SNP 
intron_variant Dmbt1 MODIFIER chr7 131108204 131108204 T G SNP 
intron_variant Dmbt1 MODIFIER chr7 131108216 131108216 C G SNP 
splice_region_variant Muc2 LOW chr7 141701334 141701334 A C SNP 
intron_variant Whsc1l1 MODIFIER chr8 25675611 25675611 G T SNP 
intron_variant Nae1 MODIFIER chr8 104524260 104524260 C G SNP 
intron_variant Nae1 MODIFIER chr8 104524270 104524270 C T SNP 
intron_variant Mmp1b MODIFIER chr9 7384438 7384438 A G SNP 
synonymous_variant Fat3 LOW chr9 16031274 16031274 G A SNP 
intron_variant Dlat MODIFIER chr9 50640183 50640183 A G SNP 
intron_variant Acad11 MODIFIER chr9 104073753 104073753 T C SNP 
splice_region_variant Slc6a20b LOW chr9 123612135 123612135 A G SNP 
intron_variant Enpp1 MODIFIER chr10 24662084 24662084 T G SNP 
intron_variant Lama2 MODIFIER chr10 27212014 27212014 C G SNP 
intergenic_region   MODIFIER chr10 58224383 58224383 C T SNP 
intergenic_region   MODIFIER chr10 58225195 58225195 T C SNP 
intron_variant Cdh23 MODIFIER chr10 60305432 60305432 T C SNP 
intron_variant Bicc1 MODIFIER chr10 70927801 70927801 A G SNP 
downstream_gene_variant Gm867 MODIFIER chr10 75937468 75937468 T C SNP 
intron_variant Lrp1 MODIFIER chr10 127546182 127546182 C T SNP 
intron_variant Sfi1 MODIFIER chr11 3185947 3185947 T C SNP 
intron_variant Sfi1 MODIFIER chr11 3186270 3186270 A G SNP 
intron_variant Sfi1 MODIFIER chr11 3186277 3186277 G A SNP 
intron_variant Sfi1 MODIFIER chr11 3187064 3187064 G T SNP 
intron_variant Sfi1 MODIFIER chr11 3187081 3187081 C T SNP 
intron_variant Sfi1 MODIFIER chr11 3187106 3187106 C T SNP 
intron_variant Sfi1 MODIFIER chr11 3187119 3187119 C T SNP 
intron_variant Sfi1 MODIFIER chr11 3187136 3187136 C T SNP 
intron_variant Sfi1 MODIFIER chr11 3187209 3187209 C A SNP 
synonymous_variant Sfi1 LOW chr11 3187266 3187266 C T SNP 
missense_variant Sfi1 MODERATE chr11 3187367 3187367 T C SNP 
intron_variant Sfi1 MODIFIER chr11 3188750 3188750 A T SNP 
intron_variant Sfi1 MODIFIER chr11 3188892 3188892 A G SNP 
5_prime_UTR_variant Sfi1 MODIFIER chr11 3189023 3189023 T C SNP 
202	
intron_variant Eml6 MODIFIER chr11 29758777 29758777 A G SNP 
synonymous_variant Slc22a21 LOW chr11 53979573 53979573 T C SNP 
intron_variant Sap30l MODIFIER chr11 57807809 57807809 A T SNP 
intron_variant Obscn MODIFIER chr11 59005912 59005912 A G SNP 
downstream_gene_variant Kdm6b MODIFIER chr11 69398251 69398251 G C SNP 
5_prime_UTR_variant Acap1 MODIFIER chr11 69895499 69895499 A G SNP 
intron_variant Zmynd15 MODIFIER chr11 70462763 70462763 T C SNP 
intron_variant Nup88 MODIFIER chr11 70958214 70958214 C A SNP 
intron_variant Itgae MODIFIER chr11 73114651 73114651 A T SNP 
intron_variant Cluh MODIFIER chr11 74662199 74662199 A G SNP 
intron_variant Slc26a4 MODIFIER chr12 31531592 31531592 C A SNP 
intron_variant Gphn MODIFIER chr12 78350874 78350874 A G SNP 
missense_variant Ror2 MODERATE chr13 53117204 53117204 C T SNP 
intron_variant Cdhr2 MODIFIER chr13 54730843 54730843 T C SNP 
intergenic_region   MODIFIER chr13 66244274 66244274 A G SNP 
intergenic_region   MODIFIER chr13 66874762 66874762 C A SNP 
intron_variant Pde4d MODIFIER chr13 109324967 109324967 G A SNP 
intron_variant Nnt MODIFIER chr13 119408581 119408581 A C SNP 
3_prime_UTR_variant Paip1 MODIFIER chr13 119457151 119457151 G T SNP 
intergenic_region   MODIFIER chr14 6727139 6727139 T C SNP 
intron_variant Ptprg MODIFIER chr14 11952996 11952996 G T SNP 
intron_variant Ptprg MODIFIER chr14 11953023 11953023 A G SNP 
intron_variant Vcl MODIFIER chr14 20995117 20995117 A G SNP 
intergenic_region   MODIFIER chr14 44367726 44367726 T C SNP 
intron_variant Mcpt9 MODIFIER chr14 56028491 56028491 A G SNP 
intron_variant Matn2 MODIFIER chr15 34316704 34316704 T G SNP 
intron_variant Pkhd1l1 MODIFIER chr15 44501422 44501422 C T SNP 
intron_variant Fbxo32 MODIFIER chr15 58192211 58192211 C A SNP 
intergenic_region   MODIFIER chr15 101517464 101517464 C T SNP 
splice_acceptor_variant Zc3h7a HIGH chr16 11162678 11162678 G A SNP 
intergenic_region   MODIFIER chr16 21080434 21080434 C G SNP 
intron_variant Ubxn7 MODIFIER chr16 32332440 32332440 G C SNP 
synonymous_variant Muc4 LOW chr16 32754133 32754133 C A SNP 
synonymous_variant Muc4 LOW chr16 32754333 32754333 T A SNP 
missense_variant Muc4 MODERATE chr16 32755684 32755684 T A SNP 
missense_variant Muc4 MODERATE chr16 32755690 32755690 C A SNP 
missense_variant Muc4 MODERATE chr16 32755717 32755717 G C SNP 
intron_variant Rpl35a MODIFIER chr16 33058552 33058552 C T SNP 
intron_variant Nxpe3 MODIFIER chr16 55865709 55865709 A G SNP 
intron_variant Dscr3 MODIFIER chr16 94499085 94499085 G A SNP 
intron_variant Pacrg MODIFIER chr17 10597385 10597385 C G SNP 
intron_variant Myo1f MODIFIER chr17 33575777 33575777 A C SNP 
non_coding_exon_variant Rn45s MODIFIER chr17 39843999 39843999 T C SNP 
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non_coding_exon_variant Rn45s MODIFIER chr17 39844028 39844028 A G SNP 
non_coding_exon_variant Rn45s MODIFIER chr17 39844034 39844034 A C SNP 
non_coding_exon_variant Rn45s MODIFIER chr17 39844227 39844227 A G SNP 
non_coding_exon_variant Rn45s MODIFIER chr17 39844434 39844434 G A SNP 
non_coding_exon_variant Rn45s MODIFIER chr17 39844458 39844458 T C SNP 
intron_variant Ino80c MODIFIER chr18 24121526 24121526 T C SNP 
intron_variant Dmxl1 MODIFIER chr18 49934757 49934757 G C SNP 
intergenic_region   MODIFIER chrUn 29314 29314 C T SNP 
 
 
 
 
  
204	
Michelle L. Robinette 
Washington University in St. Louis, School of Medicine  
Division of Biology and Biomedical Sciences 
660 S. Euclid Ave 
St. Louis, MO, 63110 
Phone: (850) 376-5909 
Email: robinem@wustl.edu 
 
 
Education           
MD/PhD Medical Scientist Training Program                                         Expected: May 2018 
Washington University in St. Louis, St. Louis, MO 
• Program: Immunology 
• Thesis Advisor: Dr. Marco Colonna 
 
Bachelor of the Science                                                       2011 
University of Michigan, Ann Arbor, MA 
• B.S. Neuroscience, summa cum laude 
• High Honors and High Distinction in Neuroscience 
• Undergraduate Thesis Advisor: Dr. Sean J. Morrison 
 
 
 
Graduate Publications  
Primary Research 
• Robinette ML, Cella M, Telliez JB, Ulland TK, Barrow AD, Capuder K, Gilfillan S, Lin LL, 
Notarangelo LD, Colonna M. Jak3 deficiency blocks innate lymphoid cell development. Mucosal 
Immunol 11(1): 50-60 (2018). 
• Costa ML, Robinette ML, Bugatti M, Longtine MS, Colvin BN, Lantelme E, Vermi W, Colonna M, 
Nelson DM, Cella M. Two distinct myeloid subsets at the term human fetal-maternal interface. Front 
Immunol. doi: 10.3389/fimmu.2017.01357 (2017). 
• Cortez VS, Ulland TK, Cervantes-Barragan L, Bando JK, Robinette ML, Wang Q, White AJ, 
Gilfillan S, Cella M, Colonna M. SMAD4 impedes the conversion of NK cells into ILC1-like cells by 
curtailing non-canonical TGF-β signaling. Nat Immunol 18(9): 995-1003 (2017). 
• Robinette ML, Bando JK, Song W, Ulland TK, Gilfillan S, Colonna M. IL-15 sustains IL-7R-
independent ILC2 and ILC3 development. Nat Commun 8, 14601 doi:10.1038/ncomms14601 (2017). 
• Koues OI*, Collins PL*, Cella M*, Robinette ML*, Porter SI, Pyrform SC, Colonna M, Oltz EM. 
Distinct Gene Regulatory Pathways for Human Innate versus Adaptive Lymphoid Cells. Cell 165(5): 
1134-46 (2016). *Authors contributed equally 
• Cortez VS, Cervantes-Barragan L, Robinette ML, Bando JK, Wang Y, Geiger TL, Gilfillan S, Fuchs 
A, Vivier E, Sun JC, Cella M, Colonna M. Transforming Growth Factor-β Signaling Guides the 
Differentiation of Innate Lymphoid Cells in the Salivary Glands. Immunity 44(5): 1127-39 (2016). 
• Song C, Lee JS, Gilfillan S, Robinette ML, Newberry RD, Stappenbeck TS, Mack M, Cella M, 
Colonna M. Unique and redundant functions of NKp46+ ILC3s in models of intestinal 
inflammation. J Exp Med 212(11): 1869-82 (2015). 
• Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S, Colonna M. TREM2 
sustains microglial expansion during aging and response to demyelination. J Clin Invest 125(5): 2161-
70 (2015). 
• Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, 
Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M. TREM2 lipid sensing sustains 
205	
the microglial response in an Alzheimer’s disease model. Cell 160(6): 1061-71 (2015). 
• Robinette ML, Fuchs A, Cortez VS, Lee JS, Wang Y, Durum SK, Gilfillan S, Colonna M; 
Immunological Genome Consortium. Transcriptional programs define molecular characteristics of 
innate lymphoid cell classes and subsets. Nat Immunol 16(3): 306-17 (2015). 
• Durrant DM, Robinette ML, Klein RS. IL-1R1 is required for dendritic cell-mediated T cell 
reactivation within the CNS during West Nile virus encephalitis. J Exp Med 210(3): 503-16 (2013). 
 
Reviews 
• Robinette ML, Colonna M. Immune modules shared by innate lymphoid cells and T cells. J Allergy 
Clin Immunol 138(5): 1243-51 (2016). 
• Robinette ML, Colonna M. Innate lymphoid cells and the MHC. HLA. 87(1): 5-11 (2016). 
• Cortez VS, Robinette ML, Colonna M. Innate lymphoid cells: new insights into function and 
development. Curr Opin Immunol 32:71-7 (2015). 
• Robinette ML, Colonna M. GI motility: microbiota and macrophages join forces. Cell 158(2): 239-
40 (2014). 
  
 
 
Honors and Awards 
• Robert Silverman and Randi Leavitt Fellowship                     2018 
 
• AAP/ASCI/APSA Joint Meeting Best Poster Award, Chicago, IL                   2016 
 
• AAP/ASCI Travel Award, Chicago, IL                                 2016 
 
• NIH F30 NRSA Predoctoral Fellowship (NIDDK F30DK107053-01)         2015-present 
 
• Barry M. Goldwater Scholar                 2010 
 
 
 
Professional Experience 
 
Washington University in St. Louis School of Medicine                         2013-2016 
• Teaching assistant and tutor for M1 Immunology. Created and instructed course review sessions, led 
lab sessions, and wrote exams with course master Dr. Brian Edelson (2016). 
• Contributing author of the LCME Student Survey Report, focusing on Research Opportunities at 
Washington University (2014). 
• Teaching assistant for the M1 Histology course, leading a laboratory section of 40 students (2013) 
 
University of Michigan                           2010 
• Designed and taught the freshman honors seminar, “Regenerative Medicine’s Moral Achilles Heel: A 
Closer Look at The Biology and Ethics of Stem Cell Research.” 
 
 
 
